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SUMMARY
There is a need to produce safe, highly immunogenic vaccines that can elicit 
both systemic and mucosal immune responses. Control over the type of 
immune responses elicited following immunization has traditionally been 
confined to manipulating the immunogenicity of vaccines with adjuvants 
and altering the immunization route. In doing so, most studies focus 
predominantly on the ability of vaccines to elicit humoral immune 
responses. As result, the modulatory effect of immunization route or 
adjuvant on the immune response, in particular, the nature and extent of 
changes to leukocyte populations following immunization, and the 
importance of these changes for eliciting the final immunological outcomes 
remain poorly characterized. Knowledge of these changes may contribute to 
the development of safe and effective vaccines.
Immunization by the intradermal route elicits strong immune responses in 
different animal species. Therefore, one aim of this project was to quantify 
the changes in leukocyte populations in different murine tissues of 
intradermally immunized mice that may contribute to the adaptive 
immune responses ultimately elicited. Mice were immunized with either 
SAMA4, a generic liposome-iscom hybrid skin and mucosal adjuvant 
(Adjuvant group), outer membrane proteins (OMP) purified from 
Actinobacillus p leu ropn eu m on iae  (OMP Antigen group), SAMA4- 
adjuvanted OMP (OMP Vaccine group), or PBS (Control group).
Summary IX
Intradermal administration of OMP vaccine greatly altered leukocyte 
homeostasis and haematopoiesis in the tissues examined. A significant 
component of the strong innate cellular responses elicited by SAMA4- 
antigen complexes was recruitment of polymorphonuclear leukocytes 
(PMN) and monocytes to the blood, spleen and lungs. Significant thymus 
and bone marrow depletion were also rapidly induced by the SAMA4-OMP 
vaccine. The absence of similar responses in mice given OMP or SAMA4 
alone suggested that antigen and adjuvant interacted synergistically to 
produce the effects observed. Identical changes to leukocyte populations 
were elicited when the innocuous antigen, ovalbumin, replaced OMP in the 
SAMA4 complexes, therefore excluding the possibility of any effects from 
toxic bacterial or adjuvant components on the results obtained.
Intradermal immunization with OMP stimulated strong systemic IgG and 
IgA and mucosal IgG responses. However, complexing of OMP with SAM A4 
significantly prolonged the duration of the responses and increased 
reactivity against T dependent antigens in OMP. Cytotoxic responses against 
OVA-expressing cell lines also occurred only in the OVA Vaccine group. 
These results suggested that enhanced antigen processing by PMN was a 
beneficial product of the strong innate immune responses elicited in these 
mice. Mucosal antibody responses against OMP were demonstrated in both 
the OMP Vaccine and OMP Antigen groups by increases in OMP-specific IgG 
and IgA antibodies in respiratory tract washings and increases in the number 
of IgG and IgA antibody secreting cells in lung digests of immunized mice
Summary x
following intranasal re-exposure to a sub-immunogenic dose of OMP. Both 
groups also cleared live A. p leu ropn eu m on iae  from the lungs more rapidly 
than Control mice, and had significantly lower morbidity. Therefore, this 
route was efficacious for eliciting protective systemic and mucosal 
immunity against the respiratory pathogen, A. pleuropneumoniae.
Summary
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CHAPTER 1
General Introduction
1.1 INTRODUCTION
Many attenuated live or inactivated organisms have been successfully used 
as vaccines to prevent disease (Table 1.1) [1]. For safety and economic 
reasons, subunit vaccines that contain only a restricted number of putative 
protective antigens are also being developed [1-3]. One prominent example 
of this is acellular pertussis vaccines that are being evaluated to replace 
current cellular vaccines [4-7]. Irrespective of whether whole cell or subunit 
vaccines are used, generation of immunity depends on the qualitative and 
quantitative characteristics of the immune responses induced by vaccination 
[8]. Therefore, there is a requirement to produce vaccines that are safe and 
strongly immunogenic in order to activate innate and adaptive im m une 
mechanisms. Because the majority of human and animal pathogens 
colonize and invade via the mucosal surfaces of the lung, gut or urogenital 
tracts [9], there is an additional requirement for vaccines to elicit both 
mucosal and systemic immune responses. In practice, adjuvants and 
different vaccination routes are used to achieve these attributes.
1.2 ADJUVANTS AND THE IMMUNE RESPONSE
1.2.1 Adjuvants increase the immunogenicity of vaccines
Adjuvants are widely used in vaccines to increase the im m une
responsiveness against co-administered antigens [3]. According to Byars et al
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TABLE 1.1 Vaccines containing attenuated or live organisms [1]
Disease Agent used Vaccination route
Cholera killed Vibrio cholerae SC, IM, ID
Influenza killed Influenza virus IM
Measles live Measles virus SC
Mumps live Mumps virus SC
Pertussis killed Bordetella pertussis IM
Plague killed Yersinia pestis IM
Polio live or killed Polio virus Oral, IM
Rabies killed Rabies virus IM, ID
Rubella live Rubella virus SC
Small pox live Vaccinia virus ID
Tuberculosis live attenuated Mycobacterium bovis ID, SC
Typhoid killed Salmonella typhi SC, Oral
Yellow fever killed virus SC
SC: subcutaneous; ID: intradermal; IM: intramuscular
[10], adjuvant action encapsulates a range of desirable activities that results 
in increased immune responsiveness against administered antigens, and 
that ultimately confers protection against disease. The requirement for safe, 
highly immunogenic vaccines that elicit strong mucosal immune responses 
has increased the prominence of adjuvant in vaccine design [8, 11]. 
However, because of the heterogeneity in the chemical composition of 
adjuvants, and differences in the recommended delivery routes of vaccines, 
unravelling the precise mechanisms of adjuvant action and defining 
favourable attributes of adjuvants has proven difficult [3, 11]. Consequently, 
despite the use and research into adjuvants over at least 80 years by many
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different groups [12-17], the choice of adjuvants for incorporation in 
commercial vaccines is currently still limited. Alum is used in hum an 
vaccines [1, 8, 11], while the situation for veterinary vaccines is only slightly 
better, with DEAE-Dextran and saponin-based adjuvants also available for 
use [18,19].
The concern for safety is one factor resulting in the paucity of suitable 
adjuvants. Adjuvants, including those commonly used in commercial 
vaccines (eg. alum) and experimental immunology (eg. Freund's complete 
and incomplete adjuvants, Muramyl Dipeptide, Quil A and 
immunostimulating complexes or iscoms), can elicit local and systemic 
adverse post-vaccination reactions [1, 20, 21]. Although the reactions are 
usually mild and self limiting, documented reactions to vaccines include: 
local tissue damage at the site of injection [22], fever [23] or systemic effects 
[20, 24]. Apprehension over such adverse reactions has, in cases like the 
pertussis vaccine, deterred widespread acceptance of vaccination [25]. In 
agriculture, local reactions to vaccination reduce carcass quality and decrease 
economic returns [22, 24].
Humoral or cell-mediated immune responses are effectively used to assess 
vaccine efficacy, and allow comparisons to be made between different 
formulations of the same vaccine [20, 26-32], By contrast, the absence of well- 
accepted parameters that define adjuvant action has resulted in an ad h oc  
approach to investigating adjuvant action and comparing different 
adjuvants [15, 26, 28, 33-40]. Consequently, adjuvant selection is often
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confined to pragmatic considerations, such as shelf-life and commercial 
availability, with less consideration devoted to determining which vaccine 
formulations most efficiently elicit the immune response desired [39].
1.2.2 Established adjuvant action
Adjuvants can greatly influence the way antigens are detected and processed 
by the immune system. Macrophage activation is one well established action 
by which adjuvants stimulate responses against antigens [14, 15, 41, 42]. 
However, one common, yet incorrect, perception is that adjuvants activate 
macrophages by similar mechanisms. Recent comprehensive reviews of 
adjuvant action [8, 11], demonstrate that the mechanisms of adjuvant action 
are poorly understood. The examples below illustrate the wide variation in 
mechanisms used by adjuvants to improve antigen presentation and initiate 
immune responses.
1.2.1.1 R epository (zvater-in-oil em ulsion) adjuvants. Repository adjuvants, 
such as alum and Freund's complete adjuvant, were initially believed to 
form an 'antigen depot' at the injection site, allowing the slow release of 
antigen and prolonging the time for antigen uptake by antigen presenting 
cells (APC) [12]. Prolonged antigenic stimulation by slow antigen release 
from the depot was also thought to account for the persistence of high 
serum antibody levels over long periods [43]. The evidence now indicates 
that the presence of small amounts of antigen on the surface of follicular 
dendritic cells located within the lymphoid follicles of draining lymph 
nodes sustains the long-term antibody response [44].
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Aluminium phosphate or aluminium hydroxide-precipitated antigens have 
been widely used in human and animal vaccines [10, 45]. Aluminium salts 
can increase antibody synthesis, particularly the IgGl subclass in mice [10]. By 
contrast, Freund's adjuvant is limited to use in experimental immunology 
because of the painful granulomas that form at the injection site, and the 
carcinogenicity of the mineral oil and emulsifier. Additionally, 
emulsification of protein antigens also results in the denaturation of 
unstable antigens and can result in loss of protective epitopes, rendering the 
vaccine unsuitable for use [10].
1.2.1.2 O il-in-w ater em u lsions. Oil-in-water emulsions are generated when 
adjuvants such as N-acetylmuramyl-L-analyl-D-iso-glutamine or muramyl 
dipeptide (MDP) are combined with antigen. MDP is a component of the 
mycobacterial cell wall and is responsible for the adjuvant activity of 
Freund's adjuvants. Oil-in-water emulsions do not form a depot following 
injection [46]. Also, because antigen is added to preformed emulsions, 
antigens are not subjected to the mixing or shearing forces encountered 
during the emulsification process used to prepare Freund's adjuvant. 
Antigens in MDP vaccines can, therefore, be expected to retain their original 
structure. It is believed that multimeric antigen presentation on the surface 
of adjuvant oil microdroplets facilitates antigen uptake by APC [46]. 
Activated C3b bound to the surfaces of antigen-coated MDP particles is also 
believed to be targeted by follicular dendritic cells, facilitating endocytosis 
and antigen processing [24].
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MDP and its analogues, including a-aminobutyryl derivatives, Syntex
Adjuvant Formulation (SAF; N-acetyl muramyl-L-threonyl-D-isoglutamine 
MDP analogue) and lipophilic derivatives (such as N-acetyl muramyl-L- 
alanyl-D-isoglutaminyl-L-alanine-phosphatidylethanolamine) have been 
used experimentally to stimulate both cell-mediated and humoral im m une 
responses [10, 46, 47]. Like Freund's adjuvant, the adverse side-effects render 
MDP and many of its derivatives unsuitable for routine human or animal 
vaccination [10].
1.2.1.3 L ip id  A. Lipid A, a component of the lipopolysaccharides of Gram­
negative bacteria has significant ability to activate macrophages [10]. The 
mechanism of action is also believed to involve the regular arrangement of 
antigen on the surface of the oil microdroplets, enhancing uptake by APC 
[46]. Synthetic lipid A and Lipid A analogues, such as monophosphoryl lipid 
(MPL), have been produced in an attempt to minimize the toxicity of this 
adjuvant. The efficacy of MPL has also been enhanced by the addition of 
bacterial cell wall derivatives and trehalose dymycolate, which is responsible 
for the toxicity attributed to the mycobacteria in Freund's complete adjuvant 
[46].
1.2.1.4 Bacterial toxins. Binding of cholera toxin (CT) or cholera holotoxin 
subunit B (CTB) to the GMl ganglioside receptors in the gut-associated 
lymphoid tissue is thought to facilitate its uptake [9]. Genetic fusion of CTB 
or Escherichia coli heat labile enterotoxin B with otherwise poorly
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immunogenic heterologous proteins and administration as a purified 
fusion protein or as a heterologous fusion protein expressed in live bacterial 
vectors may serve as potent mucosal antigens for inducing specific antibody 
production [48].
1.2.1.5 H ydrocarbon adjuvants. Hydrocarbons, especially those with chain 
lengths around C16 are potent adjuvants and lead to strong induction of 
cellular immune responses [46]. The mechanism of action is unclear but 
modification of antigens by conjugation with fatty acids is known to favour 
the development of a strong delayed type hypersensitivity response. 
Electrostatic association of aliphatic amines, such as dimethyl dioctadecyl 
ammonium bromide (DDA Bromide) and avridine b^N-dioctadecyl-N^N'- 
bis(2-hydroxyethyl)propanediamine, with antigen introduces lipid groups 
that may generate organized particulate structures of high molecular weight 
and improve antigen uptake by APC [46, 49].
1.2.1.6 Cytokines. Stimulation of cytokine synthesis has been identified as an 
important part of adjuvant action. Cytokines such as interferon-gamma
(IFN-y), IL (interleukin)-l and IL-2 [50], and colony stimulating factors (CSF)
such as Macrophage-CSF and Granulocyte/Macrophage-CSF [51], mediate 
macrophage activation and the induction of adaptive immune responses. 
DDA bromide and avridine, for example, strongly induce IL-1 production in 
stimulated macrophages [46]. As a result, a number of cytokines, such as IL-1
[34], IL-2 [52], IL-12 [53] and IFN-y [50] have been evaluated for use as
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adjuvants [51]. However, despite the success of several trials, a range of 
concerns regarding the toxic effects of multiple cytokine doses, the timing of 
doses during the maturation of immune responses, the targeting of 
cytokines to the appropriate cells, the pleiotropic effects of cytokines, 
including the induction of acute inflammatory responses, and the 
immunogenicity and species-specificity of cytokines, currently render 
cytokines impractical as adjuvants [54].
12.1.7 Im m uno-stim ulating com plexes. Immuno-stimulating complexes 
(iscoms) comprise one of the most exhaustively investigated adjuvants [17, 
37, 39, 55-89]. Iscoms are synthetic, cage-like structures formed from the 
binding of Quil A and cholesterol [46, 66, 69, 70, 73, 74, 90]. Quil A is a 
saponin with well established strong adjuvant activity even at low doses [10, 
70]. Once formed, iscoms have exposed regions capable of hydrophobic 
interaction with amphipathic protein antigens. It is believed that 
multimeric presentation of antigens increases uptake by APC [69]. A wide 
range of protein antigens (predominantly viral proteins) have been 
incorporated into iscom-based vaccines (Table 1.2). The use of preformed 
iscoms has also been investigated to improve the immunogenicity of small 
peptides, namely Luteinizing hormone releasing hormone, and peptide 
fragments of the b-chain of human chorionic gonadotrophin and a malaria 
circumsporozoite epitope [64-66].
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TABLE 1.2 Examples of vaccines using iscom technology
Organism Reference
Influenza A virus [62,91]
Herpes simplex virus type 1 [57]
Parainfluenza virus [92]
Coxsackie B3 virus [93]
Pseudorabies virus [84]
Human immunodeficiency virus-1 [61]
Hepatitis B virus [75,94]
Measles virus [56,95]
Bovine herpes virus 1 [83]
Salmonella Heidelberg [96,97]
Salmonella enteritidis [96,97]
Neisseria gonorrhoeae [63]
In contrast to the good incorporation of hydrophobic proteins, iscoms 
incorporate hydrophilic proteins poorly [39, 72, 76]. Partial dénaturation with 
acid to expose hydrophobic residues [72, 75, 98], covalent attachment of fatty 
acids such as palmitic acid [76, 99], and addition of phosphatidyl choline [66], 
have been used to overcome this limitation. Using a novel liposome-iscom 
hybrid formulation of iscoms, SAMA4 (Skin and Mucosal Adjuvant 
version 4, Patent No. PCT/AU95/00206), Chin et al [100-102] have 
demonstrated that antigen uptake into iscoms is facilitated by first 
entrapping antigens within unilamellar liposomes. This approach retains 
the biological properties of iscoms and improves incorporation of both 
hydrophobic and hydrophilic protein antigens into the iscom vehicle [100­
103].
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Iscom-based vaccines can elicit very high serum antibody, delayed-type 
hypersensitivity (DTH), and class 1 MHC-restricted cytotoxic T cell responses 
when administered by peripheral and mucosal routes [73, 102]. Several 
factors are believed to contribute to the potent immunostimulating effect of 
iscoms. First, the hydrophobic nature of iscoms is thought to enable efficient 
and rapid uptake of iscom-associated antigens by APC, thereby m inim izing 
the loss of antigen [17, 87]. Watson et al (1989) [37] demonstrated that 
antigens incorporated into iscoms are more rapidly taken up by peritoneal 
macrophages than antigen emulsified with incomplete Freund's adjuvant. 
A prominent neutrophil response was obtained following im m unization 
with iscoms in this study but the importance of such a response was not 
investigated. Previous work by Beh et al (1985) [35] also demonstrated that 
injected antigen associates with neutrophils during its clearance from the 
injection site into draining lymph nodes and spleen, indicating that 
neutrophil involvement is important in the immune response following 
vaccination.
Second, multimeric antigen presentation to APC is believed to enhance the 
immunogenicity of antigens and facilitate activation of APC [59, 86, 87, 90, 
92] while the in-built presence of an adjuvant (Quil A) exerts a significant 
immunostimulatory effect [46]. The amount of Quil A required to exert an 
adjuvant effect in iscoms is several-fold lower than is required when Quil A 
is used alone as a conventional adjuvant [69, 71]. Because of this it has been 
shown to be safe when administered by intramuscular, subcutaneous and 
intranasal routes [67, 78, 99].
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Interaction between Innate and Adaptive Immune Systems 
Activation of macrophages, such as by vaccination, results in the release of 
cytokines, complement proteins, coagulation factors and other factors, that 
can cause marked and prolonged effects on the recirculation pattern of 
lymphocytes, granulocytes and other macrophages. Increasing the 
localization of immune effector cells to draining lymph nodes increases 
their exposure to antigen and can ultimately lead to induction of adaptive 
immune responses [104-106]. Recent studies [107-117] showing how the 
innate and adaptive arms of the immune systems interact may help explain 
the precise mechanisms by which specific adjuvants enhance induction of 
immune responses.
Increased interaction between the innate and adaptive immune systems 
occurs as a result of enhanced phagocytosis, processing and presentation of 
antigen by different types of APC, and the release of soluble mediators, such
as IL-1, IL-2 and IFN-y, by activated APC and T cells. The cytokines released
stimulate the growth, proliferation and differentiation of effector cells 
involved in the immune response. Primary induction of naive T helper 
cells is predominantly effected by one type of APC, called the dendritic cell 
[111]. Once activated, T cells can then respond to a broader range of APC, 
including macrophages, granulocytes and lymphocytes [108, 112, 113, 118]. 
The antigenic epitopes presented to T cells by APC determine the antigenic 
specificity and the character of the adaptive immune response by directing 
the differentiation of T helper cells into Thl and/or Th2 clones [116].
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Protein antigens taken up by phagocytic cells are processed into oligopeptide 
fragments through two distinct pathways. Exogenously encountered 
antigens, for example, antigens administered by vaccination, or those 
produced extracellularly during bacterial infections, are endocytosed and 
proteolytically cleaved into peptide fragments in acidic endosomes in the 
cytosol of APC [119]. Peptide fragments bind to class II m ajor 
histcompatibility complex (MHC) molecules and are displayed on the surface 
of APC for specific recognition by T cell receptors (TCR) on CD4+ T helper 
cells. Expression of class II MHC glycoproteins on APC is increased during
phagocytic activity and following stimulation by cytokines, such as IFN-y,
released by activated T helper cells [120, 121]. There is some evidence that 
steroid hormones may also affect expression of class II MHC molecules [122]. 
Class II MHC-antigenic peptide complexes predominantly induce an increase 
in antigen-specific antibody production by B cells.
Endogenous antigens, generated within the cytoplasm of cells infected by 
intracellular pathogens, are proteolytically cleaved into peptide fragments in  
proteasomes in the cytosol. Antigenic peptide fragments associate with class
I MHC molecules and |3-2-microglobulin and are expressed on the cell
surface of affected cells [119, 123]. Engagement of MHC class I-antigenic 
peptide complexes with CD8+ T cells increases the level of MHC-restricted 
cytotoxicity against affected cells.
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The level of expression of class I or II MHC glycoproteins is an important 
determinant of the antigen presenting ability of the APC encountering 
antigen, and indirectly of the immunogenicity of administered antigens. 
George et al (1989) [107] demonstrated that peritoneal macrophages, which 
have low expression of class II MHC molecules, presented antigen poorly to 
co-cultured T cells in vitro. By comparison, skin-derived Langerhans cells, 
with higher expression of class II MHC molecules, presented antigen with 
greater efficiency, and had a concomitantly greater increase in the number of 
proliferating T cells in vitro [107]. DeKruyff et al (1992) [110] and Gajewski et 
al (1991) [109] further noted that the type of APC that initially encountered 
the antigen plays an important role in determining the character of the 
immune response that predominates in different lymphoid tissues. For 
example, activated B cells were able to more efficiently stimulate 
proliferation of Th2 clones than macrophages [109]. Macrophages, on the 
other hand, preferentially stimulated proliferation of Thl cells.
Mikszta et al (1996) [117] demonstrated that differences in the MHC 
haplotype can influence T cell responsiveness to antigenic epitopes, and 
affect the immunogenicity of different antigens. MHC haplotype differences 
are manifested as variations in antigenic peptide binding affinity to class II 
MHC molecules, or differences in the ligand density at the cell surface, both 
of which affect antigen processing and presentation by APC [114]. Peptides 
with high binding affinity to class II MHC molecules, or peptides that are 
presented at high ligand density preferentially induce Thl responses, 
whereas peptides with lower binding affinities to class II MHC molecules or
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with lower ligand densities at the cell surface prime for Th2 responses [114, 
116,117].
The complement protein system is another component of the innate 
immune system that affects induction of adaptive immune responses. 
Binding of C3 fragments to antigen facilitates the uptake and clearance of 
antigen by APC in the lymph nodes and spleen [124]. Dempsey et al (1996) 
[115] demonstrated that complement activation by antigen reduces the 
threshold concentration of antigen required for immunogenicity. Binding of 
the C3d fragment of C3 to its receptor (CD21) on the surface of B cells acts as a 
bridge that crosslinks B cell CD19 and CD21, effecting the signal 
amplification required for normal T-dependent B cell activation [115]. In one 
study in which C3d proteins were coupled to the antigen hen-egg lysozyme 
(HEL), each additional C3d molecule attached to the HEL molecule enhanced 
the immunogenicity of HEL ten-fold [115].
Further advances in the understanding of the interactions between the 
innate and adaptive immune systems, such as those described above, may 
provide explanations for the different aspects of adjuvant action, and a 
means of more effectively manipulating the immune response. Despite the 
contributions of previous studies [13, 14, 17, 34, 35, 44, 125, 126], the in v i v o  
effects of adjuvant on the different leukocyte populations, in particular, the 
nature and extent of changes to leukocyte populations, or the importance of 
these changes for eliciting the final immunological outcomes remains 
poorly characterized.
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1.2 MUCOSAL IMMUNITY AND VACCINATION ROUTE
1.2.1 Is mucosal IgA important?
The mucosal surfaces of the lung gut and urogenital tracts contain 
specialized mucosa-associated lymphoid tissues that act as inductive sites for 
eliciting immune responses against mucosal pathogens [127, 128]. With the 
exception of the female genital tract [129], mucosa-associated lymphoid 
tissues contain predominantly IgA-committed B cell precursors with 
relatively fewer IgG and IgM-secreting cells [128]. Systemic lymphoid tissues, 
by comparison, contain predominantly IgG and IgM-committed precursors, 
with only a small proportion of IgA-committed precursors. McDermott and 
Bienenstock (1979) [130], Weisz-Carrington et al (1979) [131], Mirski et al 
(1981) [132] and others [133, 134] also demonstrated that lymphoblasts from 
mucosa-associated lymphoid tissues migrate almost exclusively to other 
mucosal sites, while lymphoblasts from peripheral lymph nodes migrate 
preferentially to other peripheral sites. This preferential migration may, in  
part, be due to expression of organ-specific recognition mechanisms on 
migrating lymphoblasts, such as the cell surface markers L-selectin, CD44 
and CD71 [135]. Such differences in the anatomical distribution, organization 
and antibody isotype responses of different lymphoid tissues have given rise 
to the now well established notion of a network of mucosal lymphoid 
tissues, or common mucosal immune system, that is functionally separate 
to the systemic immune system [136].
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The discovery by Mossman et al [137, 138] and others [109, 139-143] of distinct 
T helper cell clones (Thl and Th2 cells) provided further support for a 
common mucosal immune system. The temporal sequence of cytokine 
production by T helper cells, as well as the profile of cytokines released by T 
helper cells in response to activation, dictate the type of adaptive im m une 
response that is elicited [141, 144]. T cells residing in mucosa-associated 
lymphoid tissues predominantly secrete Th2 cytokines, IL-4, IL-5, IL-6, IL-10
and Transforming growth factor (TGF)-(3, which promote IgA production
and secretory immune responses [145]. By comparison, T cells residing in 
peripheral lymphoid tissues, such as skin-draining lymph nodes and spleen 
secrete predominantly Thl cytokines, IL-2 and interferon-gamma, which 
generate systemic immune responses [145].
Different studies have demonstrated that declines in the numbers of CD4+ T 
cells, or production of TGF-P by these cells, results in low serum and
mucosal IgA levels [146-148]. Thymectomized or athymic mice, for example, 
which have low or absent CD4+ T cells, have diminished serum and gut IgA 
responses following systemic immunization, although levels of IgM or IgG 
are not substantially diminished [149, 150]. Furthermore, reconstitution of 
depleted animals with thymus, or intraperitoneal injection of thymus cells, 
results in the reappearance of near normal levels of serum IgA and a 
considerable increase in intestinal IgA plasma cells [150]. IgA deficiency,
concomitant with low TGF-p levels [151] and low CD4+ cell numbers [152],
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also causes a combined immunodeficiency syndrome that is associated with 
increased susceptibility to infections [153].
IgA is the predominant immunoglobulin present in mucosal secretions, and 
constitutes greater than 80% of all antibodies isotypes produced in mucosa- 
associated tissues [127, 148]. Secretory IgA present in mucosal secretions 
possesses two additional components not found on other secreted or 
circulating immunoglobulins. These components are the secretory 
component (SC) and the J chain [154], The J chain is synthesized by IgA- 
secreting plasma cells and joins two IgA molecules together. The SC is 
synthesized by epithelial cells and is essential for the transport of IgA from 
the blood to the mucosa by epithelial cells which line the exocrine glands 
[119]. Secretory IgA is selectively transported into the external secretions, 
with only a small amount entering the systemic circulation [155]. The 
smaller quantities of predominantly monomeric IgA found in serum are 
produced primarily by the bone marrow. Serum IgA contributes little to 
external secretions, although export occurs via a hepatobiliary route in 
species such as sheep and man [128, 155].
Early studies demonstrated the importance of locally secreted antibodies in 
protecting against mucosal pathogens of the respiratory tract, such as 
parainfluenza virus [156] and respiratory syncytial virus [157]. Many 
subsequent studies [91, 158-165] have reinforced the notion that secreted 
antibodies, primarily IgA, can protect against mucosal pathogens. Secreted 
IgA is believed to inhibit microbial adherence and neutralize toxins more
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efficiently than other immunoglobulin isotypes [148]. IgA also mediates 
antibody-dependent cellular cytotoxicity and interferes with the utilization 
of growth factors such as iron by bacteria [166]. By preventing absorption of 
antigenic material, IgA prevents local inflammation that would otherwise 
damage the integrity of the mucosal surfaces [148].
Mucosal IgA is involved in the immune response to infections in the 
urinary tract [167], gut [168], respiratory tract [169] and skin [170] in different 
species. The correlation between locally secreted IgA and mucosal protection 
is also strengthened by other data demonstrating that IgA-deficient 
individuals, with otherwise normal cellular immune responses (for 
example, transient deficiency in early childhood), are more likely to suffer 
from recurrent infections than individuals with normal IgA levels [171-173]. 
Schmitt et al (1994) [170] also reported that IgA deficiency in dogs was 
associated with a significant decrease in chemotactic and phagocytic 
capacities by polymorphonuclear granulocytes, reflecting a decline in 
opsonophagocytosis.
1.2.2 Mucosal immunity and immunoglobulin isotypes other than IgA
According to Beard and Ferrante (1989) [174] the contribution of non-IgA 
isotypes may be an important undervalued factor in mucosal immunity. As 
well as containing IgA-committed plasma cell precursors, the mucosa- 
associated lymphoid tissues contain IgG and IgM plasma cell precursors [128]. 
The early lymphoblast transfer studies of McDermott et al (1979) [130] 
demonstrated that, like IgA lymphoblasts, relatively large numbers of the
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available IgG lymphoblasts preferentially migrate between different mucosa- 
associated lymphoid tissues. McDermott and Bienenstock (1979) [130], Weisz- 
Carrington et al (1979) [131], Mirski et al (1981) [132] and others also 
demonstrated that smaller, but detectable numbers of IgG and IgA 
lymphoblasts from peripheral lymph nodes localize in the lung and small 
intestine and differentiate into immunoglobulin-secreting plasma cells. 
Additionally, transudation of serum antibodies to mucosal surfaces, 
particularly IgG, also occurs in a range of animal species [175-178]. IgG is 
therefore a major component of mucosal secretions from the gut, lung and 
reproductive tracts because of local production and/or transudation from 
the serum [129, 179].
Elevations in mucosal IgG are usually present concurrently with elevations 
in mucosal IgA in respiratory tract washings [6, 156, 180], intestinal washings 
[175], milk, bile [181] and genital secretions [129] in response to infection or 
vaccination. These findings suggest that serum antibodies, and locally 
produced immunoglobulin isotypes other than IgA, may be important 
contributors to the protection of mucosal surfaces. However, the finding of 
several immunoglobulin isotypes in mucosal secretions also makes it 
difficult to assess the individual contributions to protection of each. Separate 
studies demonstrated that serum antibodies were associated with reduced 
viral titres [158, 159], reduced morbidity [156], or complete protection [182] 
following viral infection. Similarly, increases in serum antibodies following 
vaccination against Vibrio cholerae  [183], Actinobacillus p leu ro p n eu m o n ia e  
[184] and rotavirus [185] were also correlated with protection. In another
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study, mice vaccinated against Sendai virus, produced IgG and IgA in the 
lung mucosa, and serum IgA [160]. Significantly, passive immunization of 
mice with either IgA or IgG also elicited equivalent levels of protection 
against Sendai virus [186].
Marx et al (1989) [167] found that the level of mucosal IgA in the urinary 
tract of patients with bladder catheters, cystotomies, urinary tract infections, 
urosepsis, chronic glomerulonephritis and renal transplants, was not 
correlated with susceptibility to urinary tract infections. Even a complete 
lack of mucosal IgA in the urinary tract of patients was not necessarily 
associated with increased incidence in urinary tract infections [187]. 
Significantly however, IgG subclass deficiencies are associated with increased 
incidence of upper and lower respiratory tract infections [172, 174, 188, 189], 
bacterial meningitis [190, 191] and clostridial diarrhoea in children [192] 
suggesting that IgG is important for protection. Kzuizenga et al (1990) also 
found that IgA deficient individuals secreted larger quantities of IgM into 
lacrimal fluid [193]. Together, the data suggests at least a complementary 
protective role for IgG or IgM in mucosal secretions with IgA, and a 
compensatory role for these immunoglobulin isotypes in cases of IgA 
deficiency.
1.2.3 Mucosal immunity and the vaccination route
With few exceptions, notably polio and typhoid vaccines which can be 
administered orally, the vast majority of vaccines are given by peripheral 
routes, either intramuscularly, subcutaneously or intradermally (Table 1.1)
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[1,194]. This is as much because of the practicability of the peripheral routes 
[3, 6] as the success of the vaccines given by these routes against systemic 
diseases, such as Hepatitis B [11]. However, most human and animal 
pathogens colonize and invade via the mucosal surfaces [195]. Consequently, 
the widely held view is that vaccines delivered by peripheral routes are poor 
inducers of mucosal IgA, and primarily result in increased production of 
serum antibodies which provide only incomplete or no protection against 
mucosal pathogens [6, 136, 148, 196]. Incomplete protection may actually 
contribute to the development of asymptomatic carriers and the persistence 
of the disease in the community [197]. A number of studies [198-200] have 
also indicated that systemic lymphoid tissues, which are targeted by 
peripheral vaccination, may suffer age, nutrition and disease-associated 
declines in immune function. If so, the protective efficacy of peripheral 
vaccination in these affected groups may be compromised [9].
Mucosal vaccination strategies are of special interest because of the potential 
benefits achieved from targeting the common mucosal immune system [9, 
136]. Proponents of mucosal vaccination strategies envisage that any of the 
mucosal routes, which include oral, nasal, rectal and urogenital routes, may 
be useful for generating protective immune responses against important 
mucosal pathogens [6, 9, 129, 166, 201]. Significantly, combinations of 
different mucosal routes, or mucosal and peripheral routes, may even be 
more effective than immunization by strictly mucosal routes [6]. The 
combination of subcutaneous and oral doses, for example, elicited higher 
intestinal IgA responses in women than was possible when either route was
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used individually [202]. Nedrud et al (1987) [160] reported that combined 
oral/intranasal immunization improved protection against Sendai virus. 
Reuman et al (1990) [203] also demonstrated improved recovery of mice after 
combined nasal/oral immunization with killed respiratory syncytial virus.
It is anticipated that mucosal vaccination strategies will avoid the 
limitations of peripheral vaccination by inducing both mucosal and systemic 
responses, and have greater community acceptance than injected vaccines 
[9]. However, despite the intensive efforts devoted to developing mucosal 
vaccination strategies, only few, for example a vaginal vaccine against 
recurrent urinary tract infection [204] or oral vaccination against cholera [9] 
have reached the level of clinical evaluation. Some of the reasons for the 
poor progression of mucosal vaccination strategies from laboratory 
evaluations to commercialization are discussed below.
1.2.3.1 Im m u n otoléran ce. Oral administration of high doses of soluble 
antigen induces antigen-specific tolerance [205]. Such immunotolérance is 
the result of anergy [205] and prevents inappropriate immune responses 
being mounted against innocuous antigens. At low doses, tolerance is the
result of active cytokine-mediated (TGF-p and IL-4) suppression of the
immune response by T cells induced by vaccination [205]. Low antigen 
doses, such as those in mucosal vaccines, can induce antigen-specific 
tolerance at the mucosal surface, rendering the vaccine ineffective [206, 
207].
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1.2.3.2 Innate m echanism s. Orally or intranasally administered antigens are 
cleared rapidly by the action of innate physical and chemical protective 
mechanisms (for example bronchociliary clearance in the respiratory tract, 
and gastric acids and proteolytic enzymes in the gastro-intestinal tract) [119], 
possibly contributing to the lack of responses to some mucosal vaccines. 
The relatively small surface area of the mucosa-associated lymphoid tissues 
compared to the large surface area of the mucosal epithelium also makes 
targeting of mucosal vaccines more difficult than for peripherally 
administered vaccines [82,129, 208, 209].
A recent study by Wira et al [122] suggested that antigen presentation, and 
therefore the response to mucosal vaccination, in the female reproductive 
tract may be enhanced or suppressed at different stages of the reproductive 
cycle by changes in the levels of hormones such as oestradiol and 
progesterone. If so, then the stage of the reproductive cycle at the time of 
vaccination may be another important consideration for a successful 
outcome following vaccination. Thapar et al [82] for example, housed 
female mice adjacent to male mice in order to induce oestrus concurrently 
with daily vaginal application of vaccine-laden tampons. Even so, no 
antibody production occurred locally.
1.2.3.3 A n atom ical subcom partm entalization  o f  the com m on m u cosal 
im m une system. One of the major attractions for the development of 
mucosal immunization strategies is the capacity of lymphoblasts 
originating from mucosa-associated lymphoid tissues to specifically
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migrate to other mucosal sites [127, 130-132, 136, 148]. This migration 
pattern has the potential to generate protective immune responses at 
distant mucosal sites [136]. Ruedl et al (1993) [133] for example, 
demonstrated that oral immunization enhanced the host response in the 
respiratory tract against a number of respiratory pathogens. In another 
study by Yoshimura et al (1991) [210], intraduodenal and intragastric 
immunization decreased the morbidity in guinea pigs from otitis media. 
Vancott et al (1994) [211] also demonstrated that the antigen-specific 
antibody secreting cells generated by oral immunization migrated to the 
bronchus-associated lymphoid tissues and were associated with complete 
protection against porcine respiratory corona virus.
However, despite such optimistic results, subcompartmentalization of 
mucosal lymphoid tissues into different anatomical regions actually results 
in restricted migration patterns of immune lymphocytes [136]. Holmgren et 
al (1996) [212], for example, found that intranasal immunization stimulated 
strong IgA responses in the upper respiratory tract and vagina, but not the 
gut. Vancott et al (1994) [211] found that intranasal immunization against 
transmissible gastroenteritis virus only partially protected mice against 
enteric viral infection, whereas oral immunization provided complete 
protection. In studies by Haneberg et al (1994) [213], Holmgren (1996) [212] 
and McDermott et al (1996) [214] oral immunization elicited good im m une 
responses in saliva, upper gut and duodenum, but not the lower gut, 
rectum, or upper respiratory tract. Conversely, an intrarectal route was the 
best means for eliciting lower gut and rectal responses, but did not elicit
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responses in the upper gut or at more distant sites [212, 213]. Similarly, oral 
immunization with an oral cholera vaccine induced only weak antibody 
responses in the female genital tract compared to direct local intravaginal 
immunization [129]. Kozlowski et al (1997) [208] found that significant 
rectal, vaginal or oral antibody responses were only obtained by local 
immunization at the respective sites. These observations currently place 
strong limitations on the practical usefulness of certain mucosal 
vaccination routes for eliciting protective immunity at distant mucosal 
sites.
Different approaches have been used to improve the responsiveness to 
mucosal vaccines. The quantity of antigen administered and the number or 
frequency of vaccine doses is often much greater for mucosal vaccines than 
is necessary using peripheral vaccination strategies [89, 148, 215]. Because of 
this, practical and economic considerations are an important factor.
Alternatively, the suitability of a number of mucosal adjuvants that 
overcome mucosal tolerance and increase the immunogenicity of antigens 
is current under evaluation [21, 215, 216]. Cholera toxin [217], the cholera 
toxin B subunit [148, 195], Escherichia coli heat labile toxin [218], muramyl 
dipeptide [136] and iscoms [73] are all effective at overcoming mucosal 
tolerance to orally administered vaccines. However, because of the potential 
for adverse side-effects, such as bystander responses against normal flora, 
adjuvant toxicity, or local inflammation, the safety of some of these 
formulations is still being evaluated [3, 9, 136]. A number of alternative
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vaccine delivery systems, including live attenuated recombinant bacterial 
and viral vaccines [6,194, 218-220] or liposome-entrapped vaccines [221], that 
may overcome tolerance and bypass the problems of toxicity, are also being 
investigated.
1.2.4 Mucosal immunity and peripheral vaccination
Central to the tenet that peripheral immunization routes are unable to elicit 
protective levels of mucosal immunity is the finding that T cells in mucosa- 
associated lymphoid tissues predominantly secrete Th2 cytokines (IL-4, IL-5, 
TGF-P), which promote IgA production and secretory immune responses 
[145], whereas T cells in systemic lymphoid tissues predominantly secrete 
Thl cytokines (IL-2, IFN-y), which promote serum antibody responses.
Flowever, Daynes and Araneo [145, 222] have demonstrated that T cells 
within a particular lymphoid compartment are not irreversibly committed 
in a functional sense to effect either Thl or Th2 responses, but may be re­
programmed in v ivo  by the use of immunomodulators. They found that 
mice immunized subcutaneously, concurrently with topical applications of 
1,25-dihydroxy vitamin D, a natural immunosuppresant [223], switched 
from Thl to Th2 cytokine production, causing antigen-specific IgA 
production [145].
In fact, there are many examples in the literature where mucosal im m une 
responses are elicited alongside systemic responses following peripheral 
immunization strategies as diverse as intra-muscular [82, 209, 224],
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subcutaneous [202], and intradermal immunizations [102, 161]. One 
explanation for the ability of peripheral immunization routes to elicit 
significant mucosal immune responses may be the immunomodulatory 
properties of adjuvants used in the vaccination regimes, such as iscoms [82], 
Freund's adjuvant [225] and SAMA4 [102]. Alternatively, peripheral 
immunization routes may be inherently capable of mucosal im m une 
responses. Whether immunization without the use of adjuvant elicits the 
same response has not been tested in these cases.
The intradermal route is not as frequently used for vaccination as the 
intramuscular and subcutaneous routes [1]. However, previous studies have 
shown that intradermal vaccination can elicit greater and more rapid 
immune responses [1, 226], and with much smaller antigen doses [227] than 
the other routes. Recently, the intradermal route has also been shown to be 
more effective for eliciting antigen-specific responses to DNA vaccines than 
either intrasplenic or intranasal immunizations [228]. Chin et al [100, 103] 
demonstrated that bacterial antigens complexed with the adjuvant, SAMA4, 
stimulated strong antigen-specific IgG and IgA antibodies in the respiratory 
tract washings of intradermally immunized sheep and pigs. When other 
adjuvants were used intradermally instead of SAM A4 (incomplete Freund's 
adjuvant, aluminium hydroxide, or algammulin, cholera toxin B or antigen 
entrapped in microspheres) mucosal immune responses were not elicited 
[102].
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One reason for the ability of the intradermal route to effectively stimulate 
both mucosal and systemic antibody responses may be that the skin, like the 
mucosal surfaces of the gut, lung and reproductive tract, is a natural site 
where exogenous antigens are encountered. As a result the dermis of the 
skin is well endowed with specialized lymphoid tissues and a 
comprehensive range of immune effector cells capable of rapidly initiating
immune responses [228]. Damaged kératinocytes produce IL-1, IL-6, TNF-a 
and heat shock proteins that rapidly activate and recruit APC and 
lymphocytes to the site of injury [229]. Langerhans cells, a dendritic cell that 
resides in the skin, macrophages and polymorphs located in the skin can 
phagocytose antigen, rapidly migrate to skin-draining lymph nodes and 
initiate immune responses [35, 230].
1.3 PROJECT AIMS
The demonstration by Chin et al [100-103] that intradermal im m unization 
with SAMA4-containing vaccines induces antigen-specific systemic and 
mucosal immunity is significant given that such responses are major public 
health and veterinary objectives for disease prevention. The effect of 
immunizing via the intradermal route and the effect of SAMA4 on the 
immune response remain poorly characterized, in particular, the nature and 
extent of changes to leukocyte populations following immunization, and
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the importance of these changes for eliciting the final immunological 
outcomes. In this context, the objectives of this project were:
• To examine by flow cytometry the effects of intradermal im m unization 
on the distribution of leukocyte populations in lymphoid and non­
lymphoid compartments of the mouse (Chapters 2, 3 and 4).
• To assess the humoral and cellular immune response in mice to 
intradermal immunization (Chapters 5 and 6).
• To examine in mice the protective efficacy of an intradermal vaccine 
against the mucosal pathogen A. pleuropneumoniae (Chapter 7).
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CHAPTER 2
Flow Cytometric Analysis of 
Leukocyte Populations in 
Intradermally Immunized Mice
2.1 INTRODUCTION
Most studies of adjuvant action focus on the ability of adjuvants to enhance 
humoral immune responses against co-administered antigens [11, 26, 28, 31, 
34, 35, 44, 82, 126, 231]. Consequently there has been little advance in 
understanding the mechanisms of adjuvant action. Earlier studies [13, 14, 34, 
126] provided useful insights into adjuvants, such as identifying substances 
with adjuvant properties, describing differences in the rate of antigen 
clearance from the injection site [35] or mode of antigen presentation by 
different adjuvants [17, 44, 125], and identifying macrophage activation and 
alteration of lymphocyte recirculation patterns as a fundamental action of 
many adjuvants [14-16, 41]. However, as documented by Nervig et al [11] 
and Powell et al [8], the development of a wide range of adjuvants that differ 
in formulation and delivery routes has made it difficult to study or compare 
the mechanisms of adjuvant action. It is also significant that despite 
intensive research efforts, and the development of a plethora of adjuvants, 
very few adjuvants are registered for use in commercial vaccines [39].
Previous studies have demonstrated that antigens complexed with the 
liposome-iscom hybrid adjuvant, SAMA4, can stimulate IgG and IgA 
responses in the respiratory, reproductive and gastrointestinal tracts, and 
serum antibodies when given intranasally or intradermally [100-102]. 
Intradermal injection of SAMA4-adjuvanted ovalbumin also generates 
strong antigen-specific T cell cytotoxicity (described in Chapter 6 and
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published elsewhere [102]). Therefore, this adjuvant was used as a model to 
investigate the effect on leukocyte populations in mice.
To examine the adjuvant effect of SAM A4, outer membrane proteins (OMP) 
from the Gram-negative bacterium, Actinobacillus p leu ropn eu m on iae , 
were complexed with SAMA4. Antibodies specific against OMP are present 
in convalescent sera of infected swine and are important for protection 
against disease [232-236]. Additionally, OMP are extensively shared between 
the different A. p leu ropn eu m on iae  serovars [237] and may provide cross­
protection against different serovars. To attribute cellular changes to the 
individual effects of antigen, adjuvant or adjuvanted antigen, mice were 
also immunized intradermally with adjuvant (SAMA4) or antigen (OMP) 
alone. Flow cytometry provided a simple technique for quantifying the 
effects of immunization with the different components.
2.2. MATERIALS AND METHODS
2.2.1 Mice
Female BALB/c mice aged 8 to 12 weeks were purchased from a commercial 
supplier (CSIRO Animal Production and Processing Facility, North Ryde, 
Australia) and maintained at 23±1 °C under a 12 h diurnal cycle. Antibiotic­
free commercial mouse pellets and water were supplied ad libitum.
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Outer membrane proteins (OMP) were purified from A ctinobacillus 
pleur opneumoniae, serovar 1, strain HS54 [238] as described previously [239, 
240]. Briefly, bacteria were centrifuged (10,000 g for 20 min at 4 °C) and 
washed three times with sterile saline (0.85% NaCl) before being 
resuspended in 10% (w/v) sucrose dissolved in 10 mM N2-
hydroethypiperazine N'-2-ethane sulfonic acid (HEPES) buffer, pH 7.2, 
containing 5 mM phenylmethylsulfonylfluoride (PMSF; Sigma, St. Louis, 
MO, USA). Total bacterial cell homogenates were prepared with 3 cycles in a 
20 K French pressure cell at 845 kg cm2. Cellular debris and particulate 
matter were removed by centrifugation (10,000 g  for 30 min at 4 °C). Total 
membrane vesicles in the supernatant were pelleted by ultracentrifugation 
(150,000 g  for 90 min at 4 °C) through 20% sucrose in 10 mM HEPES, pH 7.2. 
Inner membrane protein vesicles were extracted with sodium laurel 
sarcosinate (SLS) at a final concentration of 2% w/v (in 10 mM HEPES, pH 
7.2). The suspension was rotated overnight at 4 °C and then layered onto a 
discontinuous sucrose gradient composed of successive layers of 20, 40 and 
60% (w/v) sucrose (in 10 mM HEPES, pH 7.2) and centrifuged at 150,000 g  for 
90 min at 4 °C. The band at the 40%/60% interface was aspirated and diluted 
with 10 mM HEPES, pH 7.2 before centrifugation at 150,000 g  for 90 min. The 
resulting pellet of outer membrane proteins was resuspended in 10 mM 
HEPES, pH 7.2.
2.2.2 Preparation of outer membrane proteins
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An adjuvanted vaccine was prepared by complexing OMP with SAMA4, a 
skin and mucosal adjuvant, as described previously [102]. Briefly, OMP (1 
mg/ml) was solubilized in 0.1% MEGA-10 (decanoyl-N-methylglucamide; 
Sigma) prepared in 4.5 ml of a 25 mM HEPES, 0.15 M NaCl, pH 7.4 buffer. 
OMP-containing liposomes were formed by sonicating OMP (Branson 
Sonifier Cell Disruptor B15 with microtip attachment; 70% full power, 3 x 1  
min cycles) in the presence of N-(l-(2,3-dioleoyloxy)propal)-N,N,N- 
trimethyl-ammonium methyl sulphate (DOTAP; Boehringer M annheim , 
Castle Hill, NSW, Australia). Im m unostim ulating complexes (iscoms) [69] 
were prepared by mixing the liposomes with 0.2% MEGA-10 (final 
concentration), 0.75 mg phosphatidyl choline, 0.75 mg cholesterol and 0.06% 
Quil A (Superfos Biosector a/s, Frydenlundsvej 30, DK-Vedbaek, Denmark). 
The mixture was rotated slowly overnight at room temperature. SAMA4 
was prepared in an identical manner, except that OMP was excluded from 
the formulation.
Each dose of OMP in the vaccine or as antigen given alone, delivered a 
maximum of 30 pg protein, determined by a commercial bicinchoninic acid-
based protein estimation kit (Pierce Chemical Co., Illinois, USA) and 0.6 ng
Quil A. Mice (65 per group) were vaccinated intradermally with 100 ¡ti of
either PBS, pH 7.2 (Control group), SAMA4 (Adjuvant group), OMP (OMP 
Antigen group) or SAMA4-OMP (OMP Vaccine group) on Days 0 and 7. 
Before injection, an area on the middle to upper back of the mouse was
2.2.3 Vaccine preparation and im m unization schedule
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shaved using hair clippers. A fold of skin was held between the index finger 
and thumb and the preparation injected at one site. A vesicle or blister 
formed at the injection site and disappeared over several hours. On Days 0, 
1, 3, 6, 8, 11, 14, 21 and 28, four mice from each group were euthanased by
intraperitoneal injection with 50 îl of 300 mg/ml sodium pentobarbitone 
(Jurox, Silverwater, NSW, Australia). Mice were exsanguinated and the 
spleen, lung and thymus were removed.
2.2.4 Tissue processing and recovery of cells for flow cytometry
Spleens were teased in ice-cold FACS buffer (PBS containing 1% {v/v} foetal 
calf serum {FCS} and 0.1% {w/v} NaN3, pH 7.2) and released cells were 
pelleted by centrifugation (200g for 10 min at 4 °C). Erythrocytes were 
removed by hypotonic lysis in 4.5 ml of distilled water. Isotonicity was 
restored immediately by the addition of 0.5 ml of Hanks Balanced Salt 
Solution (10 times normal concentration; Trace Scientific, Clayton Vic, 
Australia) and 5 ml of ice-cold FACS buffer. The cells were centrifuged and 
resuspended in ice-cold FACS buffer. Thymocytes were obtained by gently 
forcing the thymus through a stainless steel sieve. The cells were pelleted by 
centrifugation (200g for 10 min at 4 °C) and resuspended in ice-cold FACS 
buffer.
Peripheral blood leukocytes (PBL) were prepared from blood samples pooled 
from pairs of mice in each group. Erythrocytes were lysed with 0.83% 
ammonium chloride lysing buffer (0.83% {w / v}N H 4C1, 0.1% {w/v}KH C03,
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and 0.004% {w/v} Na4EDTA) [241]. PBL were washed three times in ice-cold 
FACS buffer.
Lung cell suspensions were prepared by collagenase-digestion of lung tissue 
[242, 243]. Briefly, the pulmonary vasculature in euthanased mice was 
perfused through the pulmonary artery with PBS, pH 7.2. Lungs were then 
removed, finely minced with a scalpel blade and suspended in 10 ml of 
RPMI-1640 (Life Technologies, Mulgrave, Vic, Australia) supplemented with 
10% (v/v) newborn calf serum (NBS; Life Technologies), 150 U/ml 
collagenase type VIII, EC 3.4.24.3 (Sigma) and 50 U/ml deoxyribonuclease I, 
EC 3.1.21.1 (Sigma). The tissue pieces were shaken at 250 rpm for 90 min at 37 
°C on a benchtop flask shaker (Adolf Kuhner AG Basel CH Minishaker) and 
then passed through a stainless steel sieve to remove undigested debris. 
Filtered cells were washed twice with ice-cold FACS buffer.
Each batch of collagenase was tested before routine use to determine to 
optimum concentration for release of cells from lung tissue. Lungs were 
removed from mice (n = 5) and divided into equal portions by weight. Lung 
pieces were minced and digested with different amounts of collagenase and 
the numbers of viable cells recovered enumerated with a haemocytometer 
(Reichert Scientific Instruments, Buffalo, NY, USA). Fig. 2.1 shows the cell 
recovery for one batch of collagenase.
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2.2.5 Histology
Spleens were removed from freshly killed mice belonging to the Control 
and OMP Vaccine groups and fixed in 10% (v/v) phosphate-buffered 
formalin. The spleens were embedded in paraffin using standard techniques.
Sections of 1 ¡im thickness were prepared and stained with haematoxylin 
and eosin (H&E) for microscopic examination.
15-1
75 U/ml 150 U /m l 150 U /m l 300 U/ ml 530U/ml 
90 min 45 min I----------------------|----------------- *
90 min
Digestion Conditions
FIGURE 2.1. Optimization of collagenase activity for digestion of lung tissue 
for lot 83H6846.
2.2.6 Phenotypic staining of cells
Routinely, cell numbers were quantified using a haemocytometer and cell 
suspensions adjusted to 2 x 107 cells/ml with ice-cold FACS buffer. 1 x 10 
cells (in 50 \d of ice-cold FACS buffer) were added to each well of a 96-well 
round-bottom plate and incubated for 5 min at room temperature with 0.02
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M-8 anti-Fcy n/IH monoclonal antibody, clone 2.4G2 (Pharmingen, San
Diego, CA, USA) to decrease non-specific Fey II/Ill-mediated antibody
binding to different cell types. Cells were then incubated with anti-m urine 
monoclonal antibodies obtained from Pharmingen (Table 2.1).
TABLE 2.1. List of antibodies used for flow cytometry
Specificity Label Class Clone Reference
C D 3 - e F IT C H a m s te r  IgG 1 4 5 -2 C 1 1 [244]
T h y  1 .2 F IT C R a t IgG 2b 3 0 -H 1 2 [244]
a ß  T cell re c e p to r F IT C H a m s te r  IgG H 5 7 -5 9 7 [245]
yô T  cell r e c e p to r P E H a m s te r  IgG G L3 [244]
C D 4 FIT C  o r  P E R a t Ig G 2 a R M 4 -5 [244]
C D 8 a P E  o r  B io tin R a t Ig G 2 a 5 3 -6 .7 [244]
C D l l b  ( M a c - l a M ) B io tin R a t IgG 2b M l /  70 [246]
G r-1 P E R a t IgG 2b R B 6 -8 C 5 [247]
C D 4 5 R /B 2 2 0 P E R a t Ig G 2 a R A 3 -6 B 2 [248]
The different antibody cocktails contained combinations of 0.04 pg of FITC- 
conjugated anti-CD3 (clone 145-201), 0.04 pg of PE-conjugated anti-CD4 
(clone RM4-5), 0.04 pg of PE-conjugated anti-CD45R/B220 (clone RA3-6B2), 
0.05 pg PE-conjugated anti-Gr-1 (clone RB6-8C5), 0.2 pg of biotin-conjugated 
anti-Mac-1 (clone M l/70) or 0.1 fig of biotin-conjugated anti-CD8a (clone 53­
6.7) in a total volume of 50 pi. Cells were incubated in the dark at 4 °C for 40
min and then washed three times by repeated centrifugation (300g for 5 m in 
at 4 °C) and resuspension in ice-cold FACS buffer. Cells stained with
biotinylated conjugates were incubated with 0.1 pg streptavidin-Cy-chrome
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(Pharmingen) dissolved in 100 ¡al FACS buffer at 4 °C for another 40 min and
washed as previously described. Cells were fixed in 200 1̂ of FACS Lysing 
Solution (Becton-Dickinson, Mountainview, CA, USA) for flow cytometry.
2.2.7 Flow cytometry
Flow cytometry of cells was performed using a FACSORT (Becton- 
Dickinson) equipped with a 15 mW air cooled argon-ion laser operating at a 
fixed wavelength of 498 nm. The fluorescent signals were collected through 
a 530 nm filter for FITC (FL1), a 585 nm filter for PE (FL2) and a 630 nm filter 
for Cy-chrome (FL3). Optimal instrument settings were established before 
each run according to the manufacturer's instructions (Table 2.2). Identical 
preparations of cells were stained with species-matched immunoglobulin 
isotype controls (purchased from Pharmingen) to determine positive and 
negative cut-offs. FSC (forward light scatter) and SSC (side light scatter) 
parameters were recorded linearly and fluorescence intensity recorded 
logarithmically. A minimum of 10,000 events were acquired and data were 
stored in list mode for each sample.
Acquired data was analysed with CellQuest research software (Becton- 
Dickinson). Fig 2.2a depicts leukocyte populations separated on the basis of 
their FSC and SSC properties. Fig. 2.2b and Fig. 2.2C, respectively, depicts the 
same cells separated on the basis of the fluorescent intensity of specific 
fluorescent cell surface markers. Cells located in the lower left quadrant were 
considered negative for both cell surface markers, while cells located in the
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upper right quadrant were positive for both cell surface markers. Cells 
located in the upper left or lower right were positive for the corresponding 
cell surface marker. The identity of different leukocyte populations was, 
therefore, deduced from the level of expression of fluorescent cell surface 
markers (Table 2.3).
TABLE 2.2. Typical FACSort instrument settings for detection of three- 
colour fluorescence
Parameter Voltage Amp Gain Mode
Detectors
FSC EOO 1.65 Linear
SSC 372 1.00 Linear
FL1 653 1.00 Log
FL2 554 1.00 Log
FL3 641 1.00 Log
Compensation
FL1 - %FL2 0.4
FL2 - %FL1 36.5
FL2 - %FL3 2.6
FL3 - %FL2 17.8
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FIGURE 2.2. (a) Two-dimensional FSC/SSC dot plot of a splénocyte 
suspension. Region RI corresponds to acquired events having light scatter 
attributes of lymphocytes and monocytes. Region R2 corresponds to acquired 
events with light scatter attributes of granulocytes, (b) Two-dimensional dot 
plot of the same splenocyte suspension stained with FITC-anti-CD4 and 
Biotin-anti-CD8 cell surface markers (c) Two-dimensional dot plot of the 
same splenocyte suspension stained with PE-anti-Gr-1 and Biotin-anti-Mac-1 
cell surface markers.
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Absolute cell numbers for the different phenotypes were obtained by 
multiplying the total cell counts for each cell suspension obtained using a 
haemocytometer [249] by the percentage value obtained by flow cytometry.
TABLE 2.3. Cell surface expression of 
leukocyte populations
leukocyte markers by different
Leukocyte Population CD3 CD4 CD8 B220 Gr-1 Mac-1
T helper cells + + - - - -
T cytotoxic cells + - + - - -
B cells - - - + - -
Monocyte / macrophage - - - - - +
Granulocytes -  - - - + +
+ : Denotes positive for cell surface expression;
Denotes negative for cell surface expression
2.2.8 Assessment of thymocyte viability by flow cytometry
In a separate experiment, in v iv o  cell necrosis and apoptosis in the thymus 
from the different groups (3 mice per group) were determined, at 12 h 
intervals over a 60 h period, following intradermal immunization. To assess 
cell necrosis, thymocytes were stained with 0.1% trypan blue (Sigma) for 2 
min and enumerated with a haemocytometer. A large number of methods 
are available for detecting apoptosis in cells [250-265]. Staining cells with 
either a hypotonic solution of propidium iodide [252] or 7-amino 
actinomycin D [253] are two such methods routinely employed for the
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detection of apoptosis in vitro. Therefore, a preliminary experiment was 
conducted to establish instrument parameters for detection of apoptosis by 
flow cytometry using these methods.
A stock solution of dexamethasone (10'3 M) was prepared by dissolving 
0.0043 g of dexamethasone Acetate (Sigma) in 10 ml AR ethanol. The stock 
solution was diluted 100-fold with RPMI-1640 supplemented with 54 mg/ml 
sodium benzyl penicillin (Commonwealth Serum Laboratories, Parkville, 
Australia), 90 mg/ml streptomycin sulfate (CSL), 2mM L-glutamine 
(Cytosystems, Castlehill, NSW, Australia), 2 mM sodium pyruvate
(Cytosystems) 58 mM (3-mercaptoethanol (Biorad, North Ryde, NSW, 
Australia) and 10% (v/v) FCS (Life Technologies).
Pooled thymocytes from 2 female BALB/c mice aged 8 to 12 weeks were 
obtained as described above. Dexamethasone was used to induce apoptosis in 
murine thymocytes [264]. Aliquots of 2 x 106 cells were resuspended to a final 
volume of 2 ml in dexamethasone to give final dexamethasone 
concentrations ranging from 10'5 to KT8 M. Cells were incubated in 24 well 
tissue culture plates for 21 h in a humidified 5% C 02 incubator at 37 °C.
22.8.1 Hypotonic Propidium Iodide M ethod. 1 ml of each thymocyte 
suspension was centrifuged (200 g  for 10 min at 4 °C) and gently resuspended
with 1 ml hypotonic propidium iodide (PI) solution (50 fxg/ml propidium 
iodide {Pharmingen} in 0.1% {w/v} tri-sodium citrate {BDH, Poole, England}
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plus 0.1% {v/v} Triton X-100 {Sigma}) in 12 x 75 ml polypropylene tubes 
(Technoplas, St.Mary's, Australia). The tubes were stored overnight at 4 °C in 
the dark before flow cytometry [252]. The propidium iodide fluorescent 
signals of individual nuclei were acquired at a low flow rate on the flow 
cytometer through the 585 nm filter (FL2) and the data recorded on a linear 
scale. FSC and SSC were simultaneously measured on a logarithmic scale. 
FL2-area and FL2-width were measured on a linear scale and used to exclude 
cell debris and dead cells as previously described [266]. A minimum of 10,000 
events were collected per sample. Apoptotic and live cells displayed 
measurable area versus width parameters, whereas debris demonstrated 
negligible width or area and low FSC and SSC parameters. Data was stored in 
list mode and analysed using CellQuest research software (Becton- 
Dickinson). Logarithmic scale histograms for cells in cell cycle were obtained 
[266]. Using this technique, apoptotic nuclei were distinguished by their 
hypodiploid DNA content from the diploid DNA content of normal nuclei.
22.8.2 7-amino-actinomycin-D m ethod . Thymocytes were initially stained 
with FITC anti-CD4 and PE anti-CD8 antibodies, as described in above. For 
detection of apoptosis cells were washed twice in PBS, pH 7.2, resuspended
in 200 pi of 20 pg/ml 7-amino actinomycin D (7-A AD; (Calbiochem, La Jolla,
CA, USA) in ice-cold FACS buffer and incubated at 4 °C in the dark for at 
least 20 min before flow cytometry [253]. At least 10,000 events were collected 
using a FACSORT through the 530 nm filter for FITC (FL1) and the 585 n m 
filter for PE (FL2). The red fluorescence from 7-AAD was collected through
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the 630 nm filter (FL3). Data was recorded on a logarithmic scale. FSC and 
SSC were simultaneously measured on a logarithmic scale. Cell debris was 
excluded by raising the FSC threshold. The correct threshold value was 
selected experimentally. Dead, apoptotic and live cells were distinguished by 
logarithmic scale dot plots of phenotypically gated subpopulations [266].
2.2.9 Assessment of natural killer (NK) cell cytotoxicity in intradermally 
immunized mice
22.9.1 Im m unization o f mice. BALB/c mice (2 per group) were 
intradermally immunized with 100 \d of either PBS, pH 7.2 (Control group),
SAMA4 (Adjuvant group), OMP (OMP Antigen group) or SAMA4-OMP 
(OMP vaccine group) on Days 0 and 7. Mice were kept at 23 ± 1 °C under a 12 
h day/night cycle. Antibiotic-free commercial mouse pellets and water were 
supplied ad libitum.
2.2.92 Positive control for  assessment of NK cell activity. Splenic NK cells 
were generated by subcutaneously immunizing one mouse with 5 x 106 
plaque-forming units (pfu) of Semliki Forest Virus (SFV) on one occasion 
[267]. These cells were used as a positive control.
2.2.9.3Target cell lines used and 51 Chrom ium -labelling o f target cells. NK- 
susceptible YAC-1 thymoma cells and NK-resistant P815 mastocytoma 
tumour cells were provided by Dr Arno Mullbacher (Division of 
Immunology and Cell Biology, John Curtin School for Medical Research).
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YAC-1 and P815 target cells were suspended at a concentration of 6 x 106 
cells/ml in 500 pi of F15 medium (Gibco-BRL, Life Technologies, Mulgrave,
Vic, Australia) supplemented with 5% (v/v) FCS and incubated with 100 pi
of 6 mCu/ml 51Cr (Amersham, Arlington Heights, IL, USA) for 1 h at 37 °C. 
Cells were washed twice and resuspended in F15 medium to give a final cell 
concentration of 2 x 105 cells/ml.
22.9.4 Phenotyping of effector cells. Splenocyte suspensions (107 cells/ml) 
were prepared in F15 medium as described in Chapter 6, Section 6.2.4. 
Splenocytes were obtained from the SFV-immunized mouse on Day 2 post­
infection and from intradermally immunized mice on Day 9 (Day 2 post­
immunization). To determine the phenotype of the effector cell 
populations, splenocytes were selectively depleted by treatment with 
antibodies and complement. Cells (107) were incubated for 30 to 40 min at 4 
°C with either 50 pi of anti-Thy 1.2 (Serotec, Australian Laboratory Services,
Rockdale, Australia; clone F7D5; 1/400 dilution), 250 pi of anti-CD8 (Olac,
Bicester, Oxon, UK; clone 31M; 1/30 dilution) or 100 pi of anti-asialo GM: 
(Wako Chemicals, US; 1/100 dilution). Cells were incubated for a further 45 
min at 37 °C after adding 100 pi of rabbit complement (Low Tox M; Cedar
Lane Laboratories, Hornby, Ontario, Canada). Following incubation, cells 
were washed twice in F15 medium and resuspended in 1 ml of the same 
medium for use in NK cell assays.
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2.2.9.5Measurement of NK cell activity. NK cell activity was assayed by a 6 h 
51Cr-release assay as described elsewhere [267]. Splenocytes (effector cells) 
were assayed in triplicate for cytotoxicity against 2 x 104 51Cr-labelled YAC-1 
target cells by incubating cells at effector-to-target ratios ranging from 30:1 to 
1:1. After incubating cells at 37 °C for 6 h in a humidified C 02 incubator, 100
pi of cell-free supernatants were removed and the radioactivity measured in 
a gamma-counter. To measure non-specific cytotoxicity, splenocytes were 
incubated with 51Cr-labelled P815 mastocytoma tumour cells in a similar 
fashion. Spontaneous 51Cr release was determined by incubating 51Cr- 
labelled target cells in culture medium. Maximal 51Cr release was 
determined by incubating 51Cr-labelled target cells in 2% Triton X-100. 
Percentage cytotoxicity was calculated as follows:
% cytotoxicity = Experimental release - spontaneous release x 100%
Total release - spontaneous release
2.2.10 Statistical analyses
Except for the assessment of thymocyte viability, the experiments described 
were repeated on three separate occasions. The results reported here 
represent the combined mean (± standard error of the mean, or sem). The 
means of different groups at individual time points were compared by two­
tailed Students f-test. Changes were considered significant at P < 0.05.
Chapter 2 page 48
2.3 RESULTS
2.3.1 Cellular changes in the spleen following intradermal immunization
No significant differences were detected in the body weights of mice in the 
different groups following immunization (Fig. 2.3a). Over the same period, 
the spleens of mice in the OMP Vaccine group increased in weight and were 
significantly heavier than the spleens in all other groups between Day 3 (P < 
0.05) and Day 21 (P < 0.0005) (Fig. 2.3b). The spleens of mice in the Adjuvant 
group also increased in weight by 2-fold on Day 3 (P < 0.008) before declining 
by Day 8. In response to the booster injection with adjuvant, spleen weight 
increased again (2-fold) at Day 11 (P < 0.01) in the Adjuvant group. 
Thereafter spleen weight returned to normal by Day 21. Smaller increases in 
spleen weight of about 1.4-fold were observed between Days 11 and 14 in 
mice belonging to the OMP Antigen group (P < 0.0005).
Splenocyte numbers in the different treatment groups remained unchanged 
following primary immunization (Fig. 2.4) but rose significantly (2- to 3-fold) 
in all groups (except controls) in response to booster immunization, 
reaching a peak at Day 8 (P < 0.02). Splenocyte numbers in mice belonging to 
the OMP Antigen group returned to normal levels rapidly whereas 
splenocyte elevations in mice from the Adjuvant group were sustained for a 
slightly longer period. The greatest and most sustained elevations in 
splenocyte numbers were elicited following booster immunization of mice 
in the OMP Vaccine group. Splenocyte numbers in this group did not return 
to normal until Day 21.
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Day
FIGURE 2.3. Temporal change in (a) total body weight and (b) spleen weight 
of mice from Control (unfilled squares), OMP Antigen (unfilled diamonds), 
Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups 
following intradermal immunization. Each data point represents the mean 
(± sem) of at least 4 mice per group. Arrows designate the time of 
vaccination.
FIGURE 2.4. Temporal change in total splenocyte numbers in mice from 
Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant 
(filled circles) and OMP Vaccine (filled diamonds) groups following 
intradermal immunization. Each data point represents the mean (± sem) of 
at least 4 mice per group. Arrows designate the time of vaccination.
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The proportion of granulocytes (Mac-1+Gr-1+) increased significantly (3-fold) 
by Day 3 after primary immunization in mice from the OMP Vaccine group 
(P < 0.001) (Fig. 2.5). This rise was enhanced by a further 4.6-fold following 
the second injection, peaking between Days 8 to 11 (P < 0.005). The 
proportion of granulocytes declined thereafter but remained significantly 
elevated for greater than 28 days (P < 0.0005). Injection of either antigen or 
adjuvant elicited much smaller increases in granulocyte numbers over the 
same period, with the second injection having no booster effect. By contrast, 
splenic macrophages (Mac-1+Gr-T) rose much more slowly following 
vaccination, and then only less than 2-fold in mice from the OMP Vaccine 
group (Fig. 2.6).
Significant changes in splenic T cells (CD3+CD4+ and CD3+CD8+) or B cells 
(CD3'B220+), as a proportion of total lymphocyte numbers, were not detected 
by flow cytometry over 28 days in all groups (Fig. 2.7a to c). This was most 
likely because only relatively few T or B cell clones had specificity toward the 
administered antigen. Small discrepancies in total percentages of phenotypes 
reflected the sum of errors generated from a) variations between different 
experiments; b) lack of absolute cut-off points for positivity of staining; and 
c) the sum of percentages from different stains. This result demonstrated 
that, although immunization did not significantly alter the total lymphocyte 
population, antigen-specific T and B cell clones were stimulated by 
im m unization.
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FIGURE 2.5. Temporal change in the percentage of Gr-1+Mac-1+ cells 
(granulocytes) in the spleens of mice from Control (unfilled squares), OMP 
Antigen (unfilled diamonds), Adjuvant (filled circles) and OMP Vaccine 
(filled diamonds) groups following intradermal immunization. Each data 
point represents the mean (± sem) of at least 4 mice per group. Arrows 
designate the time of vaccination.
Day
FIGURE 2.6. Temporal change in the percentage of Gr-TMac-l+ cells 
(macrophages) in the spleens of mice from Control (unfilled columns), OMP 
Antigen (hatched columns), Adjuvant (stippled columns) and OMP Vaccine 
(filled columns) groups following intradermal immunization. Each data 
point represents the mean (± sem) of at least 4 mice per group.
Chapter 2 page  52
Histological analysis of spleen sections was conducted to examine changes 
elicited by intradermal immunization. At Day 11, H&E sections showed that 
splenic lymphoid nodules were comparable in size and number in both 
Control and OMP Vaccine groups. However, compared to Controls (Fig. 
2.8a), the red pulp in mice from the OMP Vaccine group was greatly 
expanded, due to congestion with blood, with an increased frequency of 
megakaryocytes (Fig. 2.8b). Oedema was also indicated by the separation of 
red pulp from the subcapsular region and an increase in interstitial space. 
Compared to mice from the Control group, the prominent myeloblasts and 
metamyelocytes in the red pulp adjacent to trabeculae indicated an increase 
in splenic haematopoiesis in mice in the OMP Vaccine group, (Fig. 2.8c and 
d). The peri-arteriolar sheaths were more prominent in mice from the OMP 
Vaccine group than in the Control group, with many of the macrophages 
surrounding the arterioles also having fine cytoplasmic vacuolations. 
Together, these observations suggested increased phagocytic activity, arising 
from immunization [16]. Pyknotic debris and mitotic figures were more 
noticeable in mice from the OMP Vaccine group than in mice from the 
Control group (Fig. 2.8c and d).
2.3.2 Cellular changes in the lung following intradermal immunization 
Prior to their removal, the vasculature of individual lungs was perfused 
extensively with PBS to minimize contamination of lung cell preparations 
with leukocytes from the peripheral circulation. Total recoverable cell 
numbers in collagenase-digested lung tissue from the four treatment groups 
did not change significantly over the 28-day period (2.9a). However,
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FIGURE 2.7. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells) 
and (c) CD3'B220+ cells (B cells) in the spleens of mice from Control (unfilled squares), OMP Antigen (unfilled 
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal immunization. 
Each data point represents the mean (± sem) of at least 4 mice per group.
FIGURE 2.8. Spleens taken on Day 11 following primary immunization 
from mice belonging to the Control (a and c) and OMP Vaccine groups (b 
and d) showing cellular changes following immunization. Note increase in 
megakaryocytes (1) and polymorphs (2) in mice from the OMP Vaccine 
group compared to mice from the Control group. Note also increased 
haematopoiesis along trabeculae (3) with myeloblasts (4), metamyelocytes (5) 
and mitotic figures (6) being more prominent in the OMP Vaccine group 
compared to Controls, (a and b) x 100 magnification, (c and d) x 400 
magnification.
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granulocyte numbers increased significantly as a proportion of total cell 
numbers in the lungs of mice from the OMP Vaccine group at Day 3 (P < 
0.005) (Fig. 2.9b). This increase was attributed to extravasation of granulocytes 
(predominantly polymorphonuclear leukocytes, or PMN) into the lung 
interstitium. The increase in interstitial granulocytes in the lungs was 
significantly enhanced (10-fold) by the second vaccine injection, peaking at 
Day 11 (P < 0.00001). Granulocyte numbers then returned to normal by Day 
28. In mice from the OMP Vaccine group the temporal changes in lung 
granulocytes coincided with the changes detected for splenic granulocytes. 
An increase in cells with monocyte/macrophage morphology was also 
observed in the interstitium of H&E-stained sections of lung tissues. The 
increase in this cell type in the lungs was not quantified, however. Injection 
of either adjuvant or antigen alone elicited relatively minor increases (2 to 
2.5-fold) in the proportion of lung granulocytes (P < 0.05). The proportion of 
CD3+CD4+, CD3+CD8+ and CD3'B220+ populations remained unchanged in all 
groups over this period (Fig. 2.10).
2.3.3 Cellular changes in peripheral blood following intradermal 
immunization
The leukocyte distribution in peripheral blood can provide a measure of 
leukocyte homeostasis throughout the body [268-270]. Therefore, peripheral 
blood leukocytes (PBL) populations were quantified on Days 3, 14 and 21 
following immunization (Table 2.4). Compared to all other groups, PBL 
numbers in mice belonging to the OMP Vaccine group rose significantly (2.3- 
fold) by Day 3 (P < 0.05) and continued to be significantly elevated (3-fold) at
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Day
FIGURE 2.9. Temporal change in (a) total cell numbers and (b) the 
percentage of Gr-1+Mac-1+ cells (granulocytes) in the lungs of mice from 
Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant 
(filled circles) and OMP Vaccine (filled diamonds) groups following 
intradermal immunization. Each data point represents the mean (± sem) of 
at least 4 mice per group. Arrows designate the time of vaccination.
Day 14 (P < 0.05), before returning to normal by Day 21. Increases at Day 3 in 
these mice were due to elevations in both granulocytes and monocytes. 
Blood granulocyte numbers rose significantly (5-fold) by Day 3 and remained 
elevated at Day 14 (P < 0.02) before returning to normal by Day 21. Blood 
monocyte numbers also rose significantly (3-fold) by Day 3 (P < 0.05) and 
remained elevated (4-fold) at Day 14 (P < 0.05) before returning to normal by 
Day 21. Blood granulocyte, but not monocyte, numbers rose significantly (2­
fold) at Day 14 in mice from the OMP Antigen group (P < 0.01). Blood 
granulocyte or monocyte numbers did not change significantly in mice from 
the Adjuvant group over this period.
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FIGURE 2.10. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T 
cells) and (c) CD3'B220+ cells (B cells) in the lungs of mice from Control (unfilled squares), OMP Antigen (unfilled 
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal 
immunization. Each data point represents the mean (± sem) of at least 4 mice per group. Arrows designate the time 
of vaccination.
TABLE 2.4. Changes in total leukocyte, granulocyte and monocyte numbers 
in the peripheral blood of mice belonging to Control, OMP Antigen, 
Adjuvant and OMP Vaccine groups at Days 3, 14 and 21 following 
intradermal immunization. Results show the mean (± sem) of 4 mice in 
each treatment group.
Post-immunisation Day:
Group 3 14 21
Total Control 3.1 ± 0.6 1.7 ±0.6 4.2 ± 0.8
Cell No. Adjuvant 2.7 ± 0.3 2.2 ± 0.9 3.6 ± 0.1
(x 106/ml) Antigen 1.6 ± 0.8 3.3 ± 0.2 4.4 ± 0.9
Vaccine 7.0 ± 0.5 5.2 ± 0.1 3.6 ± 0.6
Total Control 6.9 ±1.9 3.9 ±0.1 11.7 ± 3.2
Granulocytes Adjuvant 6.5 ± 1.4 3.1 ± 1.0
00o+1rHOO
(x 10^/ml) Antigen 4.8 ± 1.7 9.1 ± 0.4 10.5 ± 2.3
Vaccine 36.0 ± 3.6 13.1 ± 2.7 13.4 ± 0.4
Total Control 4.4 ± 1.1 3.3 ± 1.9 8.5 ± 1.6
Monocytes Adjuvant 4.6 ± 1.6 4.9 ± 2.2 7.1 ± 0.8
(x lO^/ml) Antigen 3.1 ± 1.6 5.7 ± 0.2 9.4 ± 2.1
Vaccine 13.1 ± 1.7 13.1 ± 0.4 6.3 ± 1.5
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2.3.4 Cellular changes in the thymus following intradermal 
immunization
Total thymocyte numbers decreased in all groups following immunization 
(Fig. 2.11). In mice belonging to the OMP Vaccine group, cell numbers 
declined by 95% within 3 days after primary immunization (P < 0.002). 
Thymocyte numbers in this group remained low until Day 11 (P < 0.0005) 
before spontaneously climbing to be significantly greater (by 50%) than all 
other groups at Day 28 (P < 0.005). The supranormal thymocyte numbers in 
the Vaccine group at Day 28 probably reflected a period during which 
baseline thymocyte levels were being re-established. Much smaller 
thymocyte losses occurred in Control (25%), Adjuvant (65%) and OMP 
Antigen groups (57%) within 6 days after primary immunization. These 
losses were not statistically significant. Thymocyte numbers in these groups 
spontaneously returned to normal by Day 8 and did not elicit further 
declines as a result of booster immunization.
The decline in thymocyte numbers in mice from the OMP Vaccine group 
was predominantly due to loss of CD3'CD4+CD8+ double positive (DP) cells 
(Fig. 2.12). DP cells in these mice declined by 88% within 3 days after primary 
immunization (P < 0.02). Cell numbers returned to about 50% of normal 
levels by Day 8 but booster immunization caused another drop in DP cells to 
about 25% of pre-immunization levels by Day 11 (P < 0.004). Thereafter, DP 
cells returned to normal by Day 21. DP cell numbers also fell by 50% within 3 
days after the first adjuvant injection in the Adjuvant group, but this fall 
was not significant due to the variability of responses between individual
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FIGURE 2.11. Temporal change in total thymocyte numbers in mice from 
Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant 
(filled circles) and OMP Vaccine (filled diamonds) groups following 
intradermal immunization. Each data point represents the mean (± sem) of 
at least 4 mice per group. Arrows designate the time of vaccination.
FIGURE 2.12. Temporal change in DP cell numbers in mice from Control 
(unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant (filled 
circles) and OMP Vaccine (filled diamonds) groups following intradermal 
immunization. Each data point represents the mean (± sem) of at least 4 
mice per group. Arrows designate the time of vaccination.
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mice. Absolute declines in CD3CD4CD8*, CD3+CD4+CD8‘ and CD3+CD4CD8+ 
cells following immunization were also elicited in mice belonging to the 
OMP Vaccine group (Fig. 2.13a to d). Similar losses were not evident in mice 
belonging to the Control, Adjuvant or OMP Antigen groups.
2.3.5 Assessment of thymocyte viability by flow cytometry following 
intradermal immunization
In a preliminary experiment, cells stained with a hypotonic solution of 
propidium iodide displayed a diploid DNA peak (M2) which constituted 
about 83% of total DNA, a minor broad peak (Ml) in the hypodiploid range 
(6% of total DNA) to the left of the diploid DNA, and a small peak (M3) 
corresponding to supradiploid DNA (2% of total DNA) to the right of the 
diploid DNA region Fig. 2.14a. All concentrations of dexamethasone 
induced apoptosis in treated cells. Fig. 2.14b shows a histogram of cells 
treated overnight with 10'5 M dexamethasone and stained with hypotonic 
propidium iodide. Treated cells displayed a greatly increased hypodiploid 
peak (Ml: 72 to 77% of total DNA) relative to the size of the diploid peak 
(M2: 10 to 17% of total DNA), and little supra diploid DNA (M3).
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FIGURE 2.13. Temporal change in the numbers of (a) CD3 CD4 CD8' cells, (b) CD3+CD4+CD8' cells and (c) CD3+CD4 CD8 
cells in the thymus of mice from Control (unfilled squares), OMP Antigen (unfilled diamonds), Adjuvant (filled 
circles) and OMP Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents 
the mean (± sem) of 3 mice per group.
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FIGURE 2.14. Histogram plots of thymocytes that were incubated overnight 
in (a) culture medium or (b) culture medium supplemented with 10'5 M 
dexamethasone. Regions M l, M2 and M3 represent the hypodiploid, diploid 
and supradiploid DNA regions, respectively.
Cells stained with 7-A AD divided into 3 groups as described elsewhere [241]. 
Non-apoptotic cells were 7-AAD', early apoptotic were 7-AADdim, and late 
apoptotic or dead cells were 7-AAD+. On this basis the majority of untreated 
cells (84%) were non-apoptotic, with a smaller percentage being apoptotic 
(8%) or dead (8%) after overnight incubation in culture medium (Fig. 2.15a).
All dexamethasone-treated cells showed a decline in the percentage of live 
cells (7-AAD*), and an increase in early apoptotic cells (7-AADdim) and late 
apoptotic and dead cells (7-AAD+). Fig. 2.15b is depicts cells treated overnight 
with 10'5M dexamethasone and stained with 7-AAD. The percentages of 7- 
AAD', 7-AADdim and 7-AAD+ after dexamethasone treatment were 62%, 25% 
and 12%, respectively.
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FIGURE 2.15. Contour plots of thymocytes that were incubated overnight in 
(a) culture medium or (b) culture medium supplemented with 10'5 M 
dexamethasone. Regions Rl, R2 and R3 represent the live, early apoptotic 
and late apoptotic or dead cells, respectively.
Both methods allowed discrimination between live, apoptotic and dead cells 
following treatment with dexamethasone. In addition, the 7-AAD staining 
method allowed simultaneous discrimination of cells on the basis of 
phenotype.
Assessment of thymocyte loss over the first 60 h period following primary 
vaccination demonstrated that total viable thymocyte numbers in the OMP 
Vaccine group fell to plateau within the first 36 h (Fig, 2.16a). Viable cell 
numbers in the Adjuvant group declined more slowly over the same 
period, while no significant changes were observed in the Control and OMP 
Antigen groups. Surprisingly, dead (trypan-blue positive) cell numbers did 
not increase above the background level in any group (Fig. 2.16b) even 
though viable cell numbers fell, and a significant increase (6-fold) in the
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FIGURE 2.16. Temporal change in the numbers of (a) total viable thymocytes, (b) total dead thymocytes and (c) the 
percentage of apoptotic DP cells in the thymus of mice from Control (unfilled squares), OMP Antigen (unfilled 
diamonds), Adjuvant (filled circles) and OMP Vaccine (filled diamonds) groups following intradermal immunization. 
Each data point represents the mean (± sem) of 3 mice per group.
level of thymocyte apoptosis (measured using 7-AAD) was detected within 
24 h in the OMP Vaccine group (P < 0.05) (Fig. 2.16c).
2.3.6 NK cell cytotoxicity in intradermally immunized mice
Splenocytes from SFV-immunized mice were used as a positive control for 
NK cytotoxicity because these cells are strongly cytotoxic against NK- 
sensitive YAC-1 target cells (Fig. 2.17a) [267]. The cytotoxicity of SFV 
splenocytes was almost completely abrogated (84% decline) by depletion of 
effector splenocytes with anti-asialo-GM! antibody plus complement (Fig. 
2.17b). The NK cytotoxic activity of splenocytes from SFV-immunized mice 
was partially abolished (33% decline) following treatment with anti-Thy 1.2 
plus complement (Fig. 2.17c), but was unaffected by treatment with anti-CD8 
plus complement (Fig. 2.17d). By comparison, Control mice had low 
background NK activity. These results were consistent with previous 
findings by Mullbacher and King (1989) indicating that NK cells had a Thy
1.2"CD8’asialo-GM1+ phenotype [267].
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FIGURE 2.17. Percentage residual splenic cytotoxic activity in mice from 
Control (unfilled columns), Adjuvant (hatched columns), OMP Antigen 
(stippled columns), OMP vaccine (filled columns) and SFV infection groups 
(wavy). Figures show residual activity following treatment with either (a) 
complement only (b) anti-asialo-GM! plus complement, (c) anti-Thy 1.2 plus 
complement or (d) anti-CD8 plus complement. Values represent the mean 
of triplicate cultures.
Splenocytes from the Adjuvant, OMP Antigen and OMP Vaccine groups had 
low NK activity, ranging from 1 to 17%. The level of NK activity was 
unaffected by selective depletion of splenocytes with anti-Thy 1.2, anti-CD8 
or anti-GMr
C hap ter 2 page  68
2.4 DISCUSSION
Flow cytometry was used to compare changes in leukocyte populations 
following intradermal immunization. The simultaneous multiparameter 
measurements possible with flow cytometry allowed differentiation of cell 
populations in heterogeneous cell suspensions prepared from different 
tissues with minimal number of purification steps, such as gradient density 
centrifugation, which have the potential to cause artefactual losses of total 
cell numbers and specific cell groups [271]. Flow cytometric detection of light 
scattering through selected angular ranges by cells provides information 
about relative cell size (forward light scatter, or FSC) and surface complexity 
(side light scatter, or SSC), allows discrimination of cell debris and dead cells 
from live cells, and can be used to distinguish between different cell 
populations, for example, erythrocytes, lymphocytes, monocytes and 
granulocytes [271]. Additionally, fluorescent light emissions at different 
wavelengths by fluorophores like fluorescein isothiocyanate, phycoeurythin 
and cy-chrome bound to antibodies against specific cell markers provide 
information on the relative proportions of different cell populations in the 
sample [271].
The effect on leukocyte populations was assessed in mice following 
intradermal immunization with either SAMA4-OMP (OMP Vaccine group), 
SAMA4 alone (Adjuvant group), OMP antigen alone (OMP Antigen group) 
or PBS (Control group). The significant change in cell numbers in the OMP 
Vaccine group may have resulted from systemic toxic effects of Quii A, as
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reported by others [37, 59, 69, 79]. However, while some contribution of 
adjuvant toxicity to changes in cell numbers cannot be excluded, the
amount of Quil A administered in each SAMA4 dose was only 0.6 \xg. This
value is 20-fold lower than that used by other groups for the formulation of 
systemic adjuvants [69, 78]. Certainly, the much less dramatic changes in cell 
numbers seen when SAMA4 was administered on its own argued against 
Quil A toxicity as a major cause of changes in leukocyte populations.
From previous work done by others [272-275] demonstrating the necrotic 
effects of bacterial toxins or LPS, it was also possible that the presence of one 
or more toxic bacterial components in the purified OMP preparations may 
contribute to the observed cellular changes. If so, then one would expect that 
intradermal immunization with OMP alone would elicit similar cellular 
changes to those seen in the OMP Vaccine group. The strain of A. 
pleur opneumoniae  used to purify OMP produces at least one strongly 
haemolytic and cytotoxic RTX toxin, APX1 [276-278]. However, this toxin was 
not detected in OMP preparations, either by SDS-PAGE or immunoblotting 
with anti-haemolysin antibodies (Chapter 7). OMP preparations alone were 
also unable to induce necrotic cell death in in vitro analyses (J. Chin, 
personal communication). Another inducer of inflammation produced by 
Gram-negative bacteria is lipopolysaccharide (LPS). Capsular polysaccharides 
and LPS were detected in OMP preparations (Chapter 6). However, because 
identical amounts of the same OMP batch were used to immunize mice in 
the OMP Antigen and OMP Vaccine groups, one would expect almost
Chapter 2 page 70
identical responses in both groups if LPS mediated the cellular changes 
detected. The absence of a strong cellular response in all other groups clearly 
indicated that the cellular responses elicited by the OMP Vaccine group were 
due to a synergistic interaction between the antigen and adjuvant 
components.
An increase in the numbers of myeloblasts, macrophages, granulocytes 
(predominantly immature polymorphonuclear leukocytes) and 
megakaryocytes in the splenic red pulp of mice in the OMP Vaccine group 
contributed to the increases in spleen size following the second 
immunization. Granulocytes and macrophages are recognized as major 
components of inflammatory and immunological reactions in the body 
[279]. During the period of heightened cellular activity these cell types 
emigrate in a non-random fashion to the site of inflammation where they 
are involved in host defense, and to the draining lymph nodes and spleen 
where they participate in generation of adaptive immune responses [35, 104, 
106]. In mice, activation of innate immune responses during periods of 
heightened demand for phagocytic cells, for example, during infection or 
stress, results in upregulation of splenic haematopoiesis [280, 281]. It was 
possible, based on the flow cytometric and histological data, that the cellular 
changes following immunization were also due to upregulated splenic 
haematopoiesis. The rapid increases in circulating Gr-l'Mac-l+ cells 
(macrophage/monocytes) in the OMP Vaccine group may also have been 
complemented by the recruitment of tissue macrophages and the release of 
monocytes from the bone marrow [106].
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The increased numbers of granulocytes and monocyte/macrophage 
numbers in the lung tissue of the OMP Vaccine group were consistent with 
an increase in the numbers of cells that had undergone margination and 
extravasation into the lung intersitium [282]. The increased numbers of 
granulocyte and macrophage trafficking through lymphoid and non­
lymphoid tissues thus reflected the systemic effects of intradermal 
immunization. Unlike the small cellular changes seen in the blood, spleens 
and lungs of mice in the Adjuvant or OMP Antigen groups, intradermal 
immunization with SAMA4-OMP complexes was effective in evoking a 
strong innate cellular response.
NK cells are also an important component of the innate immune response. 
Chronic NK cell deficiency, for example, is often associated with an 
increased susceptibility to infection [283] and enhanced tumour susceptibility 
[284]. NK cells also modulate differentiation of haematopoietic progenitor 
cells during myelopoiesis in vitro [285] and B cell genesis in the bone 
marrow in vivo  [286]. Increased NK cytotoxic activity may therefore, have 
been an important additional component of the overall response, especially 
in the OMP Vaccine group.
Like human NK cells, murine NK cells express cell surface markers that 
allow them to be phenotypically quantified by flow cytometry [287-291]. In 
mice, these markers include NK1.1, Thy 1, Mac-1 and asialo-GMj [287, 288, 
292, 293]. Unfortunately, these markers are also expressed by other murine 
cell types, such as monocytes, granulocytes and thymocytes [119, 294]. The
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monoclonal antibody, PK136, used to detect expression of NK1.1, is the most 
specific for identifying NK cells [295], but does not react with NK cells in 
BALB/c mice. The lack of suitable NK-specific markers in BALB/c mice 
precluded the use of flow cytometry in this study. Instead, splenic NK cell 
activity was assessed by an in vitro cytotoxicity assay as previously described 
[267]. Increases in NK cytotoxic activity were not detected following 
immunization in any group, suggesting little involvement by this cell type. 
However, at least one other study [296] has also reported the lack of 
detectable NK cell cytotoxicity following immunization. It was possible that 
omission of steps to specifically enrich for NK cells may have compromised 
the sensitivity of the assay performed in these studies.
In the thymus, the rapid depletion of thymocytes following primary and 
secondary immunization with OMP vaccine was predominantly due to loss 
of DP cells, although all other thymocyte phenotypes were also affected. DP 
cells are highly susceptible to changes in the thymic micro-environment,
and an array of conditions, such as, viral infection [297], y-irradiation [298],
chemical toxicity [299, 300], withdrawal of growth factors and increased 
glucocorticoid levels [301] can increase cell necrosis and apoptosis. 
Surprisingly, significant thymic depletion induced by vaccination is 
unreported, but was seen in the current study to be an important event. 
Enumeration of dead and apoptotic cells also demonstrated that most of 
these cells did not accumulate intrathymically. These results are consistent 
with other studies [259, 302, 303] suggesting that dead or dying cells are very
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rapidly phagocytosed by resident macrophages. Alternatively, it has also 
been suggested that apoptotic cells die extrathymically [304, 305].
The inability of adjuvant or OMP alone to induce such strong thymic 
depletion was consistent with the weaker inflammatory responses observed 
in these mice. The rapidity and magnitude of thymocyte loss in the OMP 
Vaccine group together with the small (6-fold) but significant increase in 
apoptosis occurring within 24 h post-immunization, suggested a 
hormonally induced rather than activation-induced mechanism of cell 
death [301, 306]. If such prominent thymocyte loss has any physiological 
significance and is not simply an irrelevant "bystander" response, then one 
possibility may be that rapid loss of immature thymocytes prevents 
tolerance being inappropriately induced against a strong immunogen 
(SAMA4-adjuvanted OMP). The supranormal thymocyte levels later in the 
post-immunization period reflected an interval of increased T cell 
production, potentially shifting the antigenic repertoire of developing cells 
toward those with greater specificity for the immunizing antigen. 
Intrathymic circulation of activated leukocytes or antigen from the 
periphery increases during an immune response [307-309] and may also 
have provided an antigen-driven stimulus for increased turnover of T cells.
A strong innate immune response is necessary for induction of strong 
adaptive immune response [116]. The strong adjuvant activity of SAMA4 is 
reflected in its ability to evoke strong innate immune responses, 
particularly, the recruitment of PMN. The finding of qualitatively similar
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cellular changes following immunization with SAMA4-ovalbumin (OVA) 
complexes (Chapter 3) also indicates that the adjuvant effect is probably 
independent of antigen-type. Since intradermal immunization with OVA 
alone (OVA Antigen group) did not elicit antigen-specific antibody (Chapter 
5) or cytotoxic responses (Chapter 6), these data suggest that complexing of 
antigen with SAMA4 enhances the immunogenicity of antigens and 
promotes their efficient uptake and processing by phagocytic cells.
The changes elicited when SAMA4 is complexed with different antigens 
may be similar to the effects elicited by other adjuvants. Although such 
effects have not been specifically investigated for most adjuvants, 
knowledge of the presence and extent of changes to the immune system may 
be helpful for developing vaccines whose components are efficacious and 
safe. As demonstrated here, flow cytometric measurement of post­
immunization changes in the cell populations that are targeted by vaccines 
can provide a precise measure of the effects of vaccination.
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CHAPTER 3
Effect of Antigen-type on 
Cellular Changes in
Intradermally Immunized Mice
3.1 INTRODUCTION
Complexing bacterial OMP with SAMA4 elicited a rapid cellular immune 
response in intradermally immunized mice. The possibility that the 
responses elicited were due to toxic components present in OMP 
preparations or the adjuvant was small since mice given only OMP or 
SAMA4 alone elicited much weaker cellular responses. The significantly 
greater response obtained when OMP and SAMA4 were complexed 
suggested that antigen and adjuvant acted synergistically. Nevertheless, it 
was not known whether the changes described in Chapter 2 were 
representative of the type of biological responses that would be elicited when 
other antigens were similarly complexed with the adjuvant. To determine 
this, groups of mice were intradermally immunized mice with ovalbumin 
(OVA), a simple, well-characterized [35, 98, 99, 310, 311] and innocuous 
protein antigen [312], either alone or complexed with SAMA4.
It is noteworthy that OVA is also a hydrophilic protein. Hydrophilic proteins 
are incorporated poorly into iscoms, resulting in low immunogenicity [39]. 
A number of different methods have been used to increase the 
hydrophobicity of hydrophilic proteins and enhance their uptake by iscoms. 
These methods include covalent attachment of palmitic acid [76, 99], 
chemical denaturation to expose hydrophobic residues [55, 98], or chemical 
coupling to hydrophobic carrier proteins [64, 65, 88]. Chin et al [100-102] 
demonstrated that antigen uptake into iscoms can be facilitated by first 
entrapping antigens within liposomes. This approach retains the biological
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properties of iscoms, but with superior rates of incorporation of hydrophobic 
or hydrophilic proteins [102]. As part of this current study, the magnitude of 
the cellular changes elicited following intradermal immunization with 
SAMA4 complexes containing unmodified OVA or palmitoylated OVA was 
also compared.
3.2 MATERIALS AND METHODS
3.2.1 Preparation of palmitoylated ovalbumin
Ovalbumin, (Grade III; Sigma) was chemically modified by palmitoylation (J. 
Chin, personal communication). Briefly, OVA (50 mg dissolved in 50 ml
borate buffer/saline, pH 8.8) was combined with 300 pi palmitoyl chloride
(Sigma) suspended in 20 ml anhydrous ether. The mixture was slowly 
rotated for 3 days at 25 °C and then dialysed extensively against PBS, pH 7.2 
for 48 h at 25 °C.
3.2.2 Immunization of Mice and Sampling Schedule
OVA vaccine, palmitoylated OVA (POVA) vaccine or OMP vaccine were 
prepared by complexing OVA, POVA or OMP with SAMA4, respectively, as 
described in Chapter 2. Female BALB/c mice aged 8 to 12 weeks (52 per
group) were immunized intradermally with 100 pi of either PBS, pH 7.2 
(Control group), OVA (OVA Antigen group) or SAMA4-OVA (OVA 
Vaccine group) on Days 0 and 7. Mice received 30 pg protein, as determined
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by a commercial bicinchoninic add-based protein estimation kit (Pierce), in 
each dose of OVA antigen or OVA vaccine. Because the cellular responses in 
the previous study with the OMP vaccine returned to normal by Day 28 
following vaccination (Chapter 2), in this study, the cellular changes in the 
spleen, lung and thymus were assessed on Days 0, 1, 3, 6, 8, 11, 14 and 21. 
Single-cell suspensions were prepared, enumerated using a haemocytometer 
and stained for flow cytometry as described in Chapter 2.
The responses to OVA and POVA were compared in a separate experiment. 
Mice (8 per group) were intradermally immunized with 100 ¡̂ 1 of either PBS, 
pH 7.2 (Control group), SAMA4-OVA (OVA Vaccine group) SAMA4-POVA 
(POVA Vaccine group) or SAMA4-OMP (OMP Vaccine group). Mice were 
euthanased as described above on Days 11 and 14. Single-cell suspensions 
were prepared from pooled spleens, thymi or lungs were stained for flow 
cytometric analysis as described in Chapter 2.
3.2.4 Statistical analyses
The mean values in the different groups at individual time points were 
compared by two-tailed t-test. Changes were considered significant at P < 
0.05.
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3.3 RESULTS
3.3.1 Cellular changes in the spleen following intradermal immunization 
with OVA
Total body weights of mice in the different treatment groups did not change 
significantly during the 21-day period following immunization (Fig. 3.1a). 
Neither did spleen weights of mice from the Control or OVA Antigen 
groups change significantly over this period (Fig 3.1b). By comparison the 
spleens of mice in the OVA Vaccine group increased in weight (almost 2.5- 
fold) and were significantly heavier than spleens in either Control or OVA 
Antigen groups between Days 3 (P < 0.005) and 14 (P < 0.0001). Spleen 
weights in the OVA Vaccine group returned to normal by Day 21.
Splenocyte numbers did not change significantly following primary 
immunization in the different groups (Fig. 3.2a). Following the second 
injection, however, cell numbers rose (2-fold) in the OVA Vaccine group, 
reaching a peak at Day 11 (P < 0.02). Thereafter, cell numbers returned to pre­
immunization levels between Days 14 to 21. The increase in total splenocyte 
numbers was predominantly due to an increase in Gr-1+Mac-1+ cells, or 
granulocytes. The proportion of granulocytes in mice from the OVA Vaccine 
group increased significantly (2-fold) to a peak at Day 1 (P < 0.05) before 
dropping again by Day 3 (Fig. 3.2b). The second injection elicited a greater 
increase (5-fold), peaking at Day 8 (P < 0.05) before also returning to normal 
levels by Day 14. Splenic granulocyte numbers in mice from the OVA 
Antigen group changed only slightly over the same period.
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FIGURE 3.1. Temporal changes in (a) total body weight and (b) spleen weight 
of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds) 
and OVA Vaccine (filled diamonds) groups following intradermal 
immunization. Each data point represents the mean (± sem) of 4 mice per 
group. Arrows designate the time of vaccination.
FIGURE 3.2. Temporal changes in (a) total splenocyte numbers and (b) Gr- 
1+Mac-1+ cells (granulocytes) in mice from Control (unfilled squares), OVA 
Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds) groups 
following intradermal immunization. Each data point represents the mean 
(± sem) of 4 mice per group. Arrows designate the time of vaccination.
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CD3+CD4+, CD3+CD8+ and CD3'B220+ cells, which represent helper T cell, 
cytotoxic T cell and B cell phenotypes, respectively, did not change 
significantly as a proportion of the total lymphocyte numbers in the spleens 
of Controls, OVA Antigen or OVA Vaccine groups over the first 21 days 
after immunization (Fig. 3.3a-c). However, in parallel studies, significant 
increases in serum OVA-specific antibody levels (Chapter 5) and strong 
cytotoxic T cell activity (Chapter 6 and [102]) demonstrated that antigen- 
specific T and B cell clones were stimulated by immunization.
3.3.2 Cellular changes in the lung following intradermal immunization
Total cell numbers in collagenase-digested lung tissue from mice belonging 
to the OVA Vaccine group increased after the second immunization (Fig. 
3.4a). By comparison, cell numbers in the other groups did not change 
significantly over the 21-day period. Flow cytometry demonstrated a 
significant (6-fold) increase in the granulocyte population, peaking 1 day 
after the first OVA vaccine dose (P < 0.005) before returning to normal by 
Day 6 (Fig. 3.4b). Granulocyte numbers rose again, by almost 10-fold, one day 
after the second OVA Vaccine dose (P < 0.02) and rapidly returned to normal 
by Day 14. In the OVA Antigen group, granulocyte numbers rose briefly (4­
fold) between Days 1 and 3 (P < 0.02) but were unaffected by the second 
antigen injection. CD3+CD4+, CD3+CD8+ and CD3'B220+ cell populations did 
not change significantly in the lungs of mice from the OVA Antigen and 
OVA Vaccine groups over the 21-day period (Fig. 3.5a-c).
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FIGURE 3.3. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells) and (c) 
CD3'B220+ cells (B cells) in the spleens of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds) and OVA 
Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents the mean (± sem) of at 
least 4 mice per group.
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FIGURE 3.4. Temporal changes in (a) total cell numbers and (b) Gr-1+Mac-1+ 
cells (granulocytes) from the lungs of mice from Control (unfilled squares), 
OVA Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds) 
groups following intradermal immunization. Each data point represents the 
mean (± sem) of 4 mice per group. Arrows designate the time of vaccination.
3.3.3 Cellular changes in the thymus following intradermal
im m unization
Thymocyte numbers were unaffected by either one or two injections of OVA 
antigen (Fig. 3.6a). However, intradermal injection of OVA vaccine triggered 
a significant decline in thymocyte numbers, which fell by greater than 90% 
by Day 6 after the first injection (P < 0.02). Thymocyte numbers in this group 
remained low until Day 8 before spontaneously returning to normal levels 
by Day 21 (P < 0.002). The period of thymocyte depletion in the OVA Vaccine 
group was not as prolonged as previously observed in the OMP Vaccine 
group following the second vaccine dose (Chapter 2).
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FIGURE 3.5. Temporal change in the percentage of (a) CD3+CD4+ cells (T helper cells), (b) CD3+CD8+ (cytotoxic T cells) and (c) 
CD3"B220+ cells (B cells) recovered from the lungs of mice from Control (unfilled squares), OVA Antigen (unfilled diamonds) 
and OVA Vaccine (filled diamonds) groups following intradermal immunization. Each data point represents the mean (± 
sem) of at least 4 mice per group.
The decline in thymocyte numbers in the OVA Vaccine group was due 
predominantly to the loss of DP cells (Fig. 3.6b). DP cell numbers in this 
group fell by greater than 90% in the first 6 days (P < 0.02) before 
spontaneously returning to normal levels. The rate of recovery of DP cell 
was unaffected by the second OVA vaccine injection. By comparison, 
CD4+CD8', CD4"CD8+ and CD4CD8' subpopulations were unaffected by 
intradermal immunization with OVA antigen or OVA vaccine (Data not 
shown).
FIGURE 3.6. Temporal changes in (a) total thymocyte numbers and (b) 
CD4+CD8+ cells (DP cells) in mice from Control (unfilled squares), OVA 
Antigen (unfilled diamonds) and OVA Vaccine (filled diamonds) groups 
following intradermal immunization. Each data point represents the mean 
(± sem) of 4 mice per group. Arrows designate the time of vaccination.
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3.3.1 Comparison of cellular changes following intradermal 
immunization with OVA, POVA and OMP vaccines 
The OVA Vaccine and POVA Vaccine groups elicited almost identical 
increases in spleen weight (Fig. 3.7a), splenocyte (Fig. 3.7b) and granulocyte 
numbers (Fig. 3.7c) on Days 11 and 14. However, these increases were less 
prominent than the changes detected in the OMP vaccine group over the 
same period (Chapter 2). The percentage of T or B cells in the different 
Vaccine groups remained unchanged at Days 11 and 14 (data not shown).
In the lungs, total cell numbers changed only slightly in the different 
Vaccine groups at Days 11 and 14 (Fig, 3.8a). The proportion of granulocytes 
in the lungs of the OVA Vaccine and POVA Vaccine groups rose by 
equivalent amounts at Day 11 before returning to normal by Day 14 (Fig. 
3.8b). However, these increases were much less than that present in the OMP 
Vaccine group. The percentage of T or B cells in the different Vaccine groups 
did not increase at Days 11 and 14 (data not shown).
Almost identical declines in thymocyte numbers were detected in the OVA 
Vaccine and POVA Vaccine groups at Days 11 and 14 (Fig. 3.9a). The smaller 
declines in thymocyte numbers in these groups, compared to the OMP 
Vaccine group, possibly reflected the timing of the measurement as well as 
the longer period of thymocyte depletion detected in the latter group. 
Although it was likely that a decline in DP cells accounted for the drop in 
total thymocyte numbers, measurements at Days 11 and 14 detected only 
minor declines in DP cells for both groups (Fig. 3.9b). By comparison, much
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FIGURE 3.8. Change in (a) total cell numbers and (b) the percentage of Gr- 
1+Mac-1+ cells (granulocytes) recovered from the lungs of mice from Control 
(unfilled columns), OVA Vaccine (hatched columns), POVA Vaccine 
(stippled columns) and OMP Vaccine (filled columns) groups following 
intradermal immunization. Each column represents the mean of 4 mice per 
group.
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FIGURE 3.9. Change in (a) total thymocyte numbers and (b) the percentage 
of CD4+CD8+ cells (DP cells) from the thymus of mice from Control (unfilled 
columns), OVA Vaccine (hatched columns), POVA Vaccine (stippled 
columns) and OMP Vaccine (filled columns) groups following intradermal 
immunization. Each column represents the mean of 4 mice per group.
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greater declines in total thymocyte and DP cell numbers were present at this 
time in the OMP Vaccine group.
3.4 DISCUSSION
In terms of the different biological responses, the findings clearly 
demonstrated that synergism between adjuvant and antigen com ponents 
was not dependent on the antigen-type. Injecting mice with SAM A4-OVA 
complexes also confirmed that the type of cellular response elicited was not a 
specific attribute of the antigen used, but most probably reflected SA M A4 
action generally. In fact, the types of cellular changes elicited in the different 
tissues following intradermal immunization with OVA vaccine or OMP 
vaccine were, temporally and phenotypically, almost identical. As predicted 
from the results in Chapter 2, the most significant cellular changes were 
triggered in the OVA Vaccine group, with few changes in the OVA A ntigen 
group.
The results demonstrated clear similarities in the cellular responses to 
different antigens complexed with SAMA4. The increases in granulocytes in  
the spleen and lungs suggested that, as for the OMP Vaccine group, 
im m unization significantly increased the recruitment of phagocytic cells. 
Although not specifically investigated, it was also possible that enhanced 
splenic haematopoiesis and recruitment of cells from different tissue sources 
played a significant role in cellular mobilization in the OVA Vaccine group,
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as in the OMP Vaccine group. The loss of DP cells in the thymus of the OVA 
Vaccine group also suggested strongly that increased apoptosis and necrosis 
was associated with intradermal immunization in this case.
In quantitative terms the duration and magnitude of the cellular changes in 
the OVA Vaccine group were less remarkable than those elicited by the OMP 
Vaccine group in Chapter 2. This is despite the fact that both OVA and OMP 
vaccines contained equivalent amounts of protein or adjuvant. One 
explanation for the weaker cellular responses was the lower incorporation of 
OVA into SAMA4. It is well established that hydrophilic proteins, such as 
OVA, are poorly incorporated into iscoms compared with amphipathic or 
hydrophobic proteins, such as membrane proteins [39, 57, 58, 60, 63, 70, 97]. 
The expectation, therefore, was that a hydrophobically modified form of 
OVA, such as palmitoylated OVA, which readily incorporates into iscoms 
[99], would elicit quantitatively greater cellular responses. Contrary to this 
expectation, the similar biological responses to immunization with 
hydrophilic (native) or hydrophobic (palmitoylated) forms of OVA indicated 
that incorporation of proteins into SAMA4 was probably similar for both 
OVA and palmitoylated OVA. OVA is a single homogeneous and 
innocuous protein antigen [312]. Therefore, it was likely that the 
quantitative differences in responses between the OVA and OMP Vaccine 
groups were due to the greater heterogeneity and molecular and antigenic 
complexity, and hence immunogenicity, of bacterial OMP.
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In summary, two dissimilar antigens gave essentially identical cellular 
responses. A mechanistic explanation for the synergism detected between 
antigen and SAMA4 requires further investigation. However, Morein et al 
[69, 92] and others [37, 59, 87] have suggested that complexing of antigen with 
iscoms slows the rate of clearance, reducing antigen loss. Induction of an 
inflammatory response and release of inflammatory cytokines by the 
accumulation of antigen-iscom complexes in skin-draining lymph nodes 
and spleen may enhance uptake and processing of antigens [39]. Binding of 
iscoms to DEC 205, a recently identified carbohydrate binding protein present 
on the surface of phagocytic cells [313] has been suggested as a mechanism for 
the greater uptake of iscoms by APC [39]. Finally, the multimeric 
presentation of antigen on the surfaces of the cage-like, pentagonal 
dodecahedral iscoms [74] is also believed to promote more efficient 
attachment and uptake of antigen and activation of phagocytic cells than 
occurs in the absence of adjuvant, or with conventional repository 
adjuvants, such as Freund's adjuvant or aluminium hydroxide [69-71].
Chapter 3 page 92
CHAPTER 4
Flow Cytometric Analysis of Cell 
Population Changes in the Bone 
Marrow of Intradermally 
Immunized Mice
4.1 INTRODUCTION
The bone marrow is the primary source of erythroid (erythrocytes), myeloid 
(monocytes/macrophages, granulocytes and megakaryocytes) and lymphoid 
(B lymphocytes, Natural Killer cells and thymus seeding progenitors) cell 
lineages which ultimately populate peripheral lymphoid and non-lymphoid 
tissues [119, 281, 314-317]. These different lineages arise from bone marrow- 
derived self-renewing multipotential cells, called haematopoietic stem cells 
[318, 319]. Lineage-committed lymphoid and myeloid cells also undergo 
further maturation and differentiation in the peripheral organ 
compartments.
Myeloid and lymphoid cell homeostasis in the peripheral tissues is 
maintained by hormonal and cytokine modulation of bone marrow 
haematopoiesis [320] and removal of activated or self-reactive cells by 
apoptosis [268, 321]. To meet the normal cellular demands for 
haematopoietic cells in the adult mouse, nearly all the bony cavities are 
filled with red marrow [280]. During periods of increased demand, such as 
infection or stress, haematopoiesis in the spleen, which is retained as a 
haematopoietic organ in the adult mouse, compensates for the lack of 
marrow reserve haematopoietic capacity [280, 322].
As the main site of synthesis for haematopoietic cell lineages, the bone 
marrow is directly affected by any provocation of the immune system, such 
as in disease [323-327]. The morphological and cellular changes detected in
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the spleen following intradermal immunization with the OMP vaccine or 
OVA vaccine described in Chapters 2 and 3, respectively, provided evidence 
of an immunization-induced increase in demand for haematopoietic cells 
and upregulation of splenic haematopoiesis. The magnitude of these 
changes also suggested that bone marrow haematopoietic activity must also 
be affected by intradermal immunization. This study examined the effects of 
intradermal immunization on the bone marrow concurrent with the 
changes observed in the other organs.
4.2 MATERIALS AND METHODS
4.2.1 Immunization of Mice and Sampling Schedule
Female BALB/c mice aged 8 to 12 weeks (15 per group) were immunized
intradermally with 100 fxl of either PBS, pH 7.2 (Control group), SAMA4
(Adjuvant Group), OMP (OMP Antigen group) or SAMA4-OMP (OMP 
Vaccine group) on Days 0 and 7.
The investigations described in Chapters 2 and 3 demonstrated that cellular 
changes in the blood, spleen or lungs were maximal (or near maximal) at 
Days 3 and 14. By Day 21 the different cell populations were returning 
toward pre-immunization levels. Based on these findings, assessment of 
changes in the different leukocyte populations in the bone marrow was
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focused at three time points, Days 3, 14 and 21 following intradermal 
immunization.
4.2.2 Tissue processing and recovery of bone marrow cells for flow cytometry 
To obtain femoral bone marrow cells, both hind femurs were removed from 
each mouse. The surrounding muscle was stripped from the bone with 
forceps and the bone marrow cells were flushed from the marrow cavity of 
each femur with 1 ml ice-cold FACS buffer. Bone marrow cells from each 
pair of femurs were combined and pelleted by centrifugation at 200 g  for 10 
min at 4 °C before being resuspended in 1 ml ice-cold FACS buffer. Cells in 
each pool of paired femurs per mouse were enumerated using a 
haemocytometer and stained for flow cytometry as described in Chapter 2.
4.2.3 Enumeration of haematopoietic progenitor cells 
Haematopoietic stems cells (HSC) can be identified in bone marrow 
preparations on the basis of their undifferentiated phenotype. It is now 
generally accepted that HSC express the leukocyte differentiation antigen, 
Thy 1.2, but lack expression of the lineage markers: B220 (B cell lineage), CD4 
and CD8 (T cell lineage), Gr-1 (granulocyte lineage) and Mac-1 
(myelomonocytic cell lineage) [318-320, 328]. Consequently HSC have a Thy 
1.2+CD4'CD8'B220'Gr-l'Mac-l' phenotype (abbreviated to Thy 1.2Tineage‘). 
HSC also have the capacity for spontaneous self-renewal [329], and are able to 
preferentially seed and repopulate lymphoid organs depleted by irradiation 
[318, 320,328, 330].
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Recovery and accurate enumeration of HSC is difficult, however [318-320]. 
To obtain an indication of the effects of immunization on HSC in this study, 
BM cells were initially identified on the basis of their forward light scatter 
properties (FSC) and surface expression of Thy 1.2 (Fig. 4.1a) [320, 328]. Thy 
1.2+ cells were then subdivided on the basis of their expression of defined 
leukocyte lineage markers (Fig. 4.1b) [320, 328]. Because of the recognized 
limitations of the method for accurately quantifying numbers of HSC 
numbers in unenriched cell preparations, cells identified by flow cytometry 
as having the phenotype, Thy 1.2+lineage", were collectively referred to as 
putative haematopoietic progenitor cells, a grouping of bone marrow cells 
that included both HSC and the immediate multilineage ancestor 
populations of lymphoid and myeloerythroid cells.
4.2.4 Assessment of Cell Viability by Flow Cytometry
Increases in apoptosis and necrosis were detected in the thymus shortly after 
intradermal immunization (Chapter 2). Because immature B-lineage cells 
undergo apoptosis during normal development in a manner analogous to 
CD4+CD8+ cells in the thymus [331], a separate in vivo  experiment was also 
conducted to determine if cell necrosis and apoptosis were increased in the 
bone marrow following immunization. The levels of apoptosis and necrosis 
were determined in groups of 3 mice at 12 h intervals over a 60 h period 
following intradermal immunization. For detection of apoptosis, BM cells 
were initially stained with PE anti-CD45R/B220 as described in Chapter 2, 
washed twice in PBS, pH 7.2 and then resuspended in 200 pi of 20 pg/ml 7-
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A AD. Cells were incubated at 4 °C in the dark for at least 20 min before FACS 
analysis. The proportion of dead, apoptotic and live B220+ cells were 
distinguished by logarithmic scale histograms [266]. To assess cell necrosis, 
bone marrow cells were stained with 0.1% trypan blue for 2 min, before 
being enumerated using a haemocytometer.
(a) (b)
Forward Scatter CD4/CD8/B220/Gr-1
FIGURE 4.1. Identification of haematopoietic progenitor cells, (a) Cells 
recovered from the femoral bone marrow were identified on the basis of 
FSC and expression of Thy 1.2. (b) Thy-1.2+ cells were further subdivided on 
the basis of their expression of the lineage markers: CD4 and CD8 (T cells), 
B220 (B cell lineage), Gr-1 (granulocyte lineage) and Mac-1 
(monocyte/macrophage lineage). Cells located in the upper left, upper right 
and lower right quadrants expressed lineage differentiation markers. Cells 
located in the lower left quadrant were phenotypically Thy 1.2+CD4'CD8’ 
B220‘G r-l‘M ac-l' and were, therefore, regarded as lineage-undifferentiated 
haematopoietic progenitor cells.
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4.2.5 Statistical analyses
The means of different groups at individual time points were compared by 
two-tailed t-test. Changes were considered significant at P < 0.05.
4.3 RESULTS
4.3.1 Changes in total bone marrow cell numbers following intradermal 
vaccination
Compared to mice in the Control group, total bone marrow (BM) cell 
numbers in each femur pair in the OMP Vaccine and Adjuvant groups 
decreased significantly (40%) by Day 3 (P < 0.05) (Fig 4.2). A smaller decline 
(25%) in BM cell numbers in mice from the OMP Antigen group at Day 3 
was not significant. Cell numbers were normal by Day 14 in all groups. At 
Day 21, however, BM cell numbers in the OMP Vaccine group were 
significantly higher (1.5-fold) than in all other groups (P < 0.01).
4.3.2 Changes in B-lineage cells follow ing intradermal vaccination
The decline in BM cell numbers at Day 3 in the OMP Vaccine or Adjuvant 
groups was predominantly due to a drop in Thy'B220+ cells, which includes 
pro- and pre-B cell precursors and mature B cells [119] (Fig 4.3). In the OMP 
Vaccine group, Thy'B220+ cells, fell to 14% of pre-immunization levels by 
Day 3 (P < 0.01). Cells numbers in this group were also low (30% of pre­
immunization levels) at Day 14 (P < 0.001) but then rose to be significantly 
higher (2.3-fold) than in controls by Day 21 (P < 0.001). At Day 21, Thy‘B220+
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FIGURE 4.2. Temporal changes in total BM cell numbers in mice following 
intradermal immunization with either PBS (unfilled columns), adjuvant- 
only (hatched columns), OMP antigen (stippled columns) or OMP vaccine 
(filled columns). Each data point represents the mean (± sem) of 4 mice per 
group.
FIGURE 4.3. Temporal changes in Thy'B220+ cells (immature and mature B 
cells) in mice following intradermal immunization with either PBS 
(unfilled columns), adjuvant-only (hatched columns), OMP antigen 
(stippled columns) or OMP vaccine (filled columns). Each data point 
represents the mean (± sem) of 4 mice per group.
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cells numbers in the OMP Vaccine group were also 20% higher than in the 
Adjuvant group (not significant at P < 0.05), and 71% higher than in the 
OMP Antigen group (P < 0.05) at Day 21. This increase in Thy'B220+ cell 
numbers to supranormal levels possibly reflected a short period of 
overcompensation before re-establishment of baseline levels.
Thy'B220+ cell numbers in the Adjuvant group fell by 76% by Day 3 (P < 0.05) 
but returned to normal by Day 14. At Day 21, Thy*B220+ cell numbers were 
significantly greater (2-fold) than in Controls (P < 0.05). Thy‘B220+ cells in the 
OMP Antigen group fell by 30% by Days 3 and remained at this level on 14. 
At Day 21 Thy*B220+ cells numbers in this group increased 1.5-fold above the 
level in the Control group.
4.3.3 Changes in granulocytic and myelomonocytic lineage cells following 
intradermal vaccination
The numbers of Mac-1+Gr-1+ cells (which includes immature and mature 
granulocyte lineage cells) did not change significantly after intradermal 
vaccination, except in the OMP Vaccine group (Fig 4.4a). In this group, Mac- 
1+Gr-1+ cell numbers rose significantly (1.6-fold) at Day 21 (P < 0.05). By 
contrast, Mac-1+Gr-T cell numbers (which includes promonocytes and 
monocytes) increased 1.7-fold in the Adjuvant (P < 0.05) and OMP Antigen 
groups (P < 0.05) and 4-fold in the OMP Vaccine group (P < 0.0002) at Day 14 
(Fig. 4.4b). Mac-1+Gr-1' cell numbers were normal in all groups at Day 21.
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4.3.4 Changes in haematopoietic progenitor cells following intradermal 
vaccination
Thy 1.2+ lineage' (CD4‘ CD8' B220" Gr-T Mac-T) haematopoietic progenitor 
cells (which includes both the primitive haematopoietic stem cells and the 
immediate multilineage ancestors of lymphoid, and myeloerythroid cell 
populations) typically accounted for less than 0.5% of total bone marrow 
cells in the femur pairs over the 21-day period. Compared to controls, 
femoral haematopoietic progenitor cell numbers dropped (60%) in both the 
OMP Vaccine and Adjuvant groups by Day 3 (P < 0.05), before returning to 
normal at Day 14 (Fig. 4.5). Haematopoietic progenitor cell numbers in the 
OMP Vaccine group were then significantly higher (1.3-fold) than in all 
other groups at Day 21 (P < 0.05). Haematopoietic progenitor cell numbers in 
the OMP Antigen group were also slightly lower than in the Control group 
on Days 3 (not significant at P < 0.05), 14 (P < 0.05) and 21 (not significant at P 
< 0.05).
4.3.5 Cell viability following intradermal immunization
Viable BM cell numbers in the Control and OMP Antigen groups did not 
decline significantly following intradermal injection (Fig. 4.6a). However, 
significant losses in viable BM cell numbers were detected in the Adjuvant 
and OMP Vaccine groups within the first 24 h post-immunization. The 
rapid decline in viable cell numbers was not associated with an increase in 
the number of dead (Fig. 4.6b) or apoptotic cells (Fig. 4.6c) in the bone 
marrow above the background level during the first 60 h post­
immunization. The decline in BM cell numbers in the first 60 h post-
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FIGURE 4.4. Temporal changes in (a) Mac-1+Gr-1 + cells (granulocyte lineage
cells) and (b) Mac-1+Gr-1" cells (monocyte lineage cells) in mice following 
intradermal immunization with either PBS (unfilled columns), adjuvant- 
only (hatched columns), OMP antigen (stippled columns) or OMP vaccine 
(filled columns). Each data point represents the mean (± sem) of 4 mice per 
group.
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FIGURE 4.5. Temporal changes in haemopoietic progenitor cell numbers in 
mice following intradermal immunization with either PBS (unfilled 
columns), adjuvant-only (hatched columns), OMP antigen (stippled 
columns) or OMP vaccine (filled columns). Each data point represents the 
mean (± sem) of 4 mice per group.
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FIGURE 4.6. Temporal changes in (a) viable bone marrow cell numbers (b) dead cells and (c) percentage apoptotic B220+ cells 
over a 60 h period following intradermal immunization in Control (unfilled squares) Adjuvant (filled circles) OMP antigen 
(unfilled diamonds) and OMP Vaccine groups (filled diamonds). Data represents the mean (± sem) of 3 mice per group. 
Arrows designate time of intradermal vaccination.
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immunization was predominantly due to a drop in both B220+ cells (Fig. 
4.7a) and granulocyte-lineage cells (Fig. 4.7b), but also included other cell 
types that were not identified phenotypically in this study (Fig. 4.7c).
4.4 DISCUSSION
This study was undertaken to determine what changes occurred in the bone 
marrow following intradermal immunization with different vaccine 
formulations. Upregulation of splenic haematopoiesis is the principal 
mechanism in mice for responding to the acute increase in demand for 
phagocytic cells [280]. Splenic haematopoiesis and splenic hyperplasia 
following administration of 89Sr [332, 333], infection with Moloney murine 
leukaemia virus [334], malaria [325] and other diseases occurs as 
compensation for the BM depletion present in these circumstances. It was 
likely that this was also true for the OMP Vaccine or OVA Vaccine groups 
following immunization. The most prominent effect of intradermal 
immunization on the bone marrow was a rapid decline in haematopoietic 
progenitor and lineage-committed cell populations, beginning within 12 to 
24 h post-immunization. The decline occurred in all the immunization 
groups, but was most striking in the Adjuvant and the OMP Vaccine groups, 
confirming an important role for the adjuvant in stimulating these events. 
This finding of significant bone marrow depletion induced by vaccination, 
like the dramatic depletion of the thymus, has not been previously reported.
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FIGURE 4.7. Temporal changes following intradermal immunization in the numbers of (a) 13220+ lineage cells, (b) 
granulocyte lineage cells and (c) all other cells in bone marrow from Control (unfilled squares), OMP antigen (unfilled 
diamonds), Adjuvant (filled circles) and OMP vaccine (filled diamonds) groups. Each data point represents the mean (± sem) 
of 3 mice per group. Arrows designate time of intradermal vaccination.
It is important to note that although the decline in cell numbers occurred in 
all the cell lineages identified, the B cell lineage suffered the greatest losses. 
Previous studies [331, 333] have estimated that at least 60 to 70% of pre-B cells 
undergo apoptosis during normal B cell, so this may account for B220+ cell 
losses. The magnitude of B220+ cell losses in the bone marrow following 
intradermal immunization was also reminiscent of the dramatic DP cell loss 
occurring simultaneously in the thymus (Chapter 2). Although newly 
formed B cells are continuously exported from the bone marrow to the 
spleen, the absence of a parallel decline in peripheral B cell numbers, or 
histological evidence of an increase in splenic lymphopoiesis suggested that 
splenic B cell numbers were not sensitive to short term changes in bone 
marrow lymphopoiesis. The suggestion by Xenocostas et al (1991) [324], that 
long-lived recirculating B cells in the spleen maintain splenic B cell levels, 
may account for these findings.
The rapidity and magnitude of BM cell depletion suggested that an increase 
in apoptosis was the most likely mechanism. Colony stimulating factors 
(CSF) and cytokines secreted by bone marrow stromal and haematopoietic 
cells control the survival, proliferation and development of BM cells [335­
337]. CSF (IL-3, Granulocyte Macrophage (GM)-CSF, Granulocyte (G)-CSF, 
Macrophage (M)-CSF, stem cell factor, IL-6) and chemokines, IL-7 and Pre-B- 
cell growth stimulating factor/stromal cell-derived factor-1 (PBSF/SDF-1), 
are essential for growth and differentiation of haematopoietic stem cells and 
lineage-committed cells [338, 339]. Modulation of serum and bone marrow 
CSF levels by cytokines (such as IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-11, IL-12, IL-
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13, IFN-y, TNF-a and M IP-la) released by activated granulocytes,
macrophages, T lymphocytes, and bone marrow cells during infection, 
inflammation or stress, can affect haematopoiesis [327, 330, 340-352]. Other 
immunomodulators, including heat shock proteins, steroid hormones, 
prostaglandins, kinins and complement proteins, that may be released into 
the chemical milieu during stress or inflammatory responses can also 
inhibit bone marrow haematopoiesis [353-357]. A decline in the level of any 
essential factors, in response to administration of SAMA4-antigen 
complexes, may have resulted in increased BM cell apoptosis and necrosis 
[338, 355, 358, 359].
Surprisingly, the rapid decline in BM cell numbers in the OMP Vaccine 
group was not associated with detectable increase in dead and apoptotic cells. 
It was likely that rapid removal of early apoptotic cells by resident 
macrophages [303, 360, 361] resulted in the low level of apoptotic and dead 
cells in vivo.  Nevertheless, from this result it was apparent that although 
flow cytometry with DNA intercalatants (7-AAD and PI) could detect 
apoptosis in vitro (as shown in Chapter 2), where phagocytic removal of cells 
is minimized [252, 266, 362-364], it had limited usefulness for detecting 
apoptosis in vivo  in my hands. Alternative techniques, such as in situ 
terminal deoxynucleotide transferase-mediated dUTP nick end-labelling 
(TUNEL), detection of apoptosis-related markers (such as CD69 and CD25) 
[263] or measurement of mitochondrial transmembrane potential [261], to 
name just three, may more readily detect early increases in apoptosis and 
necrosis in vivo [259],
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Compared to the large decline in B lineage cells, granulocyte and monocyte 
losses were only short-lived. Granulocytes could be readily distinguished 
from the monocytic lineage by the expression of the Gr-1 surface antigen 
[247, 365], but the monoclonal antibody, M l/70, used in this study to detect 
Mac-1+Gr-T cells [246, 366], could not distinguish between monocytes, 
macrophages and dendritic cells (DC). This antibody reacts with CDllb, a 
component of the surface adhesion molecule, CDllb/CD18, expressed on 
granulocytes, monocytes, macrophages and DC [246, 366]. Although DC are 
the most potent inducers of activation of naive T cells, they only represent a 
minor population compared to monocytes and macrophages [111, 367, 368]. 
Therefore, the rapid rise detected in the circulating numbers of Mac-1+Gr-T 
cells in the OMP Vaccine group following intradermal immunization 
(Chapter 2) was consistent with increases predominantly in monocytes and 
macrophages. Activation of Mac-1+Gr-T cells is a potent stimulator of bone 
marrow cell proliferation [323, 326, 327]. Cycling of activated Mac-1+Gr-1'cells 
into the bone marrow may have been one stimulus for increases in the de  
novo synthesis of haematopoietic cells of all lineages.
Exposure to antigen in the form of SAMA4-OMP complexes, was a potent 
stimulus for bone marrow depletion. However, this study did not address all 
the questions regarding the effect of immunization on the bone marrow. 
Future studies may need to investigate the impact of immunization on the 
rate of migration of granulocyte and macrophage colony-forming units to 
the spleen, and thymus-seeding progenitors to the thymus, as a direct 
measure of BM performance following immunization. The skin possesses a
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comprehensive range of immune effector cells, such as Langerhans cells, a 
type of DC that resides in the skin, and macrophages and polymorphs that 
can phagocytose antigen and initiate immune responses [35, 230]. The 
question of whether or not the skin route uniquely provokes the BM 
responses detected can be addressed by assessing changes by other 
immunization routes. Preliminary data indicate that intramuscular 
immunization also provokes a greater declines in BM (and thymus) cell 
numbers than by intradermal immunization, whereas the subcutaneous 
route provokes only a minimal response (data not shown). Splenic NK cell 
activity on Day 9 following intradermal immunization was not increased 
(Chapter 2). However, the apparent link between NK-like cell activity and 
BM depletion [286] needs to be further examined. Additional studies, 
including in situ staining of bone marrow may also indicate the impact of 
immunization on bone marrow stromal cells, which nurse the developing 
cell lineages. Finally, it remains to be determined whether or not other host 
species are similarly affected by immunization.
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CHAPTER 5
Generating Mucosal and
Systemic Immunity By
Intradermal Vaccination
5.1 INTRODUCTION
Actinobacillus p leuropneum oniae ,  a Gram-negative coccobacillus, is the 
etiological agent responsible for pleuropneumonia in pigs [369]. Current 
commercially available bacterins reduce the morbidity and mortality 
associated with acute infections but do not prevent animals from becoming 
chronically infected or asymptomatic carriers of the disease [370]. One major 
deficiency of commercial vaccines is that bacterins primarily provide serovar- 
specific protection, whereas immunity from natural infection is believed to be 
cross-protective against all serovars [371-373]. To further improve the 
protective efficacy of vaccines, virulence factors of A. p leuropneum oniae ,  
such as capsular polysaccharide [235], haemolysin [278], lipopolysaccharide 
(LPS) [374], IgA proteases [375], permeability factor or outer membrane proteins 
(OMPs) [376] have also been evaluated, but with varying degrees of success.
While considerable effort has been directed towards an assessment of the 
protective capacity of different antigen preparations of A. pleuropneum oniae ,  
little attention has been given to the immunization route. It is surprising that 
pleuropneumonia vaccines are primarily administered intramuscularly or 
subcutaneously [370, 377] even though these delivery routes are not renown 
for promoting mucosal immunity. The ability to elicit mucosal IgA is 
considered to be an important requirement in the development of protective 
immunity against a range of respiratory pathogens like A. p l eu rop n eu m on ia e  
[196, 378]. However, currently numerous factors, such as inefficient antigen 
delivery, mucosal tolerance and the lack of suitable mucosal adjuvants, make
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most mucosal vaccination strategies impracticable [9].
Intradermal immunization with SAMA4 promotes both mucosal and 
systemic antibody responses in different livestock species without any adverse 
immunological or physiological side-effects [100, 102]. Intranasal re-exposure 
to the immunizing antigen also elicits strong IgG and IgA responses in both 
serum and respiratory tract washings, indicating that intradermally 
immunized animals developed local and systemic immunological memory 
[102]. Therefore, this study was undertaken to determine whether intradermal 
immunization with SAMA4-OMP complexes promoted systemic and mucosal 
immunity in mice. Since capsular polysaccharides and lipopolysaccharides are 
co-purified with proteins during OMP extraction [237, 240], the antibody 
specificity of the immune response toward the polysaccharide components of 
OMP was also examined.
5.2 MATERIALS AND METHODS
5.2.1 Immunization of Mice and Sampling Schedule
Female BALB/c mice aged 8 to 12 weeks were immunized intradermally
(78/group) with 100 [d of either PBS, pH 7.2 (Control group), SAMA4
(Adjuvant Group), OMP (OMP Antigen group) or SAMA4-OMP (OMP 
Vaccine group) on Days 0 and 7, as described in Chapter 2.
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On weeks 0, 1, 2, 3, 4, 6, 13 and 21, mice from each treatment group were 
euthanased by intraperitoneal injection with 50 pi of 300 mg/ml sodium
pentobarbitone (Jurox). Blood was collected after euthanasia and allowed to 
clot at room temperature for 1 h before being centrifuged at 1500 g  for 10 
min. Respiratory tract washings (RTW) were obtained by inflating and 
deflating the lungs 5 times with 1 ml PBS. Vaginal washings (VW) were
obtained by repeatedly flushing the vagina 20 times with 200 pi PBS. Faecal 
extracts (FE) were prepared by homogenizing faecal pellets in PBS (200 pi per
pellet) containing 0.05% (w/v) Thiomersal (BDF1) and 1 mM PMSF (Sigma). 
Cells and other debris were removed from RTW, VW and FE by 
centrifugation (1500 g  for 10 min). Serum, RTW, VW and FE were stored at - 
20 °C.
5.2.2 Preparation of deproteinised polysaccharide-rich samples from OMP
OMP purified from A. pleur opneu m on iae  contained both protein and 
polysaccharide components. Polysaccharides were purified by proteinase K
digestion of OMP proteins [379]. Briefly, a stock OMP solution (900 pg OMP 
suspended in 180 pi PBS) was diluted with 60 pi of 4x non-reducing Laemmli
buffer [380] and 50 pi of 600 pg/ml proteinase K solution (Boehringer
Mannheim), and incubated at 37 °C for 2 h. The sample was heated at 95 °C 
for 10 min, and allowed to cool. A second proteinase K digestion step was 
done for 1 h at 37 °C to ensure complete digestion of OMP proteins. OMP- 
derived polysaccharide preparations contained no protein detectable by
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silver-staining of polyacrylamide gels, and were stored at -20 °C until use.
5.2.3 Determination of anti-OMP and anti-polysaccharide responses by 
enzyme-linked immunosorbent assay (ELISA)
OMP- or polysaccharide-specific immunoglobulins in serum, RTW, V W
and FE were detected by ELISA. A 25 îg/ml OMP solution was prepared by
diluting stock OMP (5 mg OMP/ml PBS) with coating buffer (50 mM 
bicarbonate buffer, pH 9.6, 0.15% {w/v} Na2C03, 0.29% {w/v} NaHC03). The 
stock deproteinised polysaccharide-rich fraction was diluted in coating buffer
by an equivalent amount. In separate assays, 50 îl of the OMP or OMP-
derived polysaccharide preparations were dispensed into each well of 96- 
well plates (Immulon, Dynatech Labs, USA) and incubated overnight at 4 °C. 
Unbound antigen was removed with 2 washes of distilled water, one wash 
with Tris-Saline-Tween-20 (TSTw; 25 mM Tris-HCl in 0.15 M NaCl and 
0.05% Tween 20, pH 7.2) and a further 2 washes of distilled water.
To determine the optimal dilution for samples, a preliminary ELISA was 
done with pooled sera or RTW from the different time points. Sera were 
assayed after being serially two-fold diluted from 1/100 to 1/800 in TSTw, 
while pooled RTW were assayed neat or after being serially two-fold diluted 
from 1/2 to 1/8. From these data, a 1/200 dilution was used to determine the 
anti-OMP and anti-polysaccharide responses in individual sera and a 1/4 
dilution was used for individual RTW. VW and FE were assayed without 
further dilution. Samples (50 (utl) were added in triplicate to the wells and
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incubated for 1.5 h at 37 °C. Plates were washed as before and 50 pi of the
following dilutions of horseradish peroxidase (HRP)-conjugated anti­
murine antibodies (diluted in TSTw) were added to the respective plates: IgG 
(1/1000 dilution; Silenus, Hawthorn, Vic, Australia), IgA (1/400 dilution; 
Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA), IgM (1/1000 
dilution; Silenus), IgE (1/1000 dilution; Southern Biotechnology Assoc. Inc., 
Birmingham AL, USA), IgGl (1/600 dilution; Zymed, San Francisco, CA, 
USA), IgG2a (1/200 dilution; Zymed), IgG2b (1/600 dilution; Zymed) or IgG3 
(1/1000 dilution; Zymed). Plates were incubated for 1.5 h at 37 °C, washed as
before, and visualized by adding 50 pi of freshly prepared 0.4% (w/v) o-
phenylenediamine dihydrochloride (0.4% w/v o-phenylenediamine 
dihydrochloride {Sigma} dissolved in citrate phosphate buffer {0.025 M Citric 
acid, 0.05 M Na2H P04, pH 5) and 0.03% {v/v} H20 2) to each well. Colour 
development was stopped after 10 min by adding 25 pi of 2.5 M H2S 0 4 to each
well. Optical densities were measured at 492 nm with an iEMS microplate 
reader (Labsystems, Norway).
5.2.4 Optimization of OMP dose for assessment of immunological recall 
in immunized mice
8 to 12 wk old naive female BALB/c mice (4 per group) were injected 
intraperitoneally with 300 pi of an anaesthetic mixture containing 0.4
mg/ml xylazine HC1 (Troy Laboratories, Smithfield, NSW, Australia) and 4 
mg/ml ketamine HC1 (Parnell Laboratories, Silverwater, NSW, Australia). 
Anaesthetized mice were inoculated intranasally with either 5, 50, 500 or
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5000 ng OMP (in 25 \xl PBS, pH 7.2). Anti-OMP IgG and IgA responses were 
assessed in serum and RTW after 7 days.
5.2.5 Recall of immunity in immunized mice
Recall of immunity against OMP was assessed 21 weeks after primary 
immunization by intranasally inoculating mice with 50 ng of OMP. This 
dose of OMP was established in a preliminary experiment (described in 
Section 5.2.4). Serological responses to OMP in serum and RTW of 
intradermally immunized mice were assessed over a 3 week period 
following intranasal inoculation.
5.2.6 Enumeration of OMP-specific antibody-secreting cells by ELISPOT
The number of OMP-specific IgG or IgA antibody-secreting cells (ASC) in the 
spleens and lung tissue of mice were determined over a 3-week period 
following intranasal inoculation of mice with .50 ng OMP. Single-cell 
suspensions from pools of 3 to 4 collagenase-digested lung tissue were 
prepared for each group as described in Chapter 2. Cells were washed twice 
with RPMI-1640/10% (v/v) NBS and resuspended in cell culture medium 
(RPM1-1640 containing 54 mg/ml sodium benzyl penicillin {CSL}, 90 mg/ml 
streptomycin sulfate {CSL}, 2mM L-glutamine {Cytosystems}, 2 mM sodium 
pyruvate {Cytosystems}, 58 mM b-MSH {Koch} and 10% {v/v} FCS {Gibco- 
BRL, Life Technologies, Mulgrave, Vic, Australia}). Erythrocyte-free 
splenocytes were prepared from individual spleens as described in Chapter 2 
and resuspended in culture medium.
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ASC were enumerated by the ELISPOT technique [381], Briefly, 96-well nitro­
cellulose bottom plates (Multiscreen HA 96 well filtration plate, Millipore,
Lane Cove, NSW, Australia) were pre-coated with 100 pi of 50 pg/ml OMP 
in PBS, pH 7.2 at 4 °C overnight. Unbound antigen was removed by washing 
plates 3 times with PBS. Plates were blocked for 1 h at 37 °C with 200 pi/well 
of RPMI-1640/5% (v/v) foetal calf serum (CSL). Routinely, 2 xlO5 cells (in 100 
pi of supplemented RPMI-1640) were added in triplicate to ELISPOT plates
and incubated for either 3 h (for splenocytes) or overnight (for lung cells) at 
37 °C in a 5% C 02 humidified incubator. Plates were washed three times in 
PBS to remove cells. To each well was added 100 pi of a 1/1000 dilution (in
TSTw) of HRP-conjugated anti-murine IgG (Silenus) or a 1/400 dilution of 
HRP-conjugated anti-murine IgA (Kirkegaard and Perry Laboratories). Plates 
were incubated for 1.5 h at 37 °C and then washed as before. Wells were
incubated with 200 pi 10 mM Tris-HCl, pH 7.6 at room temperature for 5
min. Plates were flicked dry and 100 pi of freshly prepared 0.04% (w/v) AEC 
substrate (3-amino-9-ethycarbazole {Sigma}; 20 mg dissolved in 2.5 m l 
dimethylformamide and made up to 50 ml in 50 mM acetate buffer; filtered 
through a 0.22 m filter {Millipore}, and containing 0.02% {v/v} H20 2.) was 
added for spot colour development.
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5.2.7 Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) and immunoblotting
OMP or OMP-derived polysaccharide preparations were electrophoresed by 
discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) in a Mini-PROTEAN II assembly (Biorad) under reducing 
conditions described elsewhere [380]. Samples were reduced and denatured 
by boiling at 95 °C for 5 min in the presence of 20% (v/v) 2-|3-
mercaptoethanol (Biorad), 4% (v/v) glycerol and 8% (w/v) sodium dodecyl 
sulphate in 0.25 mM Tris-HCl, pH 6.8. Denatured OMP and polysaccharide 
samples were loaded onto a 12% (w/v) acrylamide (Biorad) gel overlaid with 
a 4% stacking gel. Samples were electrophoresed at a constant voltage (130V) 
in Tris-Glycine buffer (25 mM Tris-HCl, 0.19 M glycine, 0.1% {w/v} SDS, pH 
8.6). Electrophoresis was stopped when the 0.05% (w/v) bromophenol blue 
tracking dye had migrated to the bottom of the gel. Electrophoretically 
resolved polypeptides were stained with 0.025% (w/v) coomassie brilliant 
blue R-250 dissolved in 40% (v/v) methanol, 7% (v/v) glacial acetic acid) at 
37 °C and destained with a solution containing 13.5% (v/v) ethanol and 3% 
(v/v) acetic acid. Polysaccharides were silver-stained as described elsewhere 
[382].
Electrophoretically resolved OMP or polysaccharide preparations were 
transferred onto nitrocellulose membranes (Optitrans BA-S 85, Schleicher & 
Schuell) overnight in a Hoefer TE series transphor blotting apparatus under 
conditions described elsewhere [383]. Immunoblots were washed in TSTw
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for 5 min and then blocked for 1 h at 25 °C with 5% (w/v) skim m ilk 
(Allowrie, Eastwood, NSW, Australia) dissolved in TSTw. The blots were 
washed 3 times with TSTw and then reacted for 1.5 h at 25 °C with either 
pooled sera (1/500 dilution) or pooled RTW (1/10 dilution) from the 
Control, OMP Antigen or OMP Vaccine groups. Blots were washed as before 
and incubated with HRP-conjugated anti-murine immunoglobulin 
(Silenus; 1/2000 dilution) for 1.5 h at 25 °C. After further washes, blots were 
incubated in 10 mM Tris-HCl, pH 7.6 for 10 min at 25 °C and then reacted 
with freshly prepared 0.05% (w/v) DAB substrate (freshly prepared solution 
of 0.5 mg/ml 3,3-diaminobenzidine substrate {Sigma} dissolved in 10 mM 
Tris-HCl, pH 7.6 and 0.03% {v/v} H20 2). Colour development was stopped by 
rinsing blots in water.
5.2.8 Determination of antibody responses against SAMA4 iscoms by 
enzyme-linked immunosorbent assay (ELISA)
Serum antibody reactivity (IgG) against SAMA4 was assayed by ELISA as 
described above. SAMA4 was prepared as described in Chapter 2 and coupled 
to ELISA plates at dilutions ranging from 1/10 to 1/80 prepared in coating 
buffer. A 1/40 dilution of SAMA4 was used to assay serum reactivity from 
the Adjuvant and OMP Vaccine groups. Antibody responses were 
determined on 1/100 dilutions of the individual sera prepared in TSTw.
5.2.9 Determination of antibody responses against OVA by enzyme-linked 
immunosorbent assay (ELISA)
Intradermally immunized mice elicited very similar cellular response
Chapter 5 page 120
profiles irrespective of whether the immunizing antigen was OMP or OVA 
(Chapter 2 and 3). To determine if a similar immunoglobulin response 
profiles were also elicited against OMP and OVA, female BALB/c mice aged
8 to 12 weeks (17 per group) were immunized intradermally with 100 jil of 
either PBS, pH 7.2 (Control group), OVA (OVA Antigen group) or SAMA4- 
OVA (OVA Vaccine group) as described in Chapter 3. OVA-specific 
immunoglobulins in serum and RTW were detected by ELISA as described
above, except that 10 pg/ml OVA solution was used to couple the ELISA
plates. Antibody responses were determined from 1/100 dilutions of the 
individual sera and 1/4 dilutions of the individual RTW prepared in TSTw.
5.2.10 Statistical analyses
The results reported represent the mean (± sem). The means of different 
groups at individual time points were compared by two-tailed Student's t- 
test. Changes were considered significant at P<0.05.
5.3 RESULTS
5.3.1 Serum anti-OMP antibody responses following intradermal 
immunization
The serum antibody responses elicited against OMP over a 21 week period 
following immunization are depicted in Fig. 5.1a-d. Compared to controls, 
the OMP Antigen and OMP Vaccine groups elicited a rapid increase in IgG (P
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FIGURE 5.1. Serum anti-OMP (a) IgG, (b) IgM and (c) IgA responses over a 21 
week period following primary immunization in mice from the Control 
(unfilled squares), OMP Antigen (unfilled diamonds) or OMP Vaccine (filled 
diamonds) groups, (d) IgG subclass responses at Week 13 in mice from the 
Control, OMP Antigen or OMP Vaccine groups. Total IgG (filled columns), 
IgGl (hatched columns), IgG2a (wavy columns), IgG2b (stippled columns) and 
IgG3 (unfilled columns). Each data point represents the mean (± sem) from 4 
mice per group. Arrows designate time of intradermal immunization.
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< 0.005; Fig. 5.1a), IgM (P < 0.02; Fig. 5.1b) and IgA (P < 0.02; Fig. 5.1c). Peak 
serum antibody responses in mice from the Antigen and Vaccine groups 
were essentially similar, but declined faster over time in the OMP Antigen 
group. Serum immunoglobulins in the OMP Vaccine group remained 
elevated beyond Week 21 and were significantly higher than in the OMP 
Antigen group at this time (P < 0.05).
Both groups also showed significant elevations (P < 0.01 for all subclasses) in 
IgGl, IgG2a, IgG2b and IgG3 at Week 13 post-immunization (Fig. 5.1d). IgGl 
and IgG3 were the predominant subclasses with IgG2a and IgG2b showing 
smaller increases. Significant changes in serum IgE levels was not detected at 
any time during the first 4 weeks of immunization (data not shown).
5.3.2 Mucosal anti-OMP antibody response
Intradermal immunization with OMP primarily induced an IgG response 
against OMP in the RTW of OMP Antigen and OMP Vaccine groups (Fig. 
5.2a). OMP-specific IgM or IgA were not detected (data not shown). RTW IgG 
rose significantly to a peak at Week 13 post-immunization in both groups (P 
< 0.05). The peak response in the OMP Antigen group was significantly 
greater (2.5-fold) than in the OMP Vaccine group (P < 0.05), but fell more 
rapidly than in the OMP Vaccine group. As for serum, the increase in total 
RTW IgG in both groups was due predominantly to a rise in IgGl and IgG3, 
with a smaller rise in IgG2a and IgG2b (Fig. 5.2b).
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FIGURE 5.2. (a)RTW IgG responses in mice from the Control (unfilled squares), OMP Antigen (unfilled 
diamonds) or OMP Vaccine (filled diamonds) groups over a 21 week period post-immunization, (b) IgG 
subclass responses at Week 13 in mice from the Control, OMP Antigen or OMP Vaccine groups. Total IgG 
(filled columns), IgGl (hatched columns), IgG2a (wavy columns), IgG2b (stippled columns) and IgG3 (unfilled 
columns), (c) FE IgG response over a 21 week period post-immunization. Each data point represents the mean 
(± sem) from 4 mice per group. Arrows designate time of intradermal immunization.
A small, but significant, IgG response (P < 0.05) against OMP was detected at 
Week 13 post-immunization in faecal pellet extracts (FE) prepared from the 
OMP Vaccine group, but not the OMP Antigen group (Fig. 5.2c). Significant 
increases in OMP-specific FE IgA, or VW IgG or IgA, were not detected over 
the entire 21-week post-immunization period (data not shown).
5.3.3 Antibody response against OMP polysaccharide antigens in serum  
and respiratory tract washings from mice immunized with OMP
The presence of polysaccharides in the OMP preparations was determined by 
a standard silver-staining technique for carbohydrate [379, 382]. Although the 
types of polysaccharides present in OMP preparations were not identified, 
work done by others [232] indicates that they consist of capsular 
polysaccharides and/or lipopolysaccharide co-purified with OMP.
Intradermal immunization with OMP elicited a rapid increase in serum IgG 
against the polysaccharide components of OMP in both the OMP Antigen 
and OMP Vaccine groups (P < 0.05; Fig. 5.3a). An anti-polysaccharide IgA 
response was not detected over a 21 week period post-immunization in the 
serum of the different treatment groups (data not shown). In the OMP 
Antigen group, a significant (12-fold) increase in IgG3 (P < 0.05) accounted 
for much of the rise in total IgG between 2 to 6 weeks post-immunization 
(Fig. 5.3b). IgG3 levels declined with a concomitant increase in IgGl. IgGl 
levels rose significantly (P < 0.05) to a peak at Week 13 before also declining. 
Elevations in both IgGl and IgG3 were sustained for at least 21 weeks in the 
OMP Vaccine group.
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FIGURE 5.3. (a)Serum anti-polysaccharide IgG responses in mice from the Control (unfilled squares), OMP 
Antigen (unfilled diamonds) or OMP Vaccine (filled diamonds) groups over a 21 week period post­
immunization. (b) Serum IgG subclass responses at Weeks 6 and 13 in mice from the Control, OMP Antigen or 
OMP Vaccine groups. Total IgG (filled columns), IgGl (hatched columns), IgG2a (wavy columns), IgG2b 
(stippled columns) and IgG3 (unfilled columns). Each data point represents the mean (± sem) from 4 mice per 
group. Arrows designate time of intradermal immunization.
Intradermal immunization with OMP primarily induced an IgG response 
against the polysaccharide components of OMP in RTW of the OMP Antigen 
and OMP Vaccine groups (Fig. 5.4a). RTW IgG rose significantly to a peak at 
Week 13 (P < 0.05) in both groups. The peak response was significantly 
greater (4.5-fold) in the OMP Antigen group than in the OMP Vaccine group 
(P < 0.05). The rise in total IgG in OMP Antigen and OMP Vaccine groups 
were attributed to increases in IgGl and IgG3 (Fig. 5.4b). Peak RTW  
immunoglobulin responses in the OMP Antigen group declined faster than 
in the OMP Vaccine group.
5.3.4 Immunob lotting
A typical Coomassie blue stained SDS-PAGE profile of A. 
pleuropneumoniae  serovar 1 strain HS54 is shown in Fig. 5.5, Lane 2. At 
least 36 polypeptide bands ranging in size from 14 to 94 kDa can be seen. 
Purified OMP (Fig. 5.5, Lane 3) contained five major bands with apparent 
molecular masses of 14, 22, 33, 37 and 39 kDa. Outer membrane-derived 
polysaccharides were visualized by silver-staining (Fig. 5.5, Lane 4). These 
antigens appeared as dispersed smears in two zones with a range in 
molecular mass between 45-80 kDa and between 14-22 kDa, respectively. 
These two antigen zones correspond to the capsular polysaccharide (CP) and 
lipopolysaccharide (LPS) antigens, respectively, which normally co-purify 
with OMPs prepared by the sucrose density gradient procedure. The protein 
and polysaccharide profiles were consistent to those reported by others [232, 
384].
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FIGURE 5.4. (a) RTW anti-polysaccharide IgG responses in mice from the 
Control (unfilled squares), OMP Antigen (unfilled diamonds) or OMP Vaccine 
(filled diamonds) groups over a 21 week period post-immunization, (b) RTW  
IgG subclass responses at Week 13 in mice from the Control, OMP Antigen or 
OMP Vaccine groups. Total IgG (filled columns), IgGl (hatched columns), 
IgG2a (wavy columns), IgG2b (stippled columns) and IgG3 (unfilled columns). 
Each data point represents the mean (± sem) from 4 mice per group. Arrows 
designate time of intradermal immunization.
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FIGURE 5.5. SDS-PAGE profile of A. pleuropneumoniae  antigens. Pharmacia 
low molecular weight protein standards (lane 1), denatured A. 
pleuropneum oniae  serovar 1, HS54 (lane 2) and outer membrane proteins 
(lane 3) stained with Coomassie blue; silver-stained SDS-PAGE profile of 
proteinase K-extracted polysaccharide (lane 4).
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5.3.5 Serum and RTW immunoreactivity against OMP and 
polysaccharide
The serum anti-OMP responses elicited by the OMP Antigen and OMP 
Vaccine groups were very similar, therefore, it was of interest to examine if 
any differences existed in the antigens recognized by the two groups. The 
target reactivity of sera (Fig. 5.6) and RTW (Fig. 5.7) collected at Week 13 
(peak antibody responses) from mice in different treatment groups was 
assessed by immunoblotting against either OMP or a deproteinized OMP- 
derived polysaccharide preparation. Serum or RTW antibodies from Control 
mice did not react against either OMP protein or polysaccharide components 
(data not shown). When reacted against OMP, pooled serum and RTW from 
the OMP Antigen group showed weaker reactivity against the 22, 26, 28, 33, 
36 and 37 kDa proteins (Fig. 5.6, Lane 1; Fig. 5.7, Lane 1) than the Vaccine 
group (Fig. 5.6, Lane 3; Fig. 5.7, Lane 3). Both groups showed strong reactivity 
against a 14 kDa band.
When reacted against the deproteinized OMP-derived polysaccharide 
preparation, both groups showed strong serum reactivity, but only against 
the high molecular mass polysaccharide antigens (Fig. 5.6, Lanes 2 and 4). 
Only the Antigen group had strong reactivity against polysaccharide 
antigens in RTW (Fig. 5.7, Lane 2). By comparison, the Vaccine group had 
weak reactivity against both high and low molecular mass polysaccharide 
antigens (Fig. 5.7, Lane 4).
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FIG U R E 5.6. Immunoblot profile of pooled serum samples obtained from 
mice in the OMP Antigen or OMP Vaccine groups at Week 13 post­
immunization. Serum immunoblot profile of the OMP Antigen group 
against OMP (lane 1) or OMP-derived polysaccharides (lane 2). Serum 
immunoblot profile of the OMP Vaccine group against OMP (lane 3) or 
OMP-derived polysaccharide (lane 4). Molecular weights of polypeptide 
bands were calculated using low molecular weight protein standards 
(indicated on the left).
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FIGURE 5.7. Immunoblot profiles of pooled RTW samples obtained from 
mice in the OMP Antigen or OMP Vaccine groups at Week 13 post­
immunization. RTW immunoblot profile of the OMP Antigen group 
against OMP (lane 1) or OMP-derived polysaccharides (lane 2). RTW  
immunoblot profile of the OMP Vaccine group against OMP (lane 3) or 
OMP-derived polysaccharide (lane 4). Molecular weights of polypeptide 
bands were calculated using low molecular weight protein standards 
(indicated on the left).
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5.3.6 Recall of immunological memory against OMP in serum and RTW
To test whether intradermally immunized mice developed systemic and 
mucosal immunological memory against OMP, 50 ng OMP was intranasally 
inoculated into mice 21 weeks after primary immunization. This dose was 
established by intranasally inoculating groups of naive BALB/c mice with 
either 5, 50, 500 or 5000 ng OMP. Anti-OMP IgG and IgA responses were 
detected after 7 days in serum and RTW of mice given 500 or 5000 ng OMP, 
but were not detected in mice given 5 or 50 ng (Fig. 5.8a-d).
Intranasal inoculation boosted the declining serum IgG in the OMP Antigen 
group. In this group, serum IgG rose significantly over a 3-week period (P < 
0.05), and was equivalent to that present in the OMP Vaccine group at this 
time (Fig. 5.9a). By comparison, the peak serum IgG level reached at about 
Week 6 in the OMP Vaccine group did not decline significantly by Week 21. 
As a result, intranasal inoculation with OMP did not boost serum IgG levels 
in the OMP Vaccine group further.
Intranasal inoculation with OMP also boosted the declining serum IgA 
levels in the OMP Antigen group. In this group, serum IgA rose significantly 
(3.5-fold) over a 3-week period (P < 0.05) (Fig. 5.9b). By comparison, the 
small, but significantly elevated serum IgA levels reached at about Week 6 
in the OMP Vaccine group did not decline significantly by Week 21. As a 
result, intranasal inoculation with OMP did not boost serum IgA levels 
further. Nevertheless, serum IgA was significantly higher than in the 
Control group over the entire 3-week period (P < 0.05).
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FIGURE 5.8. Titration of OMP dose for assessment of immunological recall 
in immunized mice. Serum (a) IgG and (b) IgA and RTW (c) IgG and (d) IgA 
responses in naive mice at Day 0 (unfilled columns) and Day 7 (filled 
columns) after intranasal inoculation with different doses of OMP. The 
results represent the mean (± sem) from 4 mice per group.
Intranasal inoculation with OMP boosted RTW IgG in the OMP Antigen 
group by 6-fold (P < 0.05) over a 3-week period following (Fig. 5.9c). RTW IgG 
in the OMP Vaccine group was significantly elevated (P < 0.05) as a result of
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primary immunization 21 weeks earlier. RTW IgG in the OMP Vaccine 
group did not rise further due to intranasal inoculation but was significantly 
higher than in the Control group over the entire 3-week period post­
inoculation. RTW IgA in the OMP Antigen group rose significantly (4-fold) 
over a 3-week period following intranasal inoculation (P < 0.05) (Fig. 5.9d). 
The OMP Vaccine group also elicited a small rise in RTW IgA over the same 
period.
Transudation of serum antibodies may have caused the rise in RTW IgG 
following intranasal inoculation with OMP. To clarify this, the numbers of 
OMP-specific antibody secreting cells (ASC) was determined in both lung 
and spleen tissue. Before intranasal inoculation very few OMP-specific IgA- 
ASC (Fig. 5.10a and c) or IgG-ASC (Fig. 5.10b and d) were present in lung or 
spleen tissue, respectively. However, by one week after intranasal 
inoculation the numbers of IgA or IgG-ASC in lung and spleen tissue of 
both OMP antigen and OMP vaccine groups rose significantly (P < 0.01). The 
increase in OMP-specific ASC in lung tissue confirmed that antibody was 
produced locally. The small rise in spleen IgA-ASC in the Control group 
may have represented a small primary response to intranasal inoculation 
with OMP, but was not associated with detectable increases in serum 
antibodies.
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FIGURE 5.9. Serum and RTW anti-OMP responses over a 3-week period after 
intranasal inoculation with 50 ng OMP in mice from Control (unfilled 
squares), Antigen (unfilled diamonds) or Vaccine groups (filled diamonds), (a) 
Serum IgG, (b) serum IgA, (c) RTW IgG and (d) RTW IgA. Each data point 
represents the mean (± sem) from 4 mice per group.
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FIGURE 5.10. Enumeration of IgA (a and c) and IgG (b and d) OMP-specific 
antibody secreting cells in collagenase-digested lung tissue (a and b) and spleen 
(c and d) from mice in either Control (unfilled squares), Antigen (unfilled 
circles) or Vaccine groups (filled circles) after intranasal inoculation with 50 ng 
OMP. Results represent responses in pools of 3 to 4 lungs or individual 
spleens (n= 3 to 9) and the group mean (+).
5.3.7 Antibody response against SAMA4 iscoms following intradermal 
immunization
Fig. 5.11 demonstrates the lack of detectable antibody reactivity (IgG) against 
SAMA4 in the Adjuvant or OMP Vaccine groups at Day 11 post­
immunization. The same level of reactivity was present until at least Day 28
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(data not shown) By comparison, a strong response against OMP was present 
in the OMP Vaccine group over the same period.
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FIGURE 5.11. Comparison of serum anti-SAMA4 IgG response in Control 
(unfilled column), Adjuvant (hatched column) and OMP Vaccine (filled 
column) groups at Day 11 post-immunization with the response obtained by 
the OMP Vaccine group against OMP (wavy column). Each data point 
represents the combined mean (± sem) from 3 mice.
5.3.7 Antibody response against OVA following intradermal 
immunization
Compared to controls, mice in the OVA Vaccine group elicited a significant 
increase in IgG, reaching a peak by Day 14 (P<0.0005) before declining at Day 
21 (Fig. 5.12a). An increase in serum IgG was not detected in the OVA 
Antigen group over the same period. An increase in serum IgA was not 
detected in either the OVA Vaccine or the OVA Antigen group (Fig. 5.12b) 
although a small increase in IgM was present at Day 21 in the OVA Vaccine 
group (Fig. 5.12c). The increase in total IgG in the OVA Vaccine group was 
predominantly due to a rise in IgGl (Fig. 5.12d). No increases in OVA- 
specific immunoglobulins were detected in the RTW of any group (data not 
shown).
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FIGURE 5.12. Serum anti-OVA (a) IgG, (b) IgA and (c) IgM responses in mice 
from the Control (unfilled squares), OVA Antigen (unfilled diamonds) and 
OVA Vaccine (filled diamonds) groups over a 21 Day period following 
intradermal immunization. (D) IgG subclass responses over a 21 Day period 
in mice from the Control, OVA Antigen and OVA Vaccine (filled 
diamonds) groups. Total IgG (filled squares), IgGl (filled circles), IgG2a 
(unfilled squares), IgG2b (unfilled circles) and IgG3 (crossed-squares). Each 
data point represents the combined mean (± sem) from 4 mice.
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5.4 DISCUSSION
Mucosal vaccination is believed to be the best means of achieving immunity 
against mucosal pathogens such as A. p leuropneum oniae  [196]. However, 
mucosal vaccination is not generally practiced because of the lack of 
commercially available mucosal vaccines against A. pleuropneum oniae  and 
the difficulties involved in immunizing large pig herds by a mucosal route 
[9]. There are now numerous reports demonstrating IgA production, and/or 
protection against mucosal pathogens, following peripheral immunization. 
For example, in separate studies, intra-pelvic [82, 209], subcutaneous [202], 
intramuscular [224] and intradermal immunizations [102, 161, 222] have all 
resulted in production of high levels of mucosal IgA. Against this 
background, a number of studies [100, 102, 103] have demonstrated that 
intradermal vaccination is a practicable alternative to other immunization 
routes for eliciting mucosal and systemic antibody responses in different 
livestock species, without many of the limitations imposed by other 
vaccination routes. Therefore, this study assessed the kinetics of systemic 
and mucosal antibody production, and isotype distribution of 
immunoglobulins elicited against OMP in intradermally immunized mice.
Different immunoglobulin classes have distinct functional properties in an 
immune response, for example, with respect to their ability to activate 
complement [386, 387], mediate antibody-dependent cellular cytotoxicity 
[144], mediate opsonophagocytosis [388], and react against protein or 
carbohydrate antigens [389]. Therefore, the ability to induce a range of
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different im m unoglobulin isotypes is an important attribute of prospective 
vaccines [77, 390]. In this study, intradermal immunization of mice w ith 
either OMP antigen or OMP vaccine elicited comparable increases in OMP- 
specific serum and RTW IgGl, IgG2a, IgG2b and IgG3 antibodies, w ith 
reactivity against protein and polysaccharide components. OMP-specific IgM 
and IgA were also readily detected in serum, although the reactivity in R T W  
were negligible. Antibodies directed against SAMA4 were not detected.
The complem ent-fixing and opsonizing properties of antibodies present in  
the convalescent sera of naturally or experimentally infected swine are 
considered important for clearance of A. pleuropneumoniae [232-236]. These 
antibodies are typically directed against the outer membrane proteins, 
capsular polysaccharides and lipopolysaccharide components of A.  
p l e u r o p n e u m o n i a e  [232-236]. Therefore, it was likely that the antibody 
isotypes elicited in mice following intradermal immunization would also 
play a protective role in A. p l e u r o p n e u m o n ia e  infection. The rapid 
clearance of bacteria from the lungs of intradermally immunized m ice 
following intranasal challenge w ith A. pleuropneumoniae  (Chapter 7) 
supported such a role for these antibodies.
Recovery from natural infection with A. p l e u r o p n e u m o n ia e  confers life 
long im m unity [373], therefore, an efficacious pleuropneumonia vaccine 
should also possess such an attribute. To test whether immunized m ice 
developed im m unological memory, a subimmunogenic dose of OMP (50 
ng) was inoculated intranasally 21 weeks after primary immunization. The
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increase in serum OMP-specific IgG and IgA in the OMP Antigen group 
following re-exposure to OMP suggested that intradermally immunized 
mice developed antigen-specific immunological memory. Although 
present, the recall response in the OMP Vaccine group was less evident. In 
the Vaccine group, peak serum and RTW IgG and IgA responses were 
reached at Week 6 and did not wane substantially over the 24 week period 
following intradermal immunization. The antibody increases in serum or 
RTW from mice in this group following low dose intranasal inoculation of 
OMP at Week 21 may have been attenuated by high prevailing background 
levels of OMP-specific antibodies in these mice. However, the significantly 
increased numbers of OMP-specific IgG and IgA-antibody secreting cells in 
collagenase-digested lung tissues from the OMP Antigen or OMP Vaccine 
groups confirmed that the detectable IgG and IgA responses in the lung 
following intranasal inoculation of OMPs were due to local antibody 
production. These findings indicated that, although systemic lymphoid 
tissues contain relatively few IgA-committed B cell precursors [128], 
sufficient numbers were stimulated by intradermal immunization to elicit a 
detectable recall response following re-exposure to antigen.
The prolonged immunological responses against antigen are due to the 
generation of memory T and B cells during the primary response [391]. 
Without repeated antigenic stimulation, immunological memory decays 
over a period of weeks [391]. It is not clear whether memory is due to the 
persistence of long-lived B cells in the germinal centres of secondary 
lymphoid tissues, the continuous proliferation of antigen-specific B cells, or
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the continuous generation of new short-lived B cells [392, 393]. The 
retention of antigen on the dendritic processes of follicular dendritic cells (in 
the form of immune complexes or iccosomes) is believed to be required for 
continued stimulation of antigen-specific memory B cells in the germinal 
centres of the spleen and lymph nodes, and the maintenance of 
immunological memory [392, 394]. Increased release of iccosomes by 
follicular dendritic cells shortly after re-exposure to antigen and endocytosis 
of iccosomes by antigen-specific B cells, together with T cell help, leads to 
enhanced recall of antigen-specific responses [394, 395]. UytdeHaag et al  
(1991) [396] also proposed that a distinct self-renewing B cell lineage, B-l or 
CD5+ B cells [397], may undergo antigen-driven somatic mutation after 
exposure to antigen and play a role in the maintenance of immunological 
memory in the absence of antigen. An additional component in the 
maintenance of immunological memory is the continued exposure to cross­
reactive environmental antigens, which may by itself be sufficient to 
maintain memory T and B cell numbers [398].
The presence of elevated immunoglobulins over the 24-week period 
following primary immunization was consistent with ongoing antigenic 
stimulation. One explanation was that antigen retained at the intradermal 
injection site was available for repeated secondary stimulation of B cells 
over a long period. Such a mechanism has been proposed for repository 
adjuvants, such as Freund's adjuvant [41, 43]. However, Lascelles et al (1989) 
[44] showed that the rate of release of antigen from the "depots" formed by 
repository adjuvants were insufficient to sustain maximal antibody levels in
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serum. Beh and Lascelles (1985) [35] demonstrated in sheep that soluble 
antigen disappeared from the injection site over a few hours at identical 
rates for subcutaneous or intradermal administration. Watson et al (1989) 
[37] and Lovgren Bengtsson and Sjolander (1996) [68] also showed that 
subcutaneously injected iscom-antigen complexes rapidly disappear from 
the site of injection and accumulate in the draining lymph nodes and 
spleen. Since OMP antigen or OMP vaccine were soluble preparations, it is 
unlikely that retention at the intradermal injection site explained the 
maintenance of the strong immunoglobulin responses detected.
The skin route, however, was obviously an efficient means for delivering 
antigen and prolonging stimulation of B memory cells in immunized mice. 
Skin, like the mucosal surfaces of the lungs and gut, is continuously exposed 
to environmental antigens and pathogens, and like these mucosal surfaces, 
also has a well developed immune surveillance network capable of rapidly 
initiating immune responses [228, 230]. Kératinocytes in the skin produce
cytokines, such as IL-1, IL-6 TNF-a, and heat shock proteins that can activate
and recruit APC and lymphocytes to the injection site [229]. Langerhans cells, 
which belong to the dendritic cell lineage, are abundant throughout the 
skin. Langerhans cells are very efficient antigen presenters [107] and inducers 
of naive T helper cells [111]. The skin also contains migratory and transient 
T and B cells, that circulate continuously through skin-draining lymph 
nodes. The migration of activated APC following antigen exposure to 
inductive sites in the skin-draining lymph nodes results in antigen-specific
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Fearon (1996) [116] and others [107-115, 117] proposed that the responses 
generated by the innate immune system against antigen instruct and 
modulate induction of adaptive immune responses. It was evident from the 
similar kinetics of antibody production and antibody isotype patterns in the 
OMP Vaccine and OMP Antigen groups that the innate immune responses 
promoted by SAMA4-OMP were not essential for stimulating strong 
mucosal and systemic immunity against OMP. However, differences in the 
rate and/or efficiency of phagocytosis and antigen presentation in the OMP 
Vaccine and OMP Antigen groups were manifested as differences in the 
humoral responses. Complexing of OMP with SAMA4 significantly 
prolonged the duration of serum and RTW antibody responses in the OMP 
Vaccine group, compared to the OMP Antigen group. Immunoblot analyses 
also demonstrated differences in specificity of serum and RTW antibodies 
from the OMP Antigen and OMP Vaccine groups. Serum or RTW from 
OMP Vaccine group reacted strongly against most (7 out of 10) of the OMP 
polypeptides whereas antibodies from OMP Antigen group mice reacted 
only weakly and to fewer (3) OMP polypeptides. An increase in OMP-specific 
IgG was also detected in faecal pellet extracts from the OMP Vaccine group, 
but not the OMP Antigen group. The impact of complexing antigen with 
SAMA4 on the immune response was further demonstrated with the 
weaker antigen, OVA. Whereas the OVA Antigen group did not elicit 
detectable antibody responses, the OVA Vaccine group elicited strong anti­
OVA responses in serum. Cytotoxic T cell responses against OVA-expressing
proliferation of T and B lymphocytes [230, 399].
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lines were also detected only in the OVA Vaccine group and not in the OVA 
Antigen group (Chapter 6).
Serum and RTW antibodies in the OMP Antigen and OMP Vaccine groups 
had strong reactivity against high molecular mass polysaccharide antigens. 
Previous studies [232, 237, 370, 400] have demonstrated that these 
polysaccharides are composed of surface-exposed capsular polysaccharides 
(CP) and/or lipopolysaccharides (LPS) that co-purify with OMP. CP are 
believed to be involved in adherence of A  p leu ropn eu m on iae  to the lung 
mucosal surfaces, and inhibit phagocytic clearance and complement- 
mediated killing of bacteria [401, 402]. LPS may also be involved in bacterial 
colonization and, along with the haemolysin, APX1, is responsible for the 
lung lesions that develop during infection [374].
CP and LPS can directly induce production of antibodies without T cell help 
[403]. The more rapid induction of antibodies by the T cell independent 
pathway than by the T cell dependent route [404] may facilitate a swifter 
immune response early in infection than would otherwise be possible. 
Fenwick et al (1986) [405] also showed that pigs immunized with cultures of 
A. p leu rop n eu m on iae  <18 hrs old, which have a high LPS content 
compared to older cultures, stimulated strong production of cross-reactive 
antibodies against LPS from different A. p leu rop n eu m on iae  serovars. 
Therefore, immunity against cross-reactive antigens of LPS may be 
important for protection against A. pleuropneumoniae.
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Conversely, using capsule-deficient mutants, Ward and Inzana (1994) [402] 
showed that high levels of anti-LPS antibodies actually inhibit bacterial 
clearance from the lungs. Anti-LPS antibodies block the deposition of C9, a 
component of the complement membrane attack complex. Anti-CP 
antibodies are also ineffective at initiating complement-mediated lysis in 
encapsulated strains. If so, the value of eliciting high levels of anti-CP or 
anti-LPS antibodies may be limited. Further studies are required to compare 
the contributions of opsonizing antibodies against CP or LPS to protection. If 
future studies demonstrate that induction of anti-CP or anti-LPS responses 
are beneficial for protection then, given the toxicity of LPS preparations [405], 
intradermal vaccination may be a safe and feasible approach.
In summary, the results demonstrated that intradermal immunization is a 
feasible and practicable alternative to direct mucosal immunization. 
Intradermal immunization elicits both strong mucosal and systemic 
immune responses, and stimulates long-lived antigen-specific mucosal and 
systemic immunological memory. Complexing of antigens with SAMA4 
significantly increased the duration of the antibody responses and increased 
the immune responsiveness against T dependent antigens, which are 
important for the development of long-lived immunity against pathogens.
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CHAPTER 6
Generation of T Cell Cytotoxicity 
in Intradermally Immunized 
Mice
6.1 INTRODUCTION
Although humoral responses alone are often sufficient for eliminating
extracellular pathogens, induction of cytotoxic responses are necessary to
overcome disease caused by viruses, intracellular parasites and bacteria [283,
406], or to destroy tumour cells [242]. In mice, two cell populations, natural
killer (NK) cells and CD8+ cytotoxic T lymphocytes (CTL), elicit the
predominant cytotoxic activity against affected cells. NK cells belong to the
innate immune system and can spontaneously and non-specifically lyse
virally infected target cells [267, 407] and tumour cells [284]. In disease, NK
cells limit the spread of infection during the period required for induction of
the adaptive immune response by lysing damaged or infected cells [119, 283].
\
CTL are part of the adaptive immune system and elicit antigen-specific 
cytotoxicity against target cells expressing foreign endogenous antigens 
associated with class I MHC molecules [267]. Endogenous antigens are so 
called because they are synthesised in, or introduced into, the cytoplasm of 
cells by intracellular pathogens or tumour cells [267, 283]. Endogenous 
antigens are proteolytically degraded into peptides that bind to class I MHC
glycoproteins and (32-microglobulin [123]. Expression of antigen-class I MHC
complexes at the cell surface and recognition by antigen-specific CTL lead to 
induction of cytotoxic activity against the affected cells [8]. Therefore, 
antigen-specific cytotoxic activity elicited by CTL reflects entry of antigen into 
the endogenous pathway for antigen processing.
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Exogenous antigens, such as those present in vaccines, are readily 
endocytosed and degraded via the class II MHC pathway. Recognition of 
antigen peptide-class II MHC complexes on the cell surface of APC by 
antigen-specific CD4+ T helper cells leads to induction of antibody 
production by B cells. Soluble exogenous antigens present in vaccines do not 
readily enter the class I MHC antigen-processing pathway and therefore fail 
to induce CTL responses [3, 99]. The inability of antigens in most vaccines to 
enter the class I pathway for antigen processing limits the range of effective 
immune responses that are elicited by vaccines against intracellular 
pathogens. One exception to this includes vaccines prepared from antigens 
complexed in iscoms. Previous studies [95, 98, 99] have shown that these 
vaccines can induce strong CTL responses when delivered orally, 
intraperitoneally or subcutaneously. Since induction of CTL responses is 
important for protection against disease by intracellular pathogens, the 
ability of intradermal immunization to allow entry of antigen into the class I 
MHC pathway was investigated in intradermally immunized mice.
6.2 MATERIALS AND METHODS
6.2.1 Immunization of mice
Female C57/B6 (H-2b) mice aged 8 to 12 weeks were obtained from the John 
Curtin School of Medical Research (JCSMR) Animal Facility, Australian 
National University, Canberra, ACT. Mice were kept at 23 ± 1 °C under a 12 h
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day/night cycle. Antibiotic-free commercial mouse pellets and water were 
supplied ad libitum. Mice (8 per group) were intradermally immunized with
100 1̂ of either PBS, pH 7.2 (Control group), SAMA4 (Adjuvant group),
OVA (OVA Antigen group) or SAMA4-OVA (OVA Vaccine group) on days 
0 and 7.
6.2.2 Target cell lines used
EL4, YAC-1, and G7 thymoma target cell lines were kindly provided by Dr 
Arno Mullbacher (Division of Immunology and Cell Biology, JCSMR). The 
G7 cell line originated from EL4 cells transfected with OVA cDNA [408]. G7 
cells constitutively synthesize and secrete ovalbumin.
6.2.3 51Chromium-labelling of target cells
EL4, YAC-1 and G7 target cells were suspended at a concentration of 6 x 106 
cells/ml in 500 ¡ul of F15 medium (Gibco) supplemented with 5% (v/v) FCS
and incubated with 100 ¡lxI of 6 mCi/ml 51Cr (Amersham) for 1 h at 37 °C. 
Cells were washed twice and resuspended in F15 medium to give a final cell 
concentration of 2 x 105 cells/ml. A portion of the 51Cr-labelled EL4 cells were 
resuspended in 2 ml of F15 medium containing 10"4 M OVA peptide and 
incubated for 2 hrs at 37 °C. The OVA peptide (kindly provided by Dr Arno 
Mullbacher, JCSMR) was an octamer with the amino acid sequence 
SIINKFEL-OH (amino acids 257-264 of the ovalbumin molecule). The OVA 
peptide used is known to represent the immunodominant peptide for the 
H-2Kb MHC molecule in C57/B6 (H-2b) mice [409]. This OVA peptide binds
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with high affinity to the peptide-binding groove of the class I MHC 
molecules on OVA-specific cytotoxic T cells [408]. Cells were washed twice as 
before and resuspended in F15 medium to give a final cell concentration of 2 
x 105 cells/ml. These cells were designated EL4+OVA peptide.
6.2.4 Preparation of effector cells
Splenocytes were obtained from intradermally immunized mice on Day 14 
by gently teasing apart the spleen in F15 medium supplemented with 5% 
FCS. Cells were pelleted by centrifugation (200 g  for 10 min at 4 °C) and 
erythrocytes removed by hypotonic lysis in 4.5 ml of distilled water. 
Isotonicity was immediately restored by the addition of 0.5 ml of lOx Hanks 
Balanced Salt Solution (Trace Scientific) followed by 5 ml of F15 medium. 
The cells were centrifuged (200 g for 10 min at 4 °C) and resuspended in cold 
F15 medium.
6.2.5 Measurement of OVA-specific cytotoxic activity
Splenocyte suspensions were assayed in triplicate for cytotoxic activity 
against 51Cr-labelled G7, EL4+OVA peptide, EL4 or YAC-1 target cells at 
effector-to-target cell ratios ranging from 90:1 to 3:1. After incubating cells for 
6 h at 37 °C in a humidified C 02 incubator, 100 pi of cell-free supernatants 
were removed and the radioactivity measured in a gamma-counter. 
Spontaneous 51Cr release was determined by incubating 51Cr-labelled target 
cells in culture medium. Maximal 51Cr release was determined by incubating
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3lCr-labelled target cells in 2% Triton-X 100. Percentage cytotoxicity was 
calculated as follows:
% cytotoxicity = Experimental release - spontaneous release x 100%
Total release - spontaneous release
6.3 RESULTS
Intradermal immunization with OVA vaccine primed mice for a strong 
cytotoxic T cell response against OVA-expressing target cells within 6 h of in 
vitro culture. Splenocytes from the OVA Vaccine group lysed G7 cells (EL4 
cells transfected with OVA cDNA) and EL4+OVA peptide cells (EL4 cells 
sensitized with OVA peptide) by an equivalent amount (Fig. 6.1a and b). 
These findings, together with the lack of cytotoxicity against the non- 
transfected EL4 cells (Fig. 6.1c) indicated that cytotoxic activity in the OVA 
Vaccine group was OVA-specific. Since EL4 cells express only class I MHC 
molecules [410], cytotoxic T cell activity against G7 and EL4+OVA peptide 
cells was class I MHC-restricted.
Non-specific cytotoxicity, as measured by lysis of YAC-1 cells, was always less 
than 22% (Fig. 6.1d). Mice inoculated with SAMA4 failed to lyse target cells 
at higher than background levels. Contrary to one previous report [411], but 
consistent with another [408, 412], immunization with soluble OVA antigen 
also did not prime mice for OVA-specific cytotoxic activity.
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FIGURE 6.1. Percentage OVA-specific T cell cytotoxicity in spleens taken 
from mice in Control (unfilled columns), Adjuvant (hatched columns), 
OVA antigen (stippled columns) and OVA vaccine (filled columns) groups 
following intradermal immunization. Activity against (a) G7 cells (b) 
EL4+OVA peptide cells, (c) EL4 cells and (d) YAC-1 cells is shown. Values 
represent the mean of triplicate cultures.
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6.4 DISCUSSION
Soluble antigens produced from the breakdown of bacterial products during 
infection, or purified antigens administered by vaccination, are 
phagocytosed and degraded by APC. Peptide fragments formed by 
intracellular degradation of "exogenous" antigens bind to class II MHC 
molecules and are expressed on the surface of APC. Recognition of peptide- 
class II MHC complexes by T helper cells results in induction of antigen- 
specific antibody responses. Antigen processing via the class II pathway was 
clearly reflected by the antigen-specific antibody responses elicited in OVA 
vaccine-primed mice and OMP-primed mice (Chapter 5). This present study 
further demonstrated that immunizing with SAMA4-OVA complexes also 
primed mice for class I MHC-restricted antigen-specific CTL responses. 
Therefore, the adjuvant effect of SAMA4 included promoting entry of 
intradermally administered antigen into both class I and class II MHC 
antigen processing pathways.
A number of iscom-containing vaccines, delivered subcutaneously, 
intraperitoneally or orally, have also been shown to prime mice for in v itro  
antigen-specific T cell cytotoxicity [81, 90, 95, 98, 99, 206]. By comparison, 
conventional adjuvants, such as complete or incomplete Freund's 
Adjuvant, do not generate antigen-specific cytotoxic T cell responses against 
the same antigens [81]. These data indicate that iscoms may have a 
preferential effect on CTL activity. Although the mechanism by which this 
occurs is unclear, direct fusion of antigen-bearing liposomes (SAMA4) [11,
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54] or iscoms [37, 74, 87], to the cell membrane of APC may enhance antigen 
uptake and breakdown by both antigen processing pathways. More efficient 
antigen uptake, and preferential selection of immunodominant OVA 
peptides that best bind to class I MHC molecules may be consequential to the 
strong innate immune responses in the OVA Vaccine group. If so, it may 
explain the strong CTL responses in this group and the unresponsiveness of 
OVA Antigen mice (which did not elicit a strong innate response).
The finding in this study that soluble OVA alone did not prime for CTL 
activity is in agreement with at least two other reports [408, 412]. However, 
two studies [411, 413] have shown results to the contrary. One explanation 
for the apparent difference, proposed by Ishioka et al (1989) [412], is that i n 
vitro "pre-processing" of antigen by APC, either prior to immunization or 
during in vitro  restimulation of cells, results in the generation of antigenic 
peptides that can be processed by the class I MHC pathway, and can 
circumvent the normal entry into antigen processing pathways. Staerz et al 
(1987) [411] suggested that the class I and class II pathways are not 
functionally separate, thereby providing a mechanism by which exogenous 
antigens can be presented in conjunction with class I MHC molecules to be 
presented or during restimulation of cells.
The data demonstrated that, unlike many vaccines, intradermal 
immunization with SAMA4-antigen complexes allowed entry of antigen 
into the class I and class II MHC antigen processing pathways, resulting in 
the generation of antibody and CTL responses. These attributes make
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intradermal immunization with SAMA4-antigen complexes potentially 
effective for protecting against both extracellular and intracellular 
pathogens.
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CHAPTER 7
Protective Immunity in 
Intradermally Immunized Mice 
After Exposure to Actinobacillus 
pleuropneumoniae
7.1 INTRODUCTION
Inhaled A. p leu rop n eu m on iae  very rapidly adhere to the epithelial cells of 
the lower respiratory tract, beginning the disease process [414]. Disease 
pathogenesis in swine is histologically well documented, and includes: 
alveolar and interlobular oedema; dilatation of lymph vessels; congestion 
and haemorrhage of blood vessels and alveolar capillaries; intravascular 
fibrinous thrombosis; and exudation of fluid and fibrin into the pulmonary 
parenchyma [369, 415, 416]. Previous studies have shown that the destructive 
effects of A. p leu rop n eu m on iae  infection are due in large part to the 
haemolytic and cytotoxic action of RTX toxins, designated APX1 APXII and 
APXIH [278, 417-420] and LPS [197, 374] released into the lung tissue during 
infection. Production of APX1 by phagocytosed bacteria is believed to 
inactivate phagocytes, enabling ingested bacteria to become liberated [234]. 
Pro-inflammatory factors released by damaged lung cells and phagocytes can 
exacerbate tissue damage by initiating microvascular platelet aggregation and 
thrombosis, activating the coagulation, kinin and complement pathways, 
and attracting greater numbers of phagocytes to the infection site [374, 416].
The similarities in disease pathogenesis between swine and mice infected 
with A. p leu rop n eu m on iae  has meant that mice provide a suitable 
laboratory model for investigating different aspects of the disease process 
[421-427]. Most studies with infected swine and mice have concluded that 
protection against A. p leu ropn eu m on iae  is principally the result of 
immunity against surface exposed antigens, such as OMP, LPS and capsular
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polysaccharides [235, 278, 374-376]. Although mucosal IgA is believed to be 
important for protection against A. p leu ropn eu m on iae  [428], Hensel et al 
[196] and others [160, 184] have shown, that oral immunization does not 
prevent colonization or disease, and that serum antibodies contribute 
significantly to protection. Since bacterial challenge results in significant 
increases in both systemic and pulmonary antibody levels, the relative 
contributions to bacterial clearance of locally produced IgA and IgG, and IgG 
resulting from serum transudation, remain unresolved.
Bhatia et al [423] and Fenwick et al [405] discovered that, compared to the 
strong antibody responses, cell mediated immunity (CMI) was not strongly 
implicated in protection from disease. Pabst et al [429] also found that the 
small changes in the numbers of T and B cells in bronchoalveolar lavage 
following A. p leu ropn eu m on iae  infection of swine did not account for the 
uniform protection achieved in immunized animals. Different studies [196, 
429] have coincidently observed increases in phagocytic cells, such as 
macrophages and granulocytes, in the lung following bacterial challenge. By 
incubating fluorescein-labelled bacteria with convalescent pig serum or with 
immune sera from immunized pigs, Thwaits et al [388, 430] also 
demonstrated in vitro  that antibodies to OMP are important for 
opsonophagocytosis of bacteria in pigs. Rapid recruitment of phagocytic cells 
and the presence of opsonizing antibodies may, therefore, make an 
important contribution to clinical protection.
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The aim of this study was to quantify and compare, using flow cytometry, 
changes in leukocyte populations in unimmunized and immunized mice 
following intranasal exposure to A. pleuropneumoniae. Since effective host 
defense against lung bacterial infection is primarily dependent on rapid 
clearance of the organisms from respiratory tract [279], the rates of clearance 
of bacteria from the lungs of mice were interpreted in the context of 
background antibody levels detected in unimmunized and immunized mice 
in Chapter 5, and the cellular recruitment patterns in mice.
7.2 MATERIALS AND METHODS
7.2.1 Bacteria and growth conditions
A. p leu ropn eu m on iae  serovar 1, strain HS54 was recovered from frozen 
glycerol stocks by streaking onto chocolate blood agar plates (4.5% {w/v} GC
agar {Oxoid}, 1% {w/v} soluble haemoglobin {Oxoid} and 40 pg/ml NAD
{Calbiochem}). Bacteria were grown for 24 h at 37 °C in a 5% (v/v) C 0 2 
incubator. Colonies grown on chocolate blood agar plates were inoculated
into 20 ml brain-heart infusion broth (Oxoid) supplemented with 40 pg/ml
NAD and grown overnight with shaking at 170 rpm (Gallenkamp & Kuhner 
CH orbital mini-shaker) at 37 °C. A 5 ml aliquot of the overnight culture was 
transferred into 95 ml of brain-heart infusion broth and incubated as before 
until an O.D. 650 nm of 0-8 was reached (log-growth phase). This O.D. 
corresponded to about 8 x 108 colony-forming units (CFU)/ml. A 10 ml
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aliquot of the bacterial culture was centrifuged at 30,000 g  for 10 minutes at 4 
°C in a Beckman J2-21M/E centrifuge. The bacterial pellet was washed twice 
with 10 ml sterile PBS, pH 7.2 and resuspended in sterile PBS at the desired 
concentration. The bacterial suspension was kept on ice and used to 
inoculate mice intranasally within 1 h of preparation.
7.2.2 Mice
Female BALB/c mice aged 8 to 12 weeks were immunized intradermally 
with 100 \xl of either PBS, pH 7.2 (Control group), OMP (OMP Antigen group)
or SAMA4-OMP (OMP Vaccine group) on Days 0 and 7, as described in 
Chapter 2. Mice were maintained at 23 ± 1 °C under a 12 h day/night cycle 
and given antibiotic-free commercial mouse pellets and water ad libitum  
before and after intranasal challenge with bacteria.
7.2.3 Titration of bacterial inoculum
A preliminary experiment was conducted to confirm the susceptibility of 
BALB/c mice to A. p leu rop n eu m on iae  infection and to determine the 
appropriate inoculum to be used for subsequent intranasal challenge 
experiments. Mice (10 per group) were anaesthetised as described in Chapter 
5 and intranasally inoculated with 0 (PBS only), 1 x 107, 4 x 107, 1 x 108, 5 x 108 
or 2 x 109 CFU/dose of A. p leu rop n eu m on ia e , serotype 1, strain HS54. The
number of live bacteria in the inoculum was determined by incubating 10 (xl
aliquots of serial dilutions of the bacterial suspension on chocolate blood 
agar plates overnight at 37 °C in a 5% (v/v) C 0 2 incubator. Bacteria were
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quantified according to the formula:
CFU / ml = Mean number of colonies x dilution factor x 100
7.2.4 Clinical Assessment of mice following intranasal inoculation with 
bacteria
The clinical condition of mice was assessed after intranasal inoculation 
using criteria described elsewhere [431]. At 0, 4, 12, 24 and 36 h following 
intranasal inoculation with bacteria, mice from each group were 
individually scored on the level of activity, difficulty in breathing, preening 
of fur, squinting of eyes, and hunching. Mice were given a score of 0 
(normal), 1 (mild-moderately affected) or 2 (severely affected) for each 
parameter. If necessary, because of the severity of their symptoms, mice were
euthanased by intraperitoneal injection with 50 pi of 300 mg/ml sodium
pentobarbitone (Jurox). Mice that were euthanased due to the severity of 
symptoms or that died between observation periods were given the 
maximum combined score (10).
7.2.5 Enumeration of live bacteria in the lungs following intranasal 
challenge
On Week 5 after intradermal immunization, mice (12 per group) were 
anaesthetised and intranasally inoculated with 1 x 108 CFU/dose (20 pi) of A.
p leu ro'pneum oniae, serotype 1, strain HS54. Mice (4 per group) were 
euthanased at 4, 12 or 24 h and blood and tissues removed. Blood was 
collected immediately after euthanasia into sterile 1 ml tubes containing 50
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[d sodium heparin. The lung and spleen from each infected mouse were 
removed aseptically, cut into pieces and each organ individually 
homogenized for 7 x 1 minute cycles in a Colworth Stomacher 80. Bacteria in 
the lungs were quantified as described in Section 7.2.3. Bacterial numbers in 
the spleen and blood were not quantified.
7.2.6 Assessment of cell population changes following intranasal 
challenge
On Week 5 after intradermal immunization, mice from the Control (16 per 
group), OMP Antigen (12 per group) and OMP Vaccine groups (12 per group) 
were intranasally inoculated with 1 x 108 CFU live A. p leu ropn eu m on iae. 
Lungs, spleen and femoral bone marrow were removed at 0, 12 and 36 h 
post-inoculation as described in Chapters 2 and 4. Cell suspensions prepared 
from these tissues were stained with a panel of monoclonal anti-murine 
antibodies and analysed by flow cytometry as described in Chapters 2 and 4.
7.2.7 Partial purification of APX1 haemolysin and raising of polyclonal 
antibodies against APX1 in mice
The OMP preparations used to prepare vaccines may have inadvertently 
contained APX1, a protective component of A. pleuropneum oniae [278]. To 
exclude this component as a possible contributor to the outcomes reported 
following bacterial challenge of mice, APX1 was partially purified and tested 
for its haemolytic and cytotoxic activity. The presence of APX1 in OMP 
preparations was assessed using antibodies raised in mice against APX1.
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7.2.7.2. Bacterial growth conditions. A. pleuropneum oniae was grown 
overnight (as described above) in 50 ml of brain-heart infusion broth (Oxoid) 
supplemented with 40 ng/ml NAD. A 10 ml aliquot was transferred into a
flask containing 590 ml of NAD-supplemented Columbia broth (Bacto 
Laboratories) and incubated at 37 °C with shaking (170 rpm) until an O.D. 650 
nm of about 1.0 (at approximately 5 h) was reached.
7.2.7.2. Partial purification of APX1. The bacterial culture was centrifuged at 
30,000 g  for 10 min at 4 °C in a Beckman J2-21/ME centrifuge. The culture 
supernatant was passed through a pre-filter (Millipore) and then filtered
using a 0.22 \i filter (Millipore) to remove residual bacteria. The cell-free
culture supernatant was ultrafiltered through a 100 kDa molecular weight 
cut-off membrane (YM100; Amicon Division, WR Grace and Co, USA) fitted 
to a stirred cell assembly (Amicon) and reduced from a volume of 
approximately 600 ml to about 15 ml. To decrease the retention of low 
molecular mass proteins, 300 ml PBS, pH 7.2, was added to the retentate at 
this time and then ultrafiltration resumed until the volume was once again 
reduced to about 15 ml. The retentate was passed through a 10 kDa 
molecular weight cut-off membrane (YM10; Amicon) to reduce the volume 
of the retentate to about 2.5 ml.
The relative purity of APX1 preparations was determined from coomassie 
brilliant blue-stained electrophoretic gels using an LKB laser densitometer
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(Pharmacia LKB, Uppsala, Sweden).
7.2.7.3. Assessment of in vitro haemolytic activity. In vitro haemolytic 
activity of neat culture supernatant, YM100 retentate and ultrafiltrate was 
determined using a modification of the procedures described elsewhere [420,
432]. Briefly, 100 \x\ of a 5% sheep erythrocyte suspension prepared in assay
buffer (10 mM CaCl2 in 10 mM Tris-HCl, 0.85% saline, pH 7.4) and 100 ¡il of
either cell-free culture supernatants, ultrafiltrate or retentate were incubated 
in a covered round-bottom 96-well microtitre plate, with shaking at 200 rpm 
(Ika-Vibramax-VXR electronic shaker, John Morris Scientific), for 2 h at 37 
°C. After incubation, the plate was centrifuged (300 g  for 5 min at 4 °C) to
sediment the erythrocytes. Following centrifugation, 100 jil of cell-free 
supernatant was transferred to a flat-bottom 96-well microtitre plate. Optical 
densities were measured at 541 nm with an iEMS microplate reader.
Spontaneous haemolysis was determined by incubating 100 ¡j!  sheep
erythrocytes with 100 1̂ buffer as described above. One haemolytic unit was 
defined as the absorbance at 541 nm when 50% of sheep erythrocytes were 
haemolysed. This was determined by incubating 50 \x\ sheep erythrocytes
with 150 \x\ distilled water. Percentage haemolysis was calculated as follows:
% h a e m o l y s i s  = (S a m p le  O .D .5 4 1  n m  - S p o n ta n e o u s  h a e m o ly s is  O .P .  5 4 1  n m ) x  5 0 %  
(5 0 %  S t a n d a r d  O .D . 5 4 1  n m  - S p o n ta n e o u s  h a e m o l y s i s  O .D . 5 4 1  n m )
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7.2.7A. Assessment of in vitro cytotoxic activity. To assess the cytotoxicity of 
APX1 preparations, splenocytes, thymocytes, and lung cells from 
collagenase-digested lung, were incubated at 37 °C overnight in a humidified 
5% C 0 2 incubator with serial two-fold dilutions of YM100 retentate in RPMI- 
1640/10% (v/v) FCS, pH 7.4. Cell viability was determined by propidium 
iodide exclusion using flow cytometry.
72.7.5. Raising polyclonal antisera against APX1. Polyclonal antibodies 
against APX1 were raised in BALB/c mice (n=10) by immunizing
subcutaneously with 50 pg of heat-denatured APX1 emulsified with
complete Freund's adjuvant (CSL). A booster injection of denatured APX1 
emulsified with incomplete Freund's adjuvant (CSL) was given 
subcutaneously 3 weeks later. Immune sera were obtained after a further 3 
weeks.
72.7.6. SDS-PAGE, immunoblotting and neutralizing activity of APX1 
antibodies. Culture supernatant preparations were electrophoresed by SDS- 
PAGE and immunoblotting were done as described in Chapter 5 except that 
samples were loaded onto an 8% (w/v) polyacrylamide gel overlaid with a 
4% stacking gel. To assess the APXl-neutralizing properties of antiserum, 
serial two-fold dilutions were prepared in assay buffer (10 mM CaCl2 in 10
mM Tris-HCl, 0.85% saline, pH 7.4). 200 pi of each dilution or PBS was 
incubated with or without 200 pi of neat cell-free culture supernatant for 2 h 
at 37 °C.
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7.2.8 Histology
Lungs were removed from freshly killed infected or uninfected mice and 
fixed in 10% (v/v) phosphate-buffered formalin. The lungs were embedded
in paraffin using standard techniques. Sections (4 fxm thick) were prepared 
and stained with H&E for microscopic examination.
7.2.9 Statistical analyses
The results reported represent the mean (± sem). The means of different 
groups at individual time points were compared by two-tailed f-test. 
Changes were considered significant at P < 0.05.
7.3 RESULTS
7.3.1 Susceptibility of BALB/c mice to intranasal inoculation with A. 
p leu rop n eu m on ia e
Differences in the susceptibility of different mouse strains to A. 
p leu ropn eu m on iae  infection have been documented J421-427, 433]. Since 
few studies [433, 434] have used BALB/c mice as the experimental host, it 
was necessary to establish the susceptibility of BALB/c mice to intranasal 
challenge. To determine the susceptibility of BALB/c mice to A. 
pleuropneum oniae infection, groups of mice were inoculated intranasally 
with 1 x 107, 4 x 107, 1 x 108, 5 x 108 or 2 x 109 CFU/dose. Mice were observed 
hourly for the first 12 h and then every 12 h for up to 7 days. A dose-
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dependent deterioration in the condition of mice was seen. Mice receiving 5 
x 108 or 2 x 109 CFU/dose were euthanased within 8 to 12 h of inoculation 
due to the severity of their symptoms. Mice receiving 1 x 108 CFU/dose were 
severely affected by intranasal inoculation and were euthanased within 24 h. 
Mice given 1 x 107 and 4 x 107 CFU/dose displayed only mild overt 
symptoms of infection.
Compared to control mice, which had histologically normal lung structure 
(Fig. 7.1a), the lungs from mice inoculated with 2 x 109 CFU/dose showed 
areas of mild to moderate neutrophil infiltration into alveoli (Fig. 7.1b) and 
gross thickening of alveolar walls (Fig. 7.1c). Oedema was present around the 
large peribronchiolar blood vessels as well as areas of haemorrhage (Fig. 
7.1d). Coccobacilli were present in nearly every acinus of the lung in these 
mice. The lungs of mice inoculated with 1 x 107 CFU/dose had similar areas 
of neutrophil infiltration and alveolar thickening, but bacteria were harder 
to find.
7.3.2 Clinical Assessment of mice following intranasal inoculation with 
bacteria
On the basis of the results described in Section 7.3.1, mice from the Control 
(28 per group), OMP Antigen (24 per group) and OMP Vaccine groups (24 per 
group) were intranasally inoculated with 1 x 108 CFU live A. 
p leu rop n eu m on ia e  5 weeks after primary immunization. Mice were 
euthanased at 4, 12 and 24 h for assessment of bacterial numbers (Section 
7.3.4) or 0, 12 and 36 h for flow cytometric assessment of cellular
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FIGURE 7.1. Lung sections taken from mice inoculated with 2 x 109 CFU/ml 
dose of A. pleuropneumoniae. (A) Controls lung, (B) infected lung showing 
areas of neutrophil infiltration (1), (C) infected lung showing thickening of 
the alveolar walls (2), (D) infected lung showing oedema around large blood 
vessels (3). x 400 magnification.
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changes in different organ compartments (Section 7.3.6). At 0, 4, 12, 24 and 
36 h after intranasal inoculation, the clinical condition of these mice was 
assessed using the specific criteria listed in Section 7.2.5. The clinical scores 
are shown in Table 7.1. The condition of Control mice steadily deteriorated 
following intranasal inoculation. All Control mice were euthanased before 
36 h post-inoculation due to the severity of symptoms. The condition of 
mice in the OMP Antigen or OMP Vaccine groups worsened over the first 12 
h but then did not deteriorate further in either group over the next 24 h. 
Clinical scores for mice in the OMP Vaccine group were consistently lower 
than for mice in the OMP Antigen group although this trend was not 
statistically significant. The clinical scores for immunized mice were 
generally lower than for Control mice at all time points except 0 and 4 h.
TABLE 7.1. Mean clinical scores per group following intranasal inoculation 
with A. p leu ropn eu m on iae. Results represent the median clinical score 
(range) of 24 mice per group.
Time post-inoculation (hrs)
Group 0 4 12 24 36
Controls 0(0) 1(0) 7(0) 8 (7-10) 10 (0)
OMP Antigen 0(0) 1(0) 7 (0-7) 0 (0-10) 10 (3-10)
OMP Vaccine 0(0) 1(0) 7 (0-7) 0 (0-10) 10 (0-10)
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7.3.3 Assessment of bacterial clearance following intranasal challenge
The number of bacteria in the lungs of mice was determined at 4, 12 and 24 h 
after intranasal inoculation and is shown in Fig. 7.2. At 4 h the average 
number of viable bacteria in mice from each group ranged from 2.4 x 106 to 6 
x 106 CFU/lung. Thereafter, bacterial numbers in the lungs of Control mice 
increased significantly (8-fold) in the first 12 h (P < 0.005) before declining 
slightly in the second 12 h period. By comparison, bacteria were recovered 
from 3 out of 4 mice in the OMP Antigen and OMP Vaccine groups at 12 h 
post-inoculation, with the average bacterial count dropping to 7 x 104, and 
2.7 x 105 CFU/lung, respectively. At 24 h post-inoculation, only 1 out of 4 
mice in the OMP Antigen group had recoverable live bacteria in the lungs. 
This mouse had 7.2 x 106 CFU/lung and was extremely ill. Bacteria were 
recovered from 2 out of 4 mice in the OMP Vaccine group at 24 h, with the 
average number of bacteria being 9.5 x 103 CFU/lung.
Viable A. pleur opneum oniae were also recovered, but were not quantified, 
from spleen and blood samples taken from all mice at 4 h. No bacteria were 
recovered in spleen or blood samples taken at 12 or 24 h post-inoculation in 
any group.
7.3.4 Cellular changes in the lungs following intranasal inoculation with 
A. p leu ropneum oniae.
Total numbers of viable cells (as determined by trypan blue exclusion) in the 
lungs of mice in the Control, OMP Antigen and OMP Vaccine groups 
increased significantly (2- to 3-fold) in the first 12 h post-inoculation (P <
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0.0005, P < 0.05, P < 0.01, respectively) but then declined toward normal 
levels by 36 h (Fig. 7.3a). Data is not available for Control mice beyond 12 h 
because these mice did not survive intranasal infection past 24 h.
Control OMP Antigen OMP Vaccine
Group Group Group
Post-inoculation (hrs)
FIGURE 7.2. Pulmonary clearance of A. p leu ropn eu m on iae  5 weeks after 
intradermal immunization in the PBS (unfilled squares), OMP Antigen 
(unfilled diamonds) and OMP Vaccine groups (filled diamonds). Results 
represent the CFU estimates from triplicate measurements of individual 
lungs at 4, 12 and 24 h post-inoculation.
Flow cytometric analysis demonstrated that the rise in cell numbers in the 
lung was predominantly due to increases in Mac-1+Gr-1+ cells, or 
granulocytes, (Fig. 7.3b) and Mac-1+Gr-1' cells, or macrophages (Fig. 7.3c).
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FIGURE 7.3. Changes in (a) total live cells (b) granulocyte and (c) macrophage numbers in the lungs of mice from the Control 
(unfilled columns), OMP Antigen (stippled columns) and OMP Vaccine groups (filled columns) following intranasal 
inoculation with A. pleur opneumoniae. Results represent the mean (± sem) of 4 mice per group. Control mice did not survive 
past 24 h post-inoculaton.
Compared to pre-inoculation levels, lung granulocytes in Control mice rose 
significantly (11-fold) at 12 h post-inoculation (P < 0.005). The OMP Antigen 
group showed a slightly greater increase in lung granulocytes of 14-fold (P < 
0.01), while the OMP Vaccine group showed the greatest increase (27-fold) by 
12 h post-inoculation(P < 0.02).
Increases in macrophage numbers following intranasal inoculation were 
almost identical in all groups. Macrophage numbers rose significantly (3.5- 
to 4-fold) at 12 h in all groups (P < 0.02, P < 0.0001, P < 0.01, respectively). 
Macrophage numbers declined thereafter, but at 36 h, continued to be 2- to 3­
fold higher than pre-inoculation levels in the OMP Antigen and the OMP 
Vaccine groups .
CD4+, CD8+ T cells and yô+ T cell numbers in Control mice increased (1.7, 1.6
and 3.2-fold, respectively) by 12 h post-inoculation (Table 7.2). By 
comparison, T cell numbers in the OMP Antigen and OMP Vaccine groups 
changed very little over this period, and then declined slightly in the 
subsequent 24 h. The shifts in CD4+ and CD8+ T cell numbers in the different
groups were confirmed by similar changes in total a(3-TCR+ cells over the
same period. B220+ (B) cell numbers also rose (1.3 to 1.7 fold) in all groups in 
the first 12 h, and were up to 2.5-fold higher than baseline levels (P < 0.05) by 
36 h post-inoculation in the OMP Antigen and OMP Vaccine groups.
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TABLE 7.2. Changes in T and B lymphocyte numbers in the lungs of mice 
from the Control, OMP antigen and OMP vaccine groupsfollowing 
intranasal inoculation with A. p leu rop n eu m on ia e . Results represent the 
mean (± sem) of 4 mice per group.
Time Post-inoculation (h)
Phenotype Group 0 12 36
CD4+ Control 5.7 (0.2)* 9.6 (1.0) -
Antigen - 6.4 (0.3) 5.1 (0.1)
Vaccine - 5.0 (1.2) 7.3 (2.1)
CD8+ Control 2.4 (0.3) 3.8 (1.0)
Antigen - 2.5 (0.3) 1.7 (0.1)
Vaccine - 1.9 (0.3) 2.9 (1.0)
yô+ Control 1.3 (0.3) 3.1 (1.0)
Antigen - 1.9 (0.1) 1.6 (0.6)
Vaccine - 1.1 (0.2) 1.7 (0.2)
ap+ Control 7.6 (0.6) 12 (2.3)
Antigen - 6.7 (0.6) 4.8 (0.7)
Vaccine - 5.9 (1.4) 7.3 (2.2)
B220+ Control 5.4 (0.8) 8.9 (3.3)
Antigen - 9.2 (2.8) 11.1 (3.0)
Vaccine - 7.1 (1.9) 13.4 (3.6)
* Numbers in parentheses indicate standard errors
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7.3.5 Cellular changes in the bone marrow following intranasal 
inoculation with A. pleuropneum oniae.
Viable cell numbers in the bone marrow declined in all groups following 
intranasal inoculation (Fig. 7.4a). Cell numbers in the Control and OMP 
Antigen groups dropped rapidly (40%) by 12 h post-inoculation (P < 0.03), 
whereas cell numbers in the OMP Vaccine group declined more slowly. 
Declines in all the phenotypes examined contributed to the overall loss of 
cells detected in the bone marrow. Dead cell numbers in the bone marrow 
also declined by 50 to 60% over the 36 h period (Fig. 7.4b).
Compared to pre-inoculation levels, haematopoietic progenitor cell 
numbers, which includes lineage uncommitted haematopoietic stem cells 
and early progenitor cells, dropped by 40 to 60% in Control (P < 0.01) and 
OMP Antigen groups (P < 0.03) in the first 12 h post-inoculation (Fig. 7.4c). 
This decline continued until at least 36 h post-inoculation in the OMP 
Antigen group. By comparison, the decline in haematopoietic progenitor 
cells in the OMP Vaccine group was significantly less than in the other 
groups in the first 12 h (P < 0.02), but by 36 h post-inoculation cell numbers 
had also declined significantly (60%) (P < 0.01).
B lineage cell numbers, as identified using the CD45R/B220 cell marker [435], 
dropped significantly (40 to 60%) within 12 h post-inoculation (P < 0.02) in  
the Control and OMP Antigen groups, with little decline in the OMP 
Vaccine group (Fig. 7.4d). By 36 h, cell numbers in the OMP Antigen and 
OMP Vaccine groups dropped significantly (50%) (P < 0.03).
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FIGURE 7.4. Changes in the numbers of (a) total viable cells (b) dead cells (c) 
haematopoietic progenitor cells and (d) CD3'B220+ cells in the bone marrow 
of mice from the Control (unfilled columns), OMP Antigen (stippled 
columns) and OMP Vaccine groups (filled columns) following intranasal 
inoculation with A. pleuropneumoniae. Results represent the mean (± sem) 
of 4 mice per group. Control mice did not survive past 24 h post-inoculation.
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CD4+ and CD8+ T cells, which normally comprised less than 3% of bone 
marrow cells, declined significantly over 12 and 36 h post-inoculation in all 
groups. CD4+ T cell numbers fell by 50% in the Control (P < 0.05) and OMP 
Antigen group (P < 0.02) in the first 12 h, and continued declining in the 
latter group over the 36 h period (Fig 7.5a). A smaller, insignificant decline 
was detected in the OMP Vaccine group over the entire period. CD8+ T cell 
numbers declined only slightly in all groups in the first 12 h, but then 
dropped by about 50% in the OMP Antigen and OMP Vaccine groups by 36 h 
(Fig 7.5b).
Granulocyte (Gr-1+) and monocyte (Mac-1+) lineage cell numbers declined 
following intranasal inoculation. Gr-1+ cell numbers dropped by 50 to 70% in 
the Control (P < 0.005), OMP Antigen (P < 0.05) and OMP Vaccine groups (P 
< 0.02) over the 36 h period (Fig 7.5c). Over the same period Mac-1+ cell 
numbers dropped by 30 to 50% in the Control (P < 0.005), OMP Antigen (P < 
0.001) and OMP Vaccine groups (P < 0.05) (Fig 7.5d).
7.3.6 Cellular changes in the spleen following intranasal inoculation with 
A. p leu ropneum oniae.
Total viable cell numbers in the spleens of the Control and OMP Antigen 
groups did not change significantly in the first 12 h, but then increased by 
30% in the OMP Antigen group by 36 h post-inoculation (NS) (Fig. 7.6a). By 
comparison, viable cell numbers in the OMP Vaccine group were 40% 
higher than pre-inoculation levels at 12 h (P < 0.03), before declining to pre­
inoculation levels by 36 h. Dead cell numbers rose steadily (2 to 3-fold) in the
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FIGURE 7.5. Changes in the numbers of (a) Thy+CD4+ cells, (b) Thy+CD8+ 
cells, (c) Gr-l‘M ac-l+ cells (macrophages) or (d) Gr-1+Mac-1+ cells
(granulocytes) in the bone marrow of mice from the Control (unfilled 
columns), OMP Antigen (stippled columns) and OMP Vaccine groups (filled 
columns) following intranasal inoculation with A. p leu rop n eu m on iae .  
Results represent the mean (± sem) of 4 mice per group.
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FIGURE 7.6. Changes in the numbers of (a) total viable cells, (b) dead cells, (c) 
Gr-1+Mac-1+ cells (granulocytes) or (d) Gr-l'Mac-l+ cells (macrophages) in the 
spleen from mice from the Control (unfilled columns), OMP Antigen 
(stippled columns) and OMP Vaccine groups (filled columns) following 
intranasal inoculation with A. p leuropneum oniae .  Results represent the 
mean (± sem) of 4 mice per group. Control mice did not survive past 24 h 
post-inoculation.
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spleens of all groups over the 36h period post-inoculation (P < 0.01) (Fig. 
7.6b).
Cellular changes in the spleen mainly affected granulocytes and 
macrophages. A 3-fold increase in granulocyte numbers at 12 h post­
inoculation contributed to the overall increase in viable cell numbers in the 
OMP Vaccine group (P < 0.05) (Fig. 7.6c). Granulocyte numbers in the OMP 
Vaccine group were normal at 36 h post-inoculation. Granulocyte numbers 
in the Control or OMP Antigen group changed only slightly over the same 
period. Macrophage numbers changed very little, rising only slightly (20%) 
in the OMP Vaccine group at 12 h, but showing slight overall declines in all 
groups at 36 h (Fig. 7.6d).
Intranasal inoculation had little effect on splenic T or B lymphocytes (Table 
7.3). All groups elicited little or no change in the numbers of splenic CD4+,
CD8+ or yô+ T cells over 36 h post-inoculation. The lack of movement in 
CD4+ and CD8+ T cell numbers in the different groups was confirmed by 
assessment of ap+ T cells over the same period. By comparison, B (B220+) cell
numbers increased by about 30% in the OMP Antigen and OMP Vaccine 
group over 36 h.
7.3.7 Partial purification of APX1 and detection in OMP preparations
The in vitro haemolytic activity of culture supernatant increased during the 
log-growth phase before plateauing in the late-log phase (Fig. 7.7).
Chapter 7 page 181
TABLE 7.3. Changes in T and B lymphocyte numbers in the spleen following 
intranasal inoculation with A. p leuropneum oniae  of mice from the 
Control, OMP Antigen and OMP Vaccine groups. Results represent the 
mean (± sem) of 4 mice per group. Control mice did not survive past 24 h 
post-inoculation.
Phenotype
Time Post-inoculation (h)
Group 0 12 36
CD4+ Control 16.0 (0.7) 12.7 (2.0) -
OMP Antigen - 13.0 (1.0) 17.9 (1.3)
OMP Vaccine - 16.9 (1.9) 14.0 (3.0)
CD8+ Control 8.1 (0.2) 6.8 (1.3)
OMP Antigen - 8.1 (0.9) 10.0 (0.6)
OMP Vaccine - 10.3 (0.6) 7.6 (1.6)
yô+ Control 0.2 (0.1) 0.3 (0.1)
OMP Antigen - 0.4 (0.1) 0.1 (0.1)
OMP Vaccine - 0.5 (0.1) 0.3 (0.1)
ap+ Control 24.1 (1.3) 19.3 (4.3)
OMP Antigen - 21.8 (3.1) 28.1 (2.0)
OMP Vaccine - 25.4 (4.6) 22.1 (6.0)
B220+ Control 31.0 (1.4) 23.4 (5.6)
OMP Antigen - 35.5 (3.7) 40.8 (5.8)
OMP Vaccine - 42.7 (3.3) 32.9 (6.0)
* Numbers in parentheses indicate standard errors
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Time
FIGURE 7.7. Timecourse of increase in haemolytic activity (unfilled circles) 
of culture supernatant compared with bacterial growth (filled circles) over 
the same period.
In one typical preparation, the specific haemolytic activity of culture 
supernatant was increased from 1.5 HU/mg protein (in the neat culture 
supernatant) to 437 HU/mg protein (in the retentate), or a 291-fold increase 
in specific activity. The relative purity of APX1 preparations ranged from 75 
to 88%. Fig. 7.8 shows a typical densitometer scan. YM100 retentate was also 
cytotoxic to a range of different murine cell types (Fig. 7.9). Ultrafiltrate was 
not cytotoxic to these cells.
Protein bands were not detected in coomassie blue-stained polyacrylamide 
gels of neat culture supernatant or YM100 ultrafiltrate (Figure 7.10, lanes 2 
and 3). However, a 110 kDa protein corresponding to APX1 was detected in 
the YM100 retentate (lane 4). The additional lower molecular weight 
proteins detected in culture retentate (lane 4) were most likely OMP retained
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FIGURE 7.8 LKB laser densitometer scan of a partially purified APX1 
preparations. The arrow marks the APX1 peak.
Reciprocal of Retentate Dilution
FIGURE 7.9. Cytotoxicity of YM100 retentate to splenocytes (filled circles), 
thymocytes (filled diamonds) and lung cells (filled squares) by propidium 
iodide exclusion. No cytotoxicity was present when cells were incubated with 
equivalent dilutions of YM100 filtrate (unfilled squares).
C h a p te r  7 page 184
during ultrafiltration. During growth, Gram-negative bacteria shed the outer 
membrane as blebs [239]. Native proteins embedded in outer membrane blebs 
are be trapped in the retentate during ultrafiltration. This is confirmed by 
comparing the molecular weights of these proteins with those of Lanes 5 and 
6, which show purified OMP proteins and proteins from denatured whole 
cells, respectively.
kDa
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31 
22
FIGURE 7.10. Coomassie blue-stained SDS-PAGE and immunoblot of APX1 
preparations from A. pleuropneumoniae. Lane 1: Biorad broad range molecular 
weight proteins standards; Lane 2: neat culture supernatant; Lane 3: YM100 
filtrate; Lane 4: YM100 retentate; Lane 5: purified OMP; Lane 6: denatured 
whole cells. Immunoblot showing reactivity of anti-APXl serum against YM100 
retentate (lane 7), neat culture supernatant (Lane 8) and purified OMP (Lane 9).
Immunoblotting demonstrated that pooled murine APX1 antiserum reacted 
strongly against a 110 kDa band corresponding to APX1 present in the 
YM100 retentate (Fig. 7.10, lane 7) and bacteria-free mid-log phase culture 
supernatant (lane 8). Pooled APX1 antiserum reacted against multiple lower
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molecular weight bands present in the YM100 retentate and two bands, 33 
and 37 kDa, in the OMP preparation (lane 9). These bands were consistent 
with outer membrane proteins previously identified in coomassie blue- 
stained gels (Chapter 5). The most likely cause of the reactivity of APX1 
antiserum against OMP proteins was contamination of APX1 preparations 
used for mouse immunizations with OMP. Most significantly, a protein 
band corresponding to APX1 was not detected in OMP preparations.
Murine APX1 antiserum neutralized haemolytic activity of log-phase A. 
ipleuroipneumoniae culture supernatant. Percentage residual haemolytic 
activity and percentage inhibition of haemolytic activity of culture 
supernatant is shown in Fig. 7.11.
FIGURE 7.11. The percentage residual haemolytic activity of culture 
supernatant (unfilled squares) and percentage inhibition of haemolytic 
activity of culture supernatant (filled circles) after incubation with 
antiserum raised in BALB/c mice.
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7.4 DISCUSSION
The outcome of intranasal inoculation with A. p leuropneum oniae  in  
susceptible mice stains depends on the inoculum size. This finding is 
consistent with previous results in other mouse species [425]. If the dose is 
large enough, bacteria multiply rapidly and the mouse dies [425]. Clinical 
signs, if present, can include weakness, ruffled hair, anorexia and épistaxis, 
at or near death [425]. Sublethal doses, on the other hand, can produce either 
subacute infection leading to chronic lesions or no lesions at all [425]. 
Although not as widely used for laboratory investigations of A. 
p leu rop n eu m on iae  infection [433, 434], BALB/c mice were also found to be 
susceptible to infection in a dose-dependent manner. Inoculating mice 
intranasally with 1 x 107 CFU or greater resulted in cellular changes in the 
lungs that were histologically consistent with those found in porcine 
pleuropneumonia [415, 416, 436]. Inoculating BALB/c mice intranasally with 
at least 1 x 108 CFU caused peracute (very rapid onset) infection, with 
unimmunized mice eliciting severe clinical symptoms, and death within 12 
to 24 h post-inoculation. This finding was consistent with previous reports 
in pigs demonstrating very rapid onset of clinical symptoms when infected 
intranasally with high doses of A. p leuropneum oniae  [414, 437]. A dose of 1 
x 108 CFU was used for all subsequent investigation of A. 
pleuropneumoniae  infection in mice.
The transient recovery of viable bacteria from the blood and spleen at 4 h
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post-inoculation indicated that A. p leuropneum oniae  rapidly enters the 
blood stream, possibly via the pharyngeal lymphoid tissue [421] and the 
pulmonary lymphatic circulation [369]. The disappearance of bacteria at 
subsequent time points, suggested rapid clearance of bacteria from the 
circulation. One possibility may be phagocytosis of bacteria by resident 
macrophages (Kupffer cells) and neutrophils in liver sinusoids [438]. This is 
a major mechanism for clearance of bacteria from the bloodstream [438]. 
Flow cytometric measurements demonstrated clearly that leukocyte 
populations in tissues as widespread as the lung, bone marrow and spleen 
were adversely affected by infection. It was also possible that the cellular 
changes detected in these tissues resulted from direct bacterial toxicity or 
circulating toxins in these organs.
Macrophages are the predominant resident phagocytes present in the 
normal lung, with PMN being much fewer in number [439]. However, very 
rapidly following A. pleuropneumoniae infection in mice, PMN became the 
most prominent cell type, with relatively fewer macrophages. The rapid 
influx of high numbers of PMN into the lungs from the large reservoir in 
the pulmonary vascular bed appears to be crucial for the prompt clearance of 
bacteria [279, 440] and reflects the different roles of macrophages and PMN in 
response to bacterial infection [279, 441]. Infection by pathogens as diverse as 
Pseudomonas aeruginosa  [442], Chlamydia trachomatis [443], Listeria 
monocytogenes  [444], Mycobacterium av ium  [445] and Klebsiella 
pneumoniae  [446] elicit a similar response. The greater PMN numbers may 
reflect superior bactericidal activity against a broad range of micro-organisms
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[438, 442]. Cruijsen et al (1992) [234], for example, showed that PMN have 
much greater in vitro killing capacity against A. p l eu ropn eu m on iae  than 
resident or inflammatory macrophages. Macrophages are also more 
susceptible to the cytotoxic action of RTX toxins than PMN [234]. 
Nevertheless, the rapid rise and fall in PMN and macrophage numbers in 
the first 12 to 24 h following infection clearly demonstrated a major role for 
the innate immune system as a primary defense mechanism, regardless of 
the immune status of mice.
In mice, bone marrow, blood, secondary lymphoid tissues and non­
lymphoid tissues all serve as potential sources of phagocytic cells for 
recruitment during infection, but upregulation of splenic haematopoiesis is 
a principal mechanism for meeting acute increases in demand for phagocytic 
cells [280]. Upregulation of splenic haematopoiesis in mice occurs during 
viral, bacterial and protozoan infections [325, 334, 447, 448]. It is likely, 
therefore, that strong upregulation of splenic haematopoiesis in the OMP 
Vaccine group, along with tissue recruitment of granulocytes and 
macrophages, contributed to the greatly increased numbers of these cells in 
the spleen and lung of mice during infection. The absence of such dramatic 
increases in the spleens of the Control and OMP Antigen groups did not 
exclude these mechanisms from also operating, but possibly reflected a lower 
level of upregulation in splenic haematopoiesis following infection.
Irrespective of the immune status of mice, cell numbers in the bone marrow 
declined during infection. The uniform decline in dead cell numbers in all
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groups made it unlikely that the smaller declines in viable cell numbers in 
the OMP Vaccine group was due to lower necrotic or apoptotic death in this 
group than in other groups. Efflux of cells from the bone marrow to the 
lungs and other peripheral tissues may account for the decline in viable cell 
numbers from the bone marrow [279]. The greater cell numbers, especially in 
haematopoietic progenitor cells, B lineage and monocytic lineage cells, in 
the bone marrow of the OMP Vaccine group suggested that these mice had 
been more effectively primed by intradermal immunization than the OMP 
Antigen group and were predisposed for greater proliferative responses on 
subsequent challenge.
Pro-inflammatory factors released by bacteria and damaged cells attract 
greater numbers of phagocytic cells to the infection site [374, 416]. Binding of 
LPS from Gram-negative bacteria to CD14 on macrophages and monocytes, 
for example, stimulates an increase in production of a range of cytokines,
such as IL-1, IL-2, IL-4, IL-6, IL-7, IL-11, IL-12, IL-13, IFN-y, TNF-a, M IP-la, 
and MIP-2, that stimulate recruitment of lymphocytes and phagocytic cells to 
the site of infection [105, 443, 446, 449]. Baarsch et al (1995) [450] showed that 
A. p leuropneum oniae  infection in pigs rapidly causes cellular activation
and increased production of TNF-a, IL-1 and IL-8 by alveolar macrophages. 
Other cell types, such as eosinophils [440], mast cells [451], alveolar epithelial 
cells, interstitial macrophages, endothelial cells and lymphocytes, also
recruit inflammatory cells to the site of infection by secreting TNF-a, 
RANTES and MCP-1 [446]. Cytokines, such as TNF-a, IL-1 and IL-6, stimulate
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increased production of superoxide anions and H20 2, and release of 
lysozymes by PMN that can directly destroy bacteria [442, 446, 452], while 
binding of C3b or antibodies to the surface of bacteria (opsonization) 
facilitates their phagocytosis by PMN recruited to the site of infection [449].
Despite the large post-inoculation increases in PMN (11-fold) and 
macrophage (4-fold) numbers, unimmunized mice did not clear bacteria 
from their lungs, and died within 24 h. Mice in the OMP Antigen group, on 
the other hand, elicited almost equivalent increases in granulocytes and 
macrophages, but rapidly cleared bacteria from their lungs and survived. At 
the other extreme, the rate of bacterial clearance and degree of morbidity in 
the OMP Vaccine group, which showed the greatest recruitment of PMN to 
the lungs (almost twice that for the other groups) was not significantly better 
than in the OMP Antigen group. These different outcomes clearly suggested 
that rapid recruitment and activity of phagocytic cells to the infection site, by 
itself, was insufficient to overcome lethal infection.
The high background levels of circulating and mucosal antibodies against 
OMP and LPS (Chapter 5) most likely provided the additional protective 
component in immunized mice. Numerous studies in swine [233-236, 388, 
430] have shown that antibodies in convalescent serum directed against A. 
p leu ro p n eu m on ia e , are important opsonins for phagocytic clearance of 
bacteria from the lungs, and protection. Therefore, it was likely that 
elevations in OMP- and LPS-specific antibodies in serum and respiratory 
tract washings of both groups of intradermally immunized mice enabled
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more efficient phagocytic clearance of bacteria from the lungs than was 
possible in unimmunized mice.
It is not clear from the current study whether the rapid bacterial clearance 
and reduced morbidity in immunized mice was due predominantly to the 
action of antibodies specific against OMP-derived proteins or LPS, or 
whether their effects were complementary. Both virulence factors have 
important biological functions in disease pathogenesis. OMP allow nutrient 
transport and uptake, chemosensing, motility, cell-cell communication and 
adhesion [220, 453-455]. LPS facilitates bacterial adhesion to the mucosal 
surfaces of the lung [401] and, along with secreted haemolysins, causes the 
lung lesions present during infection [374]. Antibodies against both 
virulence factors would therefore be expected to have an impact on the 
pathogen's ability to colonize and invade the host. Future studies that utilize 
vaccines containing either purified OMP-derived proteins or LPS, or passive 
immunization of animals with antisera against either component may 
determine the relative contributions to protection of both virulence factors. 
One may argue, however, that the more rapid induction of antibodies 
against T-cell independent antigens, such as LPS [404], may give an 
additional protective advantage in some cases, for example, very early 
following bacterial colonization in unimmunized animals.
A 110 kDa protein, APX1, is also considered to be an important virulence 
factor in disease pathogenesis [278, 417, 456-458]. APX1 is one of at least three 
pore-forming RTX toxins released by different serovars of A.
Chapter 7 page 192
pleuropneumoniae [418, 420, 432]. APX1 is strongly haemolytic and cytotoxic 
against a range of different cell types in vitro [459, 460] and mediates much of 
the tissue necrosis and cytotoxicity against granulocytes and macrophages 
associated with porcine pleuropneumonia [278, 416]. APXl-deficient mutants 
elicit dramatically reduced disease in infected animals [418]. The inability of 
commercial bacterin-based vaccines to fully protect swine against A. 
pleuropneumoniae  is believed to be due to the lack of important virulence 
factors, such as APX1 [197, 233].
Mice were immunized against OMP, but it was essential to exclude the 
possibility that mice were inadvertently immunized against contaminating 
APX1 co-purified with OMP. If present, anti-APXl antibodies may have 
contributed to the protection observed following challenge. Murine 
antibodies raised against anti-APXl were used as a serological reagent to 
detect the presence of APX1 in OMP preparations. The authenticity of APX1 
used to raise anti-APXl antibodies was confirmed by measuring its in vitro  
haemolytic and cytotoxic activity, detection by SDS-PAGE and 
immunoblotting and inhibition in neutralization assays. The data 
confirmed that APX1 was not detectable in OMP preparations. Surprisingly, 
despite the lack of APX1 in the OMP vaccines used, intradermally 
immunized mice were significantly protected when challenged with an 
APXl-producing strain of A. p leuropneumoniae .  These results suggested 
that antibodies against surface-exposed OMP and polysaccharides may 
mediate swift clearance of bacteria from the lungs and thereby minimize 
tissue damage to lungs caused by bacterial toxins.
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It is generally believed that IgA is the most important secreted 
immunoglobulin isotype for protection against mucosal pathogens, and that 
serum antibodies and non-IgA isotypes do not contribute significantly to 
protection [9, 148, 196]. However, a protective role for serum antibodies, and 
for immunoglobulin isotypes other than IgA, against mucosal pathogens 
has been suggested by this and other studies [158-160, 184]. In this study, 
intradermally immunized mice did not have significant levels of OMP- 
specific RTW IgA at the time of infection but had strong IgG responses in 
serum and respiratory tract washings (Chapter 5). These mice showed 
significantly better clearance of bacteria from the lungs and reduced 
morbidity than control mice. Although the relative contributions of serum 
and RTW IgG was not investigated, the results argued strongly in favour of 
a prominent role for the IgG class in protecting against disease caused by A .
;p leu rop n eu m on iae .
Previous studies [233, 405, 423, 429] have demonstrated a lack of prominent 
changes in pulmonary lymphocyte distribution and CMI involvement in 
swine following exposure to A. p leu rop n eu m on iae . Under normal 
circumstances, down-regulation of CMI responses in the lungs by resident 
macrophages prevents lymphocytes from reacting to irrelevant antigens 
[279, 441, 461, 462] and this may explain the absence of significant CMI in 
infected swine. This present study confirmed the lack of significant changes 
in T and B cells. The strong influx of granulocytes and macrophages 
demonstrates that a very strong, T cell independent, innate response is the 
first line of defence against A. pleu ropn eu m on iae  infection in
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unimmunized mice, and if they survive long enough, may limit the spread 
of infection in the period required for induction of T cell dependent 
immune responses. However, in this study the effectiveness of such a 
response for clearing A. pleuropneumoniae from the lungs was curtailed by 
the very high inoculation dose. By contrast, the efficient clearance of bacteria 
in immunized mice, which co-incidently had elevated levels of OMP- and 
LPS-specific antibodies, demonstrated that induction of adaptive im m une 
responses are ultimately necessary for the clearance of infection.
The monoclonal antibody used to detect B cells in this study, RA3-6B2, reacts 
against the 220 kDa isoform of the CD45 antigen, and is a well established B 
cell marker [248]. However, the rapidity and almost identical increase in 
B220+ cell numbers in both unimmunized or immunized mice was 
inconsistent with an antigen-specific B cell response. Since upregulated 
expression of the B220 epitope on non-T, non-B cells is associated with an 
increase in MHC-unrestricted cytolytic activity [293, 294, 463], the results 
suggested that intranasal challenge elicited an increase in the numbers of
lytically active cells in mice. This epitope is also expressed on activated afT- 
TCR+, yb-TCR+ T cells and NK cells [463, 464]. Specific staining ruled out
increased B220 expression on ap- or y^-TCR T cells in infected mice.
Increased NK cell activity was not detected shortly after intradermal 
immunization (Chapter 2), but this did not exclude an increase in NK 
activity following exposure of mice to A. p leu ro p n eu m o n ia e . In vitro  
assessment of NK cell activity was not measured and flow cytometry of NK
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In summary, an in vivo  mouse model was used to quantitatively assess 
differences in the leukocyte response to intranasal A. p leu ro p n eu m o n ia e  
infection in unimmunized and immunized mice. Although all groups 
elicited a strong innate cellular response, protection appeared to require the 
presence of specific antibodies with opsonic properties. Binding to surface 
exposed protein and polysaccharide components of A. p leu rop n eu m on ia e  
facilitated clearance of bacteria from the lungs by phagocytic cells. 
Significantly, the data indicated that, in the absence of mucosal IgA, IgG was 
important for mucosal protection. This is contrary to the accepted dogma, 
that protection against mucosal pathogens is the best achieved by mucosal 
immunization and secretion of mucosal IgA. Finally, the results 
demonstrated that intradermally immunized mice were protected against A. 
pleuropneumoniae infection.
cells was not undertaken for the reasons mentioned in Chapter 2.
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CHAPTER 8
Summary of Results and General
Discussion
In practical terms, control over the type of immune responses elicited 
following immunization is confined to: selecting the immunodominant 
antigens that correlate with protection from disease [2], choosing an 
adjuvant [18, 24, 30, 465] and deciding the immunization route to be used [8, 
107, 466]. The historical basis for using an adjuvant has been to increase the 
immunogenicity of injected antigens and thus guarantee that an im m une 
response is elicited [13-15, 35, 467]. Adjuvants increase the immunogenicity 
of antigens by provoking the innate immune system [11, 16], but beyond the 
general appreciation that adjuvants activate macrophages there is an 
incomplete understanding of adjuvant action.
This is partly because of the heterogeneity in the chemical composition of 
adjuvants [21], and because most studies have focused predominantly on the 
endproduct of immunization, namely the humoral or cell mediated 
immunity elicited [24, 33, 34, 51, 54, 102, 126, 217, 224, 231, 468, 469]. 
Nevertheless, the dependence on vaccines for disease control and the 
widespread use of adjuvants to ensure immunological responses [8] raise 
issues of vaccine safety and efficacy that require a greater understanding of 
adjuvant action in order to be resolved.
The cellular events induced in the innate immune system by vaccination 
direct the development of the adaptive immune response [116]. Therefore, it 
is meaningful to define the cellular changes that are induced with and 
without adjuvant. One outcome of this is that, if the important events are 
identified, it may be possible to manipulate them more precisely to achieve
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the desired outcomes. This type of investigation may also reveal that some 
antigens do not require adjuvant enhancement to induce the desired 
immune response. Because many adjuvants are toxic, limiting their use 
may lower the incidence of adverse reactions. Investigation of cellular 
changes induced by alterations to vaccine formulations may also show that 
dissimilar antigens incorporated into a vaccine cause adjuvants to generate 
different cellular responses. This approach would provide a rational basis for 
selecting alternative adjuvants.
A murine model was established to evaluate the leukocyte changes that 
occurred when the immune system was provoked by immunization, and to 
assess the importance of these changes for determining the final 
immunological responses. The intradermal route was used together with 
the liposome-iscom hybrid adjuvant, SAMA4 (Skin and Mucosal Adjuvant 
version 4, Patent No. PCT/AU95/00206) for vaccine delivery because 
previous studies [100-102] have shown that this combination induces both 
systemic and mucosal immune responses. Leukocyte changes induced by 
intradermal immunization were quantified by flow cytometry, a technique 
that enabled simultaneous phenotypic identification of different cell 
populations in cell suspensions prepared from murine tissues. Mice were 
immunized with either SAMA4 (Adjuvant group), OMP purified from the 
respiratory pathogen, A. pleuropneumoniae (OMP Antigen group), SAMA4- 
OMP (OMP Vaccine group) or PBS (Control group). This approach was a 
significant departure from that used by previous reports for investigating 
adjuvant action, both in the use of flow cytometry for measurement of post­
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immunization cellular changes, and in directly comparing changes in 
leukocyte populations across different vaccine formulations.
Adjuvant alone elicit moderate cellular changes following intradermal 
immunization. The combination of antigen and adjuvant, however, 
synergistically increased the magnitude of cellular changes in the OMP 
Vaccine group. Qualitatively similar changes were elicited when OVA, an 
innocuous antigen, was complexed with SAMA4, but were absent from the 
Antigen-only groups. One prominent effect of intradermal im m unization 
with SAMA4-OMP complexes was an increase in tissue and circulating 
levels of PMN and macrophages. The bone marrow in the adult mouse has 
limited reserve haematopoietic capacity for responding to increased cellular 
demands [280]. It was demonstrated that haematopoietic progenitor and 
lineage-committed precursor cell populations rapidly declined in the bone 
marrow following intradermal immunization. The splenic morphological 
and histological changes in the OMP Vaccine group suggested that the 
spleen assumes a haematopoietic role during this period, with upregulation 
of haematopoietic activity in the spleen induced by an immunization- 
induced increase in demand for phagocytic cells.
Surprisingly, a rapid effect evoked by SAMA4-OMP complexes was depletion 
of DP cells in the thymus and leukocyte precursors (predominantly B220+ 
cells and haematopoietic progenitor cells) in the bone marrow. Cell losses 
occurred within 12 to 24 h following the first intradermal injection and 
preceded the cellular increases in the spleen by several days. Although only
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a small increase in the percentage of apoptotic cells was detected in the 
thymus, and no increase was detected in the bone marrow, the susceptibility 
of DP cells and B220+ cells to apoptosis [301, 331] made this the most likely 
explanation. Apoptotic and dead cells are rapidly recognized and removed by 
macrophages [303, 470], therefore, the lack of detectable increases in apoptosis 
may have been due to the limited the ability of the method to detect in v i v o  
apoptosis. Other indicators of apoptosis, such as TUNEL, which detects in 
situ DNA fragmentation, apoptosis-related cell markers [263], and 
measurement of changes in mitochondrial transmembrane potential that 
occur during apoptosis [261], may yield a more accurate picture of the level of 
apoptosis in the thymus and bone marrow following intradermal 
im m unization.
The outcomes in the bone marrow and thymus in the OMP Vaccine group 
were significant in that they are a previously unreported outcome of 
immunization by any route. Massive cell depletion may be a bystander 
responses with no direct relevance to the immune response, but it had the 
potential to suppress or delay development of the immune response. From 
an evolutionary perspective it seems unlikely that immune suppression 
precipitated by massive lymphoid cell depletion confers any survival 
advantage to an animal faced with an immunological challenge, unless the 
depletion has a specific immunological purpose, and/or other mechanisms 
were in place for protecting the host during this period. One explanation for 
the significant loss of immature cells in the bone marrow and thymus is that 
depletion of lymphocyte precursors prevents tolerance being inappropriately
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induced against the immunizing antigen. During the period of cell loss, 
protection was achieved by a significant increase in innate defenses, namely 
polymorphonuclear granulocytes and macrophages. In disease, recruitment 
and increased phagocytosis by these cells, along with other innate defences, 
limits the spread of infection, reduces the circulating antigen load and 
stimulates induction of strong adaptive immune responses. Similarly 
following immunization, adjuvant-mediated stimulation of phagocyte 
recruitment potentially enhanced phagocytosis and antigen processing by 
these cells and induced strong humoral and cellular responses against the 
immunizing antigen. Nieuwenhuis et al (1988) [307] and Westermann et al  
(1996) [309] showed that intrathymic circulation of activated leukocytes or 
antigen from the periphery increases during an immune response. By 
analogy, antigen presentation by circulating APC may provide the stimulus 
for an antigen-driven increase in turnover of T and B cells. The 
supranormal levels of B220+ cells in the bone marrow and thymocytes later 
in the post-immunization period may have reflected a period of increased 
lymphopoiesis and lymphocyte maturation, potentially shifting the 
antigenic repertoire of developing cells toward those with greater specificity 
for the immunizing antigen.
Synergism between the antigen and the adjuvant was confirmed by the 
inability of OMP alone to provoke similar leukocyte changes. It was likely 
that the synergistic effect of SAMA4-OMP on leukocyte populations was a 
consequence of the slow lymphatic clearance of antigen-iscom complexes 
and greater accumulation of vaccine in the spleen and lymph nodes,
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compared to free antigen or adjuvant alone [37, 59, 69, 74, 87, 92]. Binding of 
iscoms to DEC 205, a carbohydrate binding protein present on the surface of 
phagocytic cells, is one mechanism proposed for enabling efficient uptake of 
antigen-iscom complexes [39]. Multimeric antigen presentation on the 
surface of iscoms [69, 92], together with high circulating phagocytes numbers, 
also provided the right environment for an increased rate of antigen uptake 
and processing, compared to free antigen.
It remained to be determined how the immune response in mice reflected 
the disparate cellular responses in the various groups. Intradermal 
immunization with free or SAMA4-complexed OMP stimulated strong 
systemic IgG and IgA, and mucosal IgG responses. Intradermal 
immunization also primed mice for recall of mucosal IgG and IgA responses 
as evidenced by increased levels of OMP-specific IgG and IgA in RTW, and 
increased numbers of IgG and IgA antibody secreting cells in the lungs after 
intranasal inoculation of a sub-immunogenic dose of OMP. Both the OMP 
Antigen and OMP Vaccine groups were equally protected against intranasal 
exposure to a lethal dose of A. p leuropneum oniae .  Bacterial challenge 
elicited a rapid influx of PMN and macrophages into the lungs, regardless of 
the immune status of mice. However, protection, as measured by rapid 
clearance of bacteria from the lungs and reduced morbidity, was ultimately 
dependent on the presence of anti- OMP and anti-LPS antibodies in the 
serum and respiratory tract.
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An obvious outcome of this investigation was that the OMP Antigen group 
elicited almost identical responses, in terms of antibody profiles and 
protective immunity, as the OMP Vaccine group. This result was consistent 
with bacterial OMP being sufficiently immunogenic, due to its chemical 
heterogeneity and antigenic complexity of its protein and polysaccharide 
components, that it did not require adjuvant enhancement to induce an 
immune response. In the case of OMP then, the adjuvant effect of SAMA4 
was to significantly prolong the duration of serum and mucosal antibody 
responses in mice, and increase reactivity against T dependent antigens in  
OMP. Considering the similar outcomes, these results would suggest that, 
for OMP at least, the strong cellular changes induced by SAMA4 were 
unnecessary. However, when mice were immunized with a simpler, 
innocuous and poorly immunogenic antigen, such as OVA, the adjuvant 
effect of SAMA4 was much more obvious. CTL and antibody responses were 
only elicited when OVA was complexed with SAMA4. These results for 
OVA clearly demonstrated that the strong cellular responses promoted by 
SAMA4 in the presence of antigen contributed to beneficial immunological 
outcomes detected. These differences between antigens places great 
emphasis on adequately evaluating the composition and efficacy of vaccine 
formulations.
The findings that intradermally immunized mice elicited mucosal im m une 
responses; that IgG was the predominant immunoglobulin isotype present 
in RTW at the time of intranasal challenge with A. pleuropneumoniae.; and 
that a protective role for IgG was strongly implicated, were contrary to the
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current dogma, that mucosal immunization is necessary to elicit mucosal 
(IgA) immunity [471]. There are many similar reports that describe the 
induction of mucosal immunity by systemic immunization strategies, 
including intra-muscular [82, 209, 224], subcutaneous [202, 225], and 
intradermal immunizations [102, 161]. These findings suggest that the idea 
of a mucosal immune system that only surveys the mucosal surfaces, 
predominantly secretes IgA, and is functionally independent to the systemic 
immune system [136, 148] is incorrect. Compartmentalization of
immunological responses and immunoglobulin isotypes in this way would 
potentially limit the range of protective responses elicited during infection. 
Daynes and Araneo [469] demonstrated that T cells may be " re-programmed" 
by the action of different immunomodulators in vivo,  thus providing a 
basis for generating both mucosal and systemic immune responses. In this 
study, the use of an adjuvant, and mobilization and recruitment of 
sufficient numbers of immune effector cells by intradermal im m unization, 
provided the necessary stimulus to induce both mucosal and systemic 
immune responses in mice.
Intradermal immunization may, in fact, be preferable to direct mucosal 
immunization in a number of circumstances. Most of the phenom ena 
associated with mucosal immunity have been investigated in rodents, 
therefore, the general applicability of mucosal vaccination strategies to other 
species is still unknown [472]. Numerous studies have shown that 
intradermal immunization may be effective in circumstances where 
mucosal immunization fails to elicit strong or protective mucosal responses,
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or when the requirement for multiple and frequent immunization doses is 
impractical [206], such as in place of oral and intravaginal im m unizations 
[82, 390] or due to economic or geographic and storage conditions. Age- 
related, dietary and biological variations in the uptake of antigen through 
the mucosal epithelium and in the composition of mucosal flora may 
influence the efficacy of mucosal vaccination [472]. The presence of 
concurrent pathology, such as vomiting or diarrhoea, intestinal allergies, 
parasitic infections, and drug therapy may also affect the rate absorption 
across the gut epithelium [472]. Intradermal immunization offers several 
practical advantages over other immunization routes in the veterinary field 
in terms of reduced animal handling; vaccination during livestock feeding; 
and automated vaccination with compressed-air guns. This latter technology 
will eliminate the requirement for needles that can often lead to extraneous 
bacterial infection under farm conditions [473, 474].
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